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ACN	   	   acetonitrile	  
APT	   	   attached	  proton	  test	  
CB	   	   cannabinoid	  
CDCl3	   	   deuterated	  chloroform	  
CD4O	   	   deuterated	  methanol	  
CPP	   	   conditioned	  place	  preference	  
d	   	   doublet	  
DCM	   	   dichloromethane	  
DEPT	   	   distortionless	  enhancement	  by	  polarization	  tranfer	  
DQF-­‐COSY	   double-­‐quantum	  filtered	  correlation	  spectroscopy	  
DOR	   	   δ	  opioid	  receptor	  
ESI	  MS	  	   electrospray	  mass	  spectrometry	  
EtOAc	   	   ethyl	  acetate	  
FDA	   	   food	  and	  drugs	  administration	  
GABA	   	   gamma-­‐aminobutyric	  acid	  
[3H]-­‐DAMGO	  	  	  [(D-­‐Ala2,	  N-­‐Me-­‐Phe4,	  Gly5-­‐ol-­‐)	  enkephalin]	  
[3H]-­‐DPDPE	  	   [(D-­‐Pen	  2,5)-­‐enkephalin]	  
HMBC	   	   heteronuclear	  multiple	  bond	  correlation	  
HPLC	   	   high	  performance	  liquid	  chromatography	  
XI 
 
HR	  ESI	  MS	   high	  resolution	  electrospray	  mass	  spectrometry	  
HSQC	   	   heteronuclear	  single	  quantum	  coherence	  
IC50	   	   inhibition	  concentration	  (50%	  inhibition)	  
µg	   	   microgram	  
µl	   	   microliter	  
Ki	   	   inhibition	  constant	  
KOR	   	   k	  opioid	  rceptor	  
MeOH	  	   methanol	  
MOR	   	   µ	  opioid	  receptor	  
NMDA	  	   N-­‐methyl-­‐d-­‐aspartate	  
NMR	   	   nuclear	  magnetic	  resonance	  
NP	   	   normal	  phase	  
OME	   	   Otanthus	  maritimus	  extract	  
PAg	   	   Periaqueductal	  grey	  
PMFs	   	   polymethoxyflavones	  
RP	   	   reversed	  phase	  
s	   	   singlet	  
spp	   	   species	  
TOF	   	   time	  of	  flight	  
THC	   	   tetrahydrocannabinol	  
t	   	   triplet	  
TFAA	   	   trifluoroacetic	  acid	  
XII 
 
TLC	   	   thin	  layer	  chromatography	  
SGE	   	   Stachys	  glutinosa	  extract	  
UV	   	   ultraviolet	  
VLC	   	   vacuum	  liquid	  chromatography	  
WSAE	   	   Withania	  somnifera	  alkaloid	  extract	  










Plants	   have	   been	   used	   for	   thousands	   of	   years	   to	   treat	   diseases	   and	  
today	   too,	   they	   are	   the	   almost	   exclusive	   source	   of	   drugs	   for	   the	  
majority	  of	  the	  world’s	  population.	  
In	  the	  19th	  century,	  with	  the	  isolation	  of	  morphine	  from	  opium,	  it	  was	  
begun	   to	   employ	   the	   pure	   active	   ingredients	   rather	   than	   whole	  
extracts.1	   After	   the	   discovery	   of	   morphine	   a	   lot	   of	   plant-­‐originated	  
drugs	   have	   been	   discovered	   and	   various	   secondary	  metabolites	   are	  
currently	  in	  use	  such	  as,	  for	  example,	  quinine	  from	  Cinchona	  species,	  
cardiac	   glicosides	   from	  Digitalis	   purpurea,	   vinblasine	   and	   vincristine	  
from	   Catharanthus	   roseus,	   taxol	   from	   Taxus	   brevifolia	   and	   the	  
antimalarian	  compound,	  artemisinin,	  from	  Artemisia	  annua. 
Higher	  plants	  are	  also	  an	  important	  source	  of	  drugs	  that	  act	  as	  agonist	  
to	  opioid	  receptors	  and	  among	  all,	  morphine,	  isolated	  from	  the	  opium	  
poppy,	  Papaver	  somniferum.	  Morphine	  is	  a	  µ	  opioid	  receptor	  agonist	  
and	   is	   the	   most	   potent	   analgesic	   currently	   used	   in	   clinic	   for	   the	  
treatment	  of	  moderate	  or	  severe	  pain.	  Salvinorin	  is	  another	  receptor	  
opioid	  ligand	  (k	  agonist)	  isolated	  from	  plants	  (Salvia	  divinorum)	  but	  it	  




A	   consistent	   number	   of	   medicinal	   and	   dietary	   plants	   have	   been	  
reported	   to	   contain	   secondary	   metabolites	   that	   interact	   with	   the	  
endocannabinoid	   system.	   These	   compounds,	   also	   called	  
phytocannabinoids,	   are	   capable	   of	   either	   directly	   interacting	   with	  
cannabinoid	   receptors	   (CB1	   and	   CB2)	   or	   sharing	   chemical	   similarity	  
with	   cannabinoids	   or	   both.3	   Δ9-­‐tetrahydrocannabinol	   (Δ9-­‐THC)	   from	  
Cannabis	   sativa	   is	   a	   non-­‐selective	   agonist	   to	   cannabinoid	   receptors	  
and	   is	   used	   for	   the	   treatment	   of	   neuropathic	   pain	   or	   for	   refractory	  
forms	  of	  treatment	  with	  morphine	  derivatives.4	  
Recently,	  N-­‐alkylamides	  from	  Echinacea	  spp.	  have	  been	   identified	  as	  
CB2	   receptor	   selective	   agonists	   and	   are	   responsible	   of	   the	  
immunomodulatory	  effect	  of	  this	  plant.5 
Powerful	   new	   technologies	   such	   as	   high-­‐throughput	   screening	   and	  
combinatorial	   chemistry	  dramatically	   increase	   the	  possibility	  of	  drug	  
discovery.	   Nevertheless,	   natural	   products	   still	   offer	   unmatched	  
structural	   variety	   when	   compared	   to	   synthetic	   compounds.	   For	  
example,	   natural	   products	   are	   more	   likely	   to	   be	   rich	   in	  
stereochemistry	  and	  concatenated	  rings	  than	  the	  structures	  obtained	  
by	  the	  combinatorial	  libraries. 
To	   date,	   natural	   products	   still	   represent	   a	   very	   important	   source	   in	  
the	   discovery	   and	   development	   of	   new	  medicines	   and	   a	   significant	  
part	  of	  the	  therapeutic	  armamentarium	  of	  doctors	   is	  represented	  by	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natural	   medicines	   or	   natural-­‐derived	   products.6	   If	   we	   consider	   the	  
new	  drugs	  approved	  in	  2010	  by	  Food	  and	  Drugs	  Administration	  (FDA),	  
half	  of	  the	  20	  fully	  approved	  small	  molecules	  were	  natural	  products	  or	  
directly	   derived	   therefrom,	   confirming	   the	   importance	   of	   natural	  






2.	  	  OPIOID	  RECEPTORS	  
 
The	  term	  opioid	  applies	  to	  any	  substance	  that	  produces	  effects	  similar	  
to	  those	  of	  morphine	  and	  that	  are	  blocked	  from	  specific	  antagonists	  
(naloxone).	   Among	   these	   there	   are	   natural	   alkaloids,	   synthesis	   or	  
semisynthesis	   compounds,	   endogenous	   opioid	   peptides.	   These	  
substances	   act	   on	   specific	   receptors	   of	   the	   peripheral	   and	   central	  
nervous	   system	   (that	   take	   the	   generic	   name	   of	   opioid	   receptors)	  
acting	   mainly	   as	   modulators	   of	   the	   painful	   sensations	   but	   also	  
through	   specific	   transcription	   factors	   nuclear	   receptors.	   The	   term	  
opioid	   is	   frequently	   used	   improperly	   to	   indicate,	   more	   restrictively,	  
the	   alkaloids	   that	   can	   be	   found	   in	   opium,	   a	   mixture	   of	   substances	  
derived	   from	   the	   latex	   of	   Papaver	   somniferum,	   and	   their	   semi-­‐
synthetic	   derivatives;	   the	   correct	   term	   to	   describe	   these	   substances	  
is,	  instead,	  opiates.	  The	  evidence	  of	  the	  use	  of	  opium	  as	  a	  medicine	  as	  
well	   as	   a	   substance	   for	   luxury,	  dates	  back	   to	  many	   centuries	  before	  
Christ,	   given	   in	   Latin	   texts	   and	   Homer,	   and	   to	   Roman	   imperial	   and	  
Republican.7	  Opioids	   act	   on	   a	   family	   of	   receptors	   in	   the	   central	   and	  
peripheral	   nervous	   system,	   which	   includes	   four	   subtypes:	   μ	   opioid	  
receptor	  (MOR),	  δ	  opioid	  receptor	  (DOR)	  and	  κ	  opioid	  receptor	  (KOR).	  
All	   these	   receptors	   belong	   to	   the	   superfamily	   of	   G	   protein-­‐coupled	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receptors.	   The	   activation	   of	   these	   receptors	   leads	   to:	   inhibition	   of	  
adenylate	   cyclase	   and	   thereby	   reduced	   synthesis	   of	   cAMP,	   the	  
inhibition	  of	  Ca2+	  channels	  that	  results	  in	  a	  reduction	  in	  the	  release	  of	  
neurotransmitter,	   the	   opening	   of	   K+	   channels	   that	   results	   in	  
hyperpolarization	  of	  the	  membrane	  and	  reduction	  of	  nerve	  activity.7	  
G	   proteins	   involved	   in	   signal	   transduction	   are	   Gi	   (inhibitor).	   These	  
cellular	   effects	   are	   reflected	   in	   a	  wide	   variety	   of	   physical	   symptoms	  
such	   as	   analgesia	   and	   sedation,	   sleep	   induction,	   respiratory	  
depression	   (caused	   by	   opioid	   action	   at	   the	   level	   of	   the	   bulbar	  
respiratory	   centre	   sensitive	   to	   arterial	   pCO2),	   central	   nervous	  
depression,	   gastrointestinal	   motility	   inhibition	   and	   inhibition	   of	   the	  
cough	   reflex.7	   All	   opioid	   receptors	   modulate	   the	   analgesic	   action	  
although	  they	  operate	  at	  different	   levels.	  MOR:	  generating	  analgesia	  
(sovraspinal	   level),	   miosis,	   and	   respiratory	   depression,	   decrease	   in	  
gastrointestinal	   activity,	   euphoria;	   KOR:	   produces	   analgesia	   (spinal	  
level),	   miosis,	   and	   respiratory	   depression,	   dysphoria	   (unlike	   μ	  
receptors);	  DOR:	  no	  analgesia,	  but	  decreases	  the	  intestinal	  transit	  and	  
depresses	   the	   immune	   system.7	   Opioids	   tend	   to	   inhibit	   neuronal	  
transmission	  at	  both	  pre	  and	  post	  synaptic	  level.	  In	  fact,	  the	  activation	  
of	   presinaptic	   µ	   receptors	   causes	   inhibition	   of	   N-­‐type	   calcium	  
channels	  and	  thus	  a	  reduction	  in	  the	  production	  of	  neurotransmitters,	  
while	   the	   activation	   of	   µ	   postsynaptic	   receptors	   produces	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hyperpolarization	   by	   activating	   potassium	   channels	   and	   inhibiting	  
calcium	  L-­‐type. 
MOR	   is	   the	   most	   widespread	   receptor	   and	   mediate	   most	   of	   the	  
pharmacological	  effects	  of	  opioid	  analgesics. 
Physiologically	   active	   molecules	   on	   these	   receptors	   are	   the	  
endogenous	   opioids	   peptides,	   β-­‐	   endorphins,	   dynorphines	   A	   and	   B,	  
and	   enkephalins,	   endogenous	   substances	   better	   defined	   as	   opioid	  
peptides	   which	   are	   synthesized	   respectively	   starting	   from	   large	  
precursor	   peptide,	   proopiomelanocortin,	   proenkephaline	   and	  
prodinorphine,	  splitting	  by	  specific	  endopeptidase.7 
The	   endogenous	   opioids,	   β-­‐endorphins,	   dynorphines	   A	   and	   B,	   and	  
enkephalins	   exert	   their	   analgesic	   action	   at	   spinal	   and	   sovraspinal	  
level.	  They	  also	  cause	  analgesia	  with	  a	  peripheral	  action	  mechanism	  
associated	   with	   the	   inflammatory	   process.	   In	   the	   central	   nervous	  
system,	   opioids	   exert	   an	   inhibitory	   action	   on	   neurotransmitters.	   At	  
sovraspinal	   level,	   activation	   of	   opioid	   receptors	   inhibit	   neuronal	  
activity	   and	   therefore	   the	   release	   of	   noradrenaline	   from	   the	   locus	  
coeruleus	   and	   	   nucleus	   reticularis	   paragigantocellularis	   (NRPG),	   and	  
the	   release	   of	   serotonin	   from	   nucleus	   Raphe	   Magnus	   (NRM),	   with	  
inhibition	  of	  pain	   transmission.	  MOR	  agonists	  prevent	   the	  release	  of	  
the	   inhibitory	   transmitter	   GABA	   activating	   the	   Periaqueductal	   grey	  
(PAG)	  systems	  that	  regulate	  the	  activity	  of	  the	  bulb.8	  In	  particular,	  the	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GABA	   transmission	   can	   have	   opposite	   effects	   on	   pain	   processing	   in	  
relation	   to	   its	   location	   within	   the	   central	   nervous	   system;	   its	  
activation	  causes	  analgesia	  at	  spinal	  level,	  while	  it	  is	  pronociceptive	  at	  
sopraspinal	  level.9,10	  The	  systemic	  administration	  of	  GABAA	  and	  GABAB	  
agonists	   such	   as	   benzodiazepines	   increases	   the	   opioid-­‐induced	  
analgesia11,12	  and	  attenuates	  the	  development	  of	  tolerance.13	  
Opioids	  also	  exert	  a	  neuromodulator	  action	  of	  pain	  signal	  on	  afferent	  
neurons	   located	   in	   the	   dorsal	   horn	   of	   the	   spinal	   cord	   and	   neuronal	  
interconnection	  paths	  for	  pain	  signal	  transmission	  in	  the	  brain.	  
At	  spinal	   level,	  the	  activation	  of	  k	  and	  µ	  receptors	  blocks	  the	  release	  
of	   substance	   P,	   peptide	   released	   following	   a	   skin	   lesion	   from	   the	  
fibers	   relating	   to	   the	   rear	  horns	  of	   the	   spinal	   cord.	   Substance	  P	   is	   a	  
neurotransmitter	   of	   the	   anguished	   transmission,	   so	   blocking	   its	  
release	  also	  locks	  the	  transmission	  of	  pain	  information.14	  
Glutamate	  is	  the	  primary	  excitatory	  neurotransmitter	  involved	  in	  the	  
transmission	   of	   nociceptive	   stimuli	   at	   spinal	   level.10	   In	   addition,	   N-­‐
Methyl-­‐D-­‐Aspartate	  (NMDA)	  receptor	  sensitization	  on	  spinal	  neurons	  
play	  a	  key	  role	   in	  the	  development	  of	  tolerance	   induced	  by	  opioids.8	  
Consistently,	   the	   co-­‐administration	   of	   NMDA	   receptor	   antagonists	  







2.1	  Natural	  Opioids	  Ligands	  	  
As	   mentioned	   before,	   the	   investigation	   of	   natural	   products	   has	  
proven	   to	   be	   an	   excellent	   source	   of	   clinical	   agents	   for	   a	   number	   of	  
therapeutic	  areas	  including	  pain.6	  	  
Morphine	  (Figure	  1)	   is	  the	  most	  abundant	  opiate	  found	  in	  opium	  (8-­‐
14%	  of	  dry	  weight),	  the	  dried	  latex	  is	  obtained	  by	  shallowly	  slicing	  the	  
unripe	   seedpods	   of	   the	   Papaver	   somniferum	   poppy.	   Morphine	   was	  
the	  first	  active	  principle	  purified	  from	  a	  plant	  source	  and	  is	  one	  of	  at	  










	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




Morphine	   is	   primarily	   used	   to	   treat	   both	   acute	   and	   chronic	   severe	  
pain	   for	   example	   in	   myocardial	   infarction,	   in	   cancer	   pain	  and	   for	  
labour	  pains.7 
In	  fact	   like	  other	  opioids,	   it	  acts	  directly	  on	  µ	  receptor	  of	  the	  central	  
nervous	  system	  (CNS)	   to	   relieve	  pain.	  Morphine	  has	  a	  high	  potential	  
for	  addiction;	   tolerance	   and	   psychological	   dependence	  develop	  
rapidly.	   Tolerance	   to	   respiratory	   depression	   and	   euphoria	   develops	  
more	   rapidly	   than	   tolerance	   to	   analgesia,	   and	   many	   chronic	   pain	  
patients	  are	  being	  maintained	  on	  a	  stable	  dose,	  for	  many	  years.7	  
In	   addition	  morphine	   acts	   on	   the	  myenteric	   plexus	  in	   the	   intestinal	  
tract,	  reducing	  gut	  motility,	  causing	  constipation.	  The	  gastrointestinal	  
effects	   of	   morphine	   are	   mediated	   primarily	   by	   µ	   receptors	  in	   the	  
bowel.7	  
New	   natural	   therapies	   are	   currently	   being	   explored	   as	   analgesic	  
potential	  alternatives	  to	  morphine	  and	  derivatives.17 
Kratom	  (Mitragyna	  speciosa	  Korth.,	  Rubiaceae)	  is	  an	  indigenous	  herb	  
of	   Southeast	   Asia	   that	   is	   traditionally	   used	   to	   treat	   fever,	   diarrhea,	  
fatigue,	   pain,	   and	   as	   a	   substitute	   for	   morphine	   in	   treating	   opioid	  
addicts.	   The	   main	   component	   of	   kratom	   is	   the	   indole	   alkaloid	  
mitragynine	  (Figure	  2),	  which	  has	  been	  reported	  to	  have	  affinities	  for	  
all	  three	  opioid	  receptors,	  though	  it	  appears	  to	  be	  relatively	  selective	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for	   MOP	   receptors.	   Additionally,	   other	   constituents	   of	   kratom	   and	  
derivatives	   of	   mitragynine,	   as	   pseudoindoxyl	   and	   7-­‐
hydroxymitragynine,	  have	  also	  been	  found	  to	  have	  affinity	  for	  opioid	  
receptors	  (Figure	  2).17	  
	  
	  
	   	   	   	   	   	   	   	   	  
mitragynine	  	  	  	  	  	  	  pseudoindoxyl-­‐mitragynine	  	  	  	  	  	  	  7-­‐hydroxymitragynine	  
	  
	  	  	  	  	  	  	  	  	  Figure	  2.	  	  Structures	  of	  Mitragyna	  speciosa	  alkaloids	  	  
	  
Research	   interest	   in	  mitragynine	   stems	   from	   its	   increasing	   use	   as	   a	  
remedy	   for	   opioid	   withdrawal	   by	   individuals	   who	   self-­‐treat	   chronic	  
pain.	  In	  addition	  this	  compound	  is	  known	  to	  produce	  antinociception	  
in	  mice	  in	  the	  hot-­‐plate	  and	  in	  the	  tail-­‐flick	  tests.17	  However,	  the	  exact	  
mechanisms	   underlying	   the	   effect	   of	   mitragynine	   are	   currently	  
unknown.	   It	   has	   been	   hypothesized	   that	   the	   MOP	   agonism	   of	  
mitragynine	   might	   avert	   withdrawal	   symptoms,	   while	   KOP	   agonism	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might	   attenuate	   reinforcement	   and	   blunt	   cravings.	   The	   collective	  
findings	  of	  the	  effects	  of	  mitragynine	   indicate	  that	  the	  molecule	  and	  
its	  derivatives	  may	  be	  useful	   for	   the	  development	  of	  new	  analgesics	  
and	  possibly	  for	  the	  treatment	  of	  opioid	  abuse.17 
Selective	  KOP	  agonists	  are	  also	  capable	  of	  producing	  clinically	  useful	  
analgesia,	   but	   lack	   the	   respiratory	   depression,	   constipation,	   and	  
addictive	   properties	   associated	  with	  MOP	   agonists.	   However,	   a	   side	  
effect	  associated	  with	  activation	  of	  KOP	   receptors	   is	  dysphoria.	   Still,	  
KOP	  agonists	  are	  targets	  for	  achieving	  pain	  relief	  without	  the	  negative	  
side	  effects	  associated	  with	  MOP	  agonists.	  Although	  KOP	  agonists	  are	  
known	   to	   produce	   dysphoric	   effects,	   there	   is	   still	   some	  hope	   that	   a	  
clinically	  useful	  analgesic	  may	  be	  found.17 
Salvinorin	   A,	   a	   neo-­‐clerodane	   diterpene	   (Figure	   3),	   is	   the	   active	  
hallucinogenic	  component	  in	  the	  Mexican	  mint	  plant	  Salvia	  divinorum	  
(Lamiaceae).	   This	   plant	   has	   been	   used	   by	   the	   Mazatec	   Indians	   in	  
Oaxaca,	  Mexico,	   as	   a	   hallucinogenic	   agent,	   and	   to	   relieve	   diarrhea,	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  3.	  Structure	  of	  salvinorin	  A	  
	  
	  
However,	  until	   recently,	   the	   target	  of	   the	  hallucinogenic	  effects	  was	  
not	  clear,	  as	  Salvinorin	  A	   lacks	  activity	  at	  the	  targets	  of	  other	  known	  
hallucinogens,	   specifically	   serotonin	   receptors,	   cholinergic	   receptors,	  
and	  cannabinoid	  receptors. 
In	   2002,	   Salvinorin	   A	   was	   identified	   as	   a	   potent	   and	   selective	   KOP	  
agonist.	  This	  result	  is	  surprising	  considering	  that	  Salvinorin	  A	  lacks	  the	  
basic	  nitrogen	   that	  has	   long	  been	   thought	   to	  be	   required	   for	  opioid	  
activity.	   However,	   given	   the	   known	   hallucinogenic	   effects	   of	   other	  
KOP	  agonists,	  this	  finding	  is	  not	  unprecedented.	  Salvinorin	  A	  produces	  
a	   discriminative	   effect	   in	   both	   rats	   and	   non-­‐human	   primates	   that	   is	  
similar	   to	   other	   KOP	   agonists.	   It	   has	   also	   been	   shown	   to	   produce	  
analgesia	  in	  mice	  that	  can	  be	  blocked	  by	  a	  KOP	  receptor	  antagonist.17	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Another	   natural	   opioid	   is	   ibogaine	   (Figure	   4),	   an	   indole	   alkaloid	  
isolated	   from	   the	   root,	   root-­‐bark,	   stems,	   and	   leaves	   of	   the	   African	  
shrub	   Tabernanthe	   iboga.	   This	   plant	   has	   been	   used	   by	   indigenous	  
people	  in	  low	  doses	  to	  combat	  fatigue	  and	  hunger	  and	  in	  higher	  doses	  
as	   a	   sacrament	   in	   religious	   rituals.	   The	   psychopharmacology	   of	  
ibogaine	   is	   complex	   due	   to	   its	   affinity	   for	   several	   receptors,	  
transporters,	  and	  ion	  channels.	  In	  addition,	  its	  primary	  metabolite,	  12-­‐
hydroxyibogamine,	   is	   also	   biologically	   active.	   The	   most-­‐studied	  
therapeutic	   effect	   of	   ibogaine	   is	   the	   reduction	   or	   elimination	   of	  
addiction	  to	  opioids.	  The	  mechanism	  by	  which	  ibogaine	  exerts	  its	  anti-­‐
addictive	   effects	   is	   presently	   unknown	   although	   several	   receptor	  
systems	   have	   been	   implicated	   in	   its	   activity.	   	   However,	   it	   has	   been	  
speculated	   that	   its	   k	   agonist	   actions	   contribute	   to	   its	   effects	   on	  
stimulant	   self-­‐administration	   and	   analogs	   of	   ibogaine	   are	   currently	  
being	  explored	  as	  potentially	  safer	  medications.18	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  4.	  Structure	  of	  ibogaine	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3. CANNABINOID RECEPTORS 
	  
The	   cannabinoid	   receptors	   are	   a	   class	   of	   cell	   membrane	   receptors	  
under	  the	  	  G	  protein-­‐coupled	  receptor	  superfamily19-­‐21	  which	  contain	  
seven	  transmembrane	  spanning	  domains.22	  
There	   are	   currently	   two	   known	   subtypes,	   termed	   CB1	   and	   CB223,24.	  
(Figure	  5).	  The	  CB1	  receptor	  is	  expressed	  mainly	  in	  the	  brain,	  but	  also	  
in	  the	  lungs,	   liver	  and	  kidneys.	  The	  CB2	  receptor	   is	  expressed	  mainly	  
in	  the	  immune	  system	  and	  in	  hematopoietic	  cells.25	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  5.	  	  CB1	  and	  CB2	  receptors	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Cannabinoid	  receptors	  are	  activated	  by	  three	  major	  groups	  of	  ligands,	  
endocannabinoids	   (such	   as	   anandamide	   and	   2-­‐arachidonoylglycerol	  
(2-­‐AG)	  (Figure	  6),	  phytocannabinoids	  (such	  as	  Δ9-­‐THC	  and	  alkylamides,	  
found	  in	  Cannabis	  and	  Echinacea	  species,	  respectively)	  (Figure	  7)	  and	  
synthetic	  cannabinoids	  (such	  as	  HU-­‐210).	  All	  of	  the	  endocannabinoids	  
and	   phytocannabinoids	   are	   lipophilic,	   i.e.	   fat	   soluble,	   compounds.	  
Cannabinoids	   bind	   reversibly	   and	   stereo-­‐selectively	   to	   the	  
cannabinoid	  receptors.	  	  
	  
	  
(1) 	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  (2)	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After	   the	   receptor	   is	   engaged,	   multiple	   intracellular	   signal	  
transduction	   pathways	   are	   activated.	   At	   first,	   it	   was	   thought	   that	  
cannabinoid	  receptors	  mainly	  inhibited	  the	  enzyme	  adenylate	  cyclase	  
(and	  thereby	  the	  production	  of	  the	  second	  messenger	  molecule	  cyclic	  
AMP),	   and	   positively	   influenced	   inwardly	   rectifying	   potassium	  
channels	   (=Kir	   or	   IRK).	   However,	   a	  much	  more	   complex	   picture	   has	  
appeared	   in	   different	   cell	   types,	   implicating	   other	   potassium	   ion	  
channels,	  Ca2+	  channels,	  protein	  kinase	  A	  and	  C,	  Raf-­‐1,	  ERK,	  p38,	   c-­‐
fos,	  c-­‐jun	  and	  many	  more.26	  
Separation	   between	   the	   therapeutically	   undesirable	   psychotropic	  
effects,	  and	   the	  clinically	  desirable	  ones	  has	  not	  been	  reported	  with	  
agonists	   that	   bind	   to	   cannabinoid	   receptors.	   Δ9-­‐THC,	   as	   well	   as	   the	  
two	  major	  endogenous	  compounds	  identified	  so	  far,	  anandamide	  and	  
2-­‐arachidonylglycerol,	  that	  bind	  to	  the	  cannabinoid	  receptor,	  produce	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most	  of	   their	  effects	  by	  binding	   to	  both	   the	  CB1	  and	  CB2	   receptors.	  
While	   the	   effects	   mediated	   by	   CB1,	   mostly	   in	   the	   central	   nervous	  
system,	   have	   been	   thoroughly	   investigated,	   those	  mediated	   by	   CB2	  
are	  not	  equally	  well	  defined.27	  
	  
3.1	  CB1	  Receptor	  	  
CB1	   receptors	   are	   expressed	   most	   densely	   in	   the	   central	   nervous	  
system	   and	   are	   largely	   responsible	   for	   mediating	   the	   effects	   of	  
cannabinoid	  binding	  in	  the	  brain.	  
The	  analgesic	  effects	  of	  cannabinoids	  are	  based	  on	  the	  interaction	  of	  
these	  compounds	  with	  CB1	  receptors	  on	  spinal	  cord	   interneurons	   in	  
the	  superficial	  levels	  of	  the	  dorsal	  horn.	  Signals	  on	  this	  track	  are	  also	  
transmitted	   to	   the	   periaqueductal	   gray	   (PAG)	   of	   the	   midbrain.	  
Endogenous	  cannabinoids	  are	  believed	   to	  exhibit	  an	  analgesic	  effect	  
on	  these	  receptors	  by	  limiting	  both	  GABA	  and	  glutamate	  of	  PAG	  cells	  
that	  relate	  to	  nociceptive	  input.28	  
They	   are	   also	   found	   in	   other	   parts	   of	   the	  body.	   For	   instance,	   in	   the	  
liver,	   activation	   of	   the	   CB1	   receptor	   is	   known	   to	   increase	   de	   novo	  
lipogenesis.29	  Activation	  of	  presynaptic	  CB1	  receptors	  is	  also	  known	  to	  
inhibit	   sympathetic	   innervation	   of	   blood	   vessels	   and	   contributes	   to	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the	   suppression	   of	   the	   neurogenic	   vasopressor	   response	   in	   septic	  
shock.30	  
Inhibition	   of	   gastrointestinal	   activity	   has	   been	   observed	   after	  
administration	  of	  Δ9-­‐THC	  or	  anandamide.	  This	  effect	  is	  assumed	  to	  be	  
CB1-­‐mediated,	   since	   this	   receptor	   is	   expressed	   by	   the	   peptide	  
hormone	   cholecystokinin,	   and	   application	   of	   the	   CB1-­‐specific	  
antagonist	  SR	  141716A	  	  Rimonabant	  	  blocks	  the	  effect.31	  
Cannabinoids	   are	   well	   known	   for	   their	   cardiovascular	   activity.	  
Activation	   of	   peripheral	   CB1	   receptors	   contributes	   to	   hemorrhagic	  
and	   endotoxin-­‐induced	   hypotension.	   Anandamide	   and	   2-­‐AG,	  
produced	   by	  macrophages	   and	   platelets,	   respectively,	  may	  mediate	  
this	  effect.32	  
Many	   studies	   suggest	   that	   the	   effects	   of	   endocannabinoids	   on	  
memory	  are	  dependent	  on	  what	  type	  of	  neurons	  are	  being	  targeted	  
(excitatory	   vs.	   inhibitory)	   and	   the	   location	   of	   these	   networks	   in	   the	  
brain.33	  
Evidence	  for	  the	  role	  of	  the	  endocannabinoid	  system	  in	  food-­‐seeking	  
behavior	  comes	  from	  a	  variety	  of	  cannabinoid	  studies.	  Emerging	  data	  
suggest	  that	  Δ9-­‐THC	  acts	  via	  CB1	  receptors	  in	  the	  hypothalamic	  nuclei	  




3.2	  CB2	  Receptor	  	  
CB2	  receptors	  are	  found	  throughout	  tissues	  of	  the	  spleen,	  tonsils,	  and	  
thymus	  gland	  mainly	  expressed	  on	  T	  cells	  of	  the	   immune	  system,	  on	  
macrophages	  and	  B	  cells,	  and	  in	  hematopoietic	  cells.	  When	  activated,	  
they	   too	   can	  affect	   the	   release	  of	   chemical	  messengers,	   in	   this	   case	  
the	   secretion	   of	   cytokines	   by	   immune	   cells,	   and	   can	   in	   addition	  
modulate	   immune	   cell	   trafficking.35	   They	   are	   also	   expressed	   on	  
peripheral	   nerve	   terminals,	   playing	   a	   role	   in	   antinociception,	   or	   the	  
relief	   of	   pain.	   In	   the	   brain,	   they	   are	  mainly	   expressed	   by	  microglial	  
cells,	  where	  their	  role	  remains	  unclear.	  
To	   be	   specific,	   this	   receptor	   has	   been	   implicated	   in	   a	   variety	   of	  
modulatory	   functions,	   including	   immune	   suppression,	   induction	   of	  
apoptosis	  and	  of	  cell	  migration.36	  
Therefore,	  they	  are	  also	  expressed	  in	  the	  brain,	  though	  not	  as	  densely	  
as	   the	   CB1	   receptor	   and	   are	   located	   on	   different	   cells.37	   Unlike	   the	  
CB1	   receptor,	   in	   the	   brain,	   CB2	   receptors	   are	   found	   primarily	   on	  
microglia,	  but	  not	  on	  neurons.	  
CB2	  receptors	  are	  also	  found	  throughout	  the	  gastrointestinal	  system,	  
where	   they	   modulate	   intestinal	   inflammatory	   response.	   Thus,	   CB2	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receptor	  agonists	  are	  a	  potential	  therapeutic	  target	  for	  inflammatory	  
bowel	  diseases,	  such	  as	  Crohn's	  disease	  and	  ulcerative	  colitis.38,39	  
The	  endocannabinoid	  system,	  through	  CB2	  signaling,	  plays	  a	  key	  role	  
in	   the	  maintenance	   of	   bone	  mass:	   CB2	   are	   expressed	   in	   osteoblast,	  
osteocytes	   and	   osteoclast.	   CB2	   agonists	   enhance	   endocortical	  
osteoblast	   number	   and	   activity	   while	   restraining	   trabecular	  
osteoclastogenesis.	   Another	   important	   effect	   is	   that	   CB2	   agonists	  
attenuate	   ovariectomy-­‐induced	   bone	   loss	   while	   increasing	   cortical	  
thickness.	   These	   findings	   suggest	   CB2	   offers	   a	   potential	   molecular	  
target	  for	  the	  diagnosis	  and	  treatment	  of	  osteoporosis.40	  
	  
3.3	  Natural	  Cannabinoids	  Ligands	  	  
Cannabis	   sativa	   have	   been	   used	   for	   centuries	   and	   are	   known	   to	  
produce	  an	  analgesic	  effect	  in	  addition	  to	  hallucinogenic	  effects	  such	  
as	  feelings	  of	  dissociation	  from	  reality.	  Cannabinoids	  are	  divided	  into	  
two	   categories:	   classical	   cannabinoids	   and	   non-­‐classical	  
cannabinoids.41	  
Classical	   cannabinoids	  are	   tricyclic	  dibenzopyran	  derivatives	   that	  are	  
both	   natural	   and	   obtained	   by	   semisynthesis	   starting	   from	   the	   first	  
one.	   This	   group	   of	   molecules	   is	   exemplified	   by	   Δ9-­‐THC;	   the	   main	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psychotropic	   principle	   of	   cannabis.	   Non-­‐classical	   cannabinoids	  
emerged	  from	  Pfizer	  SAR	  studies	  of	  the	  classical	  cannabinoids.41	  	  
These	   compounds	   are	  devoided	  of	   the	  dihydropyran	   ring	  present	   in	  
Δ9-­‐THC,	  as	  for	  example	  CP47497	  (Figure	  8).42	  	  
Δ9-­‐THC	  acts	  as	  an	  agonist	  with	  efficacy	  similar	  to	  that	  of	  anandamide.	  
It	  has	  been	  suggested	  that	  the	  hallucinogenic	  effects	  of	  	  	  Δ9-­‐THC	  arise	  
from	   the	   compound’s	   ability	   to	  mimic	   the	   action	   of	   anandamide	   at	  
cannabinoid	   receptors,	   while	   simultaneously	   antagonizing	   2-­‐AG	   at	  
these	   same	   receptors.	   This	   hypothesis	   is	   supported	   by	   the	  
observation	  that	  a	  single	  high	  dose	  of	  a	  CB1	  receptor	  antagonist	  has	  
only	   a	   limited	   ability	   to	   block	   the	   subjective	   effects	   of	   cannabis	  
ingestion.43	  
Dronabinol44,48	  is	  the	  pure	  isomer	  of	  Δ9-­‐THC,	  which	  is	  the	  main	  isomer	  
found	  in	  cannabis.	  It	  is	  sold	  as	  Marinol	  (Figure	  8)	  and	  considered	  to	  be	  
non-­‐narcotic	  with	  low	  risk	  of	  physical	  or	  mental	  dependence.	  Marinol	  
has	  been	  approved	  by	  the	  U.S.	  Food	  and	  Drugs	  Administration	  (FDA)	  
for	   the	   treatment	   of	   anorexia	   in	   AIDS	   patients,	   as	   well	   as	   for	  
refractory	   nausea	   and	   vomiting	   of	   patients	   undergoing	  
chemiotherapy.	  
An	   analog	   of	   Dronabinol,	   Nabilon44,48	   (Figure	   8),	   is	   available	  
commercially	   in	   Canada	   under	   the	   trade	   name	   Cesamet,	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manufactured	  by	  Valeant	  Pharmaceuticals.	  Cesamet	  has	  also	  received	  
FDA	  approval	  and	  began	  being	  marketed	  in	  the	  U.S.	  in	  2006.	  
Female	  cannabis	  plants	  contain	  more	  than	  60	  cannabinoids	  including	  
cannabindiol,	   thought	   to	   be	   the	   major	   anticonvulsivant	   that	   helps	  
multiplesclerosis	  patients45,	  and	  cannabichromene	  (Figure	  8),	  an	  anti-­‐
inflammatory	   	   which	   may	   contribute	   to	   the	   pain-­‐killing	   effect	   of	  
cannabis.46	   It	   takes	  over	  one	  hour	   for	  Marinol	   to	   reach	   full	   systemic	  
effect47compared	   to	   seconds	   or	   minutes	   for	   smoked	   or	   vaporized	  
cannabis.48	  
Recent	  advances	  in	  the	  understanding	  of	  the	  endocannabinoid	  system	  
have	   broadened	   the	   therapeutic	   possibilities	   resulting	   from	   its	  
manipulation.	  CB1	  receptor	  antagonists	  have	  received	  the	  most	  of	  the	  
attention	   of	   the	   potential	   drugs	   affecting	   the	   endocannabinoid	  
system.	   Their	   primary	   indication	   is	   for	  obesity.	   The	   rationale	  behind	  
this	   indication	   lies	   in	   the	  generally	  accepted	  notion	  that	   ingestion	  of	  
cannabis	   enhances	   the	   appetite,	   resulting	   in	   increased	   consumption	  
of	  rich	  foods.	  Therefore,	  CB1	  receptor	  antagonists	  should	  function	  to	  
reduce	   the	   appetite,	   thereby	   reducing	   caloric	   intake	   and	   body	  
weight.49,50	   The	   first	   reported	   CB1	   receptor	   antagonist	   was	  
rimonabant	  	  (SR141716,	  Accomplia)51	  (Figure	  8)	  wich	  show	  nanomolar	  
affinity	  for	  CB1	  receptors,	  and	  little	  affinity	  for	  CB2	  receptors.	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Another	  indication	  for	  CB1	  receptor	  antagonists	  is	  in	  the	  treatment	  of	  
drug	   abuse.	   Several	   studies	   in	   animals	   have	   observed	   that	   CB1	  
receptor	   antagonists	   such	   as	   rimonabant	   reduce	   the	   rewarding	  
properties	   of	   opioid	   receptor	   agonists.52-­‐55	   In	   fact,	   these	   rewarding	  
properties	   are	   absent	   in	   CB1	   receptor	   knock-­‐out	   mice.57	   However,	  
opioid	   receptors	   do	   not	   seem	   to	   be	   involved	   in	   the	   hallucinogenic	  
effects	   of	   CB1	   receptor	   agonists,	   as	   opioid	   receptor	   antagonists	   do	  
not	  block	  these	  effects.58	  Also,	  the	  CB1	  receptor	  seems	  to	  be	  involved	  
in	   responses	   to	  both	  nicotine	  and	  alcohol;	   CB1	   receptor	   antagonists	  
are	  able	  to	  block	  nicotine-­‐induced	  conditioned	  place	  preference	  (CPP)	  
and	   to	   decrease	   alcohol	   consumption.58	   In	   October	   2008,	   the	  
European	  Medicines	  Agency’s	  Committee	   for	  Medicinal	  Products	   for	  
Human	   Use	   (CHMP)	   had	   determined	   that	   the	   risks	   	   of	   	   Accomplia	  
outweighed	  its	  benefits,	  and	  subsequently	  recommended	  the	  product	  
be	  suspended	  from	  the	  UK	  market	  and	  doctors	  not	  prescribe	  the	  drug	  
due	  to	  the	  risk	  of	  serious	  psychiatric	  problems	  and	  even	  suicide.	  
Extracts	  of	  Cannabis	   are	   known	   to	  produce	  analgesic	  effect.	   In	  April	  
2005,	   Canadian	   authorities	   approved	   the	   marketing	   of	   Sativex,	   a	  
mouth	  spray	  for	  multiple	  sclerosis	  patients,	  who	  can	  use	  it	  to	  alleviate	  
neuropathic	   pain	   and	   spasticity.	   Sativex	   contains	  
tetrahydrocannabinol	  together	  with	  cannabindiol	  and	  is	  a	  preparation	  
of	   whole	   cannabis	   rather	   than	   individual	   cannabinoids.45	   It	   is	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marketed	  in	  Canada	  by	  GW	  Pharmaceuticals	  and	  is	  the	  first	  cannabis-­‐
based	  prescription	  drug	   in	   the	  world	   (in	  modern	   times).	   In	  addition,	  
Sativex	  received	  European	  regulatory	  approval	  in	  2010.	  
A	  particularly	  attractive	  feature	  of	  selective	  CB2	  receptor	  agonists	  as	  
therapeutics	   is	   that	   they	   are	   devoid	   of	   any	   known	   hallucinogenic	  
effects	  such	  as	  those	  associated	  with	  CB1	  receptor	  agonists.50	  
Since	  CB2	  receptors	  are	  believed	  to	  play	  an	  important	  role	  in	  distinct	  
pathophysiological	   processes,	   including	   metabolic	   dysregulation,	  
inflammation,	   pain,	   and	  bone	   loss,	   they	   have,	   therefore,	   become	  of	  
interest	   as	   new	   targets	   in	   drug	   discovery.	   Recently,	   some	  
phytocannabinoids	  have	  been	  identified	  as	  selective	  CB2	  agonist	  and,	  
among	  all,	  a	  few	  fatty	  acid	  amides	  isolated	  from	  Echinacea	  purpurea	  
that	   justify	   the	   use	   of	   Echinacea	   as	   herbal	   immunomodulators	  
worldwide	  plant.59	  
Another	   phytocannabinoid	   that	   act	   as	   potent	   and	   selective	   CB2	  
agonist	   is	   the	   sesquiterpene	  β-­‐caryophyllene.5	   This	   compound	   have	  
been	   identified	   in	   many	   food	   plants	   and	   also	   in	   Cannabis	   sativa	   L.	  
essential	   oil.	   β-­‐caryophyllene	   showed	   high	   oral	   bioavailabilty	   and	  
strong	   anti-­‐inflammatory	   and	   analgesic	   effects	   and	   may	   be	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4.	  	  AIM	  OF	  THE	  WORK	  
 
In	  our	  continuous	  search	  for	  plant	  secondary	  metabolites	  that	  bind	  to	  
CB	   and/or	   opioid	   receptors,	   we	   selected	   four	   extracts	   that	   showed	  
interesting	  affinity	  versus	  the	  above	  mentioned	  receptors	  (Table	  1).	  In	  
particular:	  the	  DCM	  extract	  obtained	  from	  the	  aerial	  parts	  of	  Stachys	  
glutinosa	   (SGE)	  was	  able	   to	  bind	  with	  a	  good	  affinity	  both	  MOR	  and	  
DOR	  with	  a	  Ki	  of	  10.3	  and	  9	  µg/mL,	  respectively	  while	  the	  DCM	  extract	  
from	   the	   leaves	  of	  Otanthus	  maritimus	   (OME)	   showed	  good	  binding	  
affinity	  to	  CB1	  (Ki	  =	  2.2	  µg/mL)	  and	  CB2	  (Ki	  =	  1.3	  µg/mL)	  and	  moderate	  
affinity	  to	  MOR	  and	  DOR.	  The	  third	  was	  an	  alkaloid	  fraction	  obtained	  
from	   the	  MeOH	   extract	   of	   the	   roots	   of	  Withania	   somnifera	   (WSAE)	  
that	  displayed	  appreciable	  affinity	  versus	  DOR	  (Ki	  =	  25.5	  µg/mL),	  CB1	  
(Ki	  =	  23.5	  µg/mL),	  CB2	  (Ki	  =	  20.3	  µg/mL)	  and	  GABAA	  (Ki	  =	  14	  µg/mL).	  
The	   in	   toto	  MeOH	  extract	   (WSE)	   bound	  with	   very	   low	  affinity	   to	  CB	  
and	   opioid	   receptors	   but	   displayed	   interesting	   affinity	   to	   GABAA	  
receptors	  (Ki	  =	  14	  	  µg/mL)	  (Table	  1).	  
Based	  on	  this	  results	  this	  study,	  carried	  out	  in	  collaboration	  with	  the	  
group	   of	   Dr.	   Stefania	   Ruiu	   of	   CNR-­‐Institute	   of	   Translational	  
Pharmacology	  of	  	  Cagliari,	  aimed	  to:	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1. Isolate	  the	  secondary	  metabolites	  that	  were	  responsible	  of	  the	  
observed	  binding	  affinity	  
2. 	  Identify	   the	   compounds	   by	   spectrometric	   and	   spectroscopic	  
methods	  
3. Evaluate	   the	   binding	   affinity	   of	   the	   isolated	   metabolites	   to	  
opioid	  and	  cannabinoid	  receptors.	  
4. Evaluate	   the	   most	   potent	   and	   abundant	   compounds	   in	  




Table	  1.	   Ki	   values	  of	  OME,	   SGE,	  WSE,	   and	  WSAE	  extracts	   for	  opioid,	  
cannabinoid,	  GABAA	  receptors	  
Receptor	  affinity	  (µg/ml)	  
	  
Extract	   µ	   δ	   k	   CB1	   CB2	   GABAA 
	         
OME	   10 ± 0.7 8.5 ± 1.3 - 2.2 ± 0.9 1.3 ± 0.3 - 
 
SGE	   10.3± 0.2 9.0 ± 1 - - - - 
 
WSE	   385 ± 14	   166 ± 11	   775 ± 56	   837 ± 74	   >1000	   13 ± 2 
	  
WSAE	   60 ± 7 25.5 ± 6 700 ± 120 23.5 ± 1 20.3 ± 2 14 ± 0.5 






5. METHODOLOGY	  OF	  ISOLATION	  PROCEDURE	  
 
The	   isolation	   of	   a	   natural	   product	   can	   be	   divided	   into	   three	   main	  
stages:	  extraction,	  fractionation,	  and	  purification.	  	  
	  
5.1	  Extraction	  	  
The	  first	  stage	  of	  the	  isolation	  procedure	  is	  the	  release	  of	  compounds	  
from	  the	  cell	  mass	  and	  the	  removal	  of	  bulk	  of	   the	  biomass.	  Most	  of	  
the	   bulk	   of	   biomass	   exists	   as	   fairly	   inert,	   insoluble,	   and	   often	  
polymeric	  material,	   such	   as	   the	   cellulose	   of	   plants.	   The	   first	   step	   of	  
the	   extraction	   is	   to	   release	   and	   solubilize	   the	   smaller	   secondary	  
metabolites	   by	   a	   thorough	   extraction	   with	   an	   organic	   solvent	   or	  
water.	  This	  can	  be	  done	  by	  a	  series	  of	  of	  stepwise	  extractions,	  using	  
solvents	  of	  varying	  polarity,	  which	  acts	  as	  the	  first	  fractionation	  step,	  
or	  by	  using	  a	  single	  solvent	  such	  as	  methanol,	  which	  should	  dissolve	  
most	  natural	  products.	  	  
	  




The	  second	  stage,	  the	  fractionation,	  consists	  to	  remove	  the	  most	  part	  
of	   the	   unwanted	   material	   and	   to	   obtain	   a	   crude	   separation	   of	   the	  
compounds	   mixture.	   Such	   step	   may	   involve	   vacuum	   liquid	  
chromatography	  and	  liquid-­‐liquid	  extractions.	  	  
	  
5.3	  Vacuum	  Liquid	  Chromatography	  (VLC)	  	  
VLC	   is	   a	   very	   convenient	   and	   simple	   chromatograpy	  method	   that	   is	  
able	  to	  produce	  good	  resolution	  in	  short	  time.	  This	  technique	  involves	  
the	  use	  of	   reduced	  pressure	   to	   increase	   the	   flow	   rate	  of	   the	  mobile	  
phase	  through	  a	  short	  bed	  of	  stationary	  phase:	  most	  of	  the	  stationary	  
phase	  could	  be	  used	  (silica	  gel,	  reversed	  phase	  material	  or	  aluminium	  
oxide)	  and	  the	  technique	  is	  applicable	  to	  large	  scale	  separations.	  The	  
advantage	  of	  this	  procedure	  includes	  its	  simplicity	  of	  equipment,	  low	  
cost	  of	  operation	  and	  low	  solvent	  consumption,	  as	  well	  as	  the	  speed	  
of	   separation.	   The	   disadvantage	   is	   that	   the	   resolution	   is	   only	  
moderate.	  	  
	  
5.4	  Purification	  	  
The	   purification	   is	   the	   last	   step	   and	   consists	   in	   a	   high-­‐resolution	  
separation	   giving	   a	   single	   pure	   compound.	   This	   procedure	   involves	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chromatographic	   techniques	   such	   as	   open	   column	   chromatography	  
and	  High	  Performance	  Liquid	  Chromatography.	  
	  
5.5	  Open	  Column	  Chromatography	  	  
The	   gravity-­‐driven	   open	   column	   chromatography	   method	   is	   still	  
widely	  used	  in	  natural	  product	  chemistry,	  as	   it	  reprsents	  a	  rapid	  and	  
efficent	  techiques	  to	  obtain	  pure	  compouds.	  The	  separation	  is	  based	  
on	   differential	   partitioning	   between	   the	   mobile	   and	   stationary	  
phases.	  Subtle	  differences	  in	  a	  compound's	  partition	  coefficient	  result	  
in	   differential	   retention	   on	   the	   stationary	   phase	   and	   thus	   changing	  
the	  separation.	  The	  main	  advantage	  of	  column	  chromatography	  is	  the	  
relatively	   low	   cost	   and	   disposability	   of	   the	  stationary	   phase	  used	   in	  
the	  process.	  The	  most	  used	  stationary	  phase	  is	  silica	  gel.	  The	  chemical	  
nature	  of	   the	  surface	  of	  silica	  gel	  consists	  of	  exposed	  silanol	  groups.	  
These	  hydroxyl	  groups	  are	  the	  active	  centers	  and	  potentially	  can	  form	  
strong	   hydrogen	   bonds	   with	   compounds	   being	   chromatographed.	  
Thus,	   in	   general,	   the	   stronger	   the	   hydrogen-­‐bonding	   potential	   of	   a	  
compound,	  the	  stronger	  it	  will	  be	  retained	  by	  silica	  gel,	  so	  that	  polar	  
compounds	   are	   strongly	   adsorbed,	   while	   non-­‐polar	   molecules	   are	  
poorly	   or	   non-­‐retained	   on	   silica	   gel.	   Other	   stationary	   phases	   are	  






5.6	  High	  Performance	  Liquid	  Chromatography	  	  
Preparative	   High	   Performance	   Liquid	   Chromatography	   (HPLC)	   is	   a	  
versatile	   and	   widely	   used	   technique	   for	   the	   final	   purification	   of	  
natural	   compound.	   The	   main	   difference	   between	   HPLC	   and	   other	  
models	   of	   column	   chromatography	   is	   that	   the	   diameter	   of	   the	  
stationary	  phase	  particles	   is	   comparatively	   low	   (3-­‐10	  µm)	  and	   these	  
particles	   are	   tightly	   packed	   to	   give	   a	   very	   uniform	   column	   bed	  
structure.	   The	   low	   particle	   diameter	   means	   that	   a	   high	   pressure	   is	  
needed	  to	  drive	  the	  eluent	  through	  the	  bed.	  However,	  because	  of	  the	  
very	  high	  total	  surface	  area	  available	  for	  interations	  with	  solutes,	  the	  




6.  METHODOLOGY	  OF	  STRUCTURE	  ELUCIDATION 
 
6.1	  	  Nuclear	  Magnetic	  Resonance	  Spectroscopy	  	  
The	  process	  of	  structural	  determination	  involves	  the	  accumulation	  of	  
data	   from	   numerous	   sources,	   each	   giving	   some	   structural	  
informations.	   All	   the	   available	   structural	   informations	   have	   to	   be	  
assimilated	   into	   a	   chemical	   structure	   that	   rigorously	   fits	   all	   the	  
parameters.	  
Of	   all	   modern	  methods	   for	   structure	   elucidation,	   Nuclear	  Magnetic	  
Resonance	   (NMR)	   Spectroscopy,	   provides	   the	   most	   complete	  
information,	   with	   or	   without	   prior	   structural	   knowledge.	   When	   a	  
single	  radiofrequency	  pulse	  of	  a	  few	  microsecond	  duration	  is	  applied	  
to	  atoms	  that	  in	  nature	  possess	  a	  non	  zero	  spin	  quantum	  number	  as	  
1H	  or	  13C,	  their	  nuclei	  has	  been	  excite	  and	  results	  in	  the	  emission	  of	  a	  
signal	  knows	  as	  free	  induction	  decays	  (FID).	  Fourier	  transformation	  of	  
this	  decay	  yelds	  the	  NMR	  spectrum.	  
In	   the	   1H	  NMR	   spectrum	  we	   observe	   different	   resonance	   lines	   that	  
rapresent	   the	   chemical	   shift	   interaction	   for	   the	   protons	   in	   different	  
position	   in	   a	   molecule.	   Thus	   it	   is	   a	   convenient	   method	   for	   the	  
determination	   of	   the	   chemical	   shift	   of	   each	   resonance	   calculated	  
33 
 
from	   their	   integrated	   intensities.	   Where	   the	   multiplicity	   and	   the	  
coupling	   pattern	   of	   a	   signal	   is	   interpretable,	   the	   number	   and	   the	  
stereochemical	   orientation	   of	   adjacent	   protons	   can	   be	   proposed	   as	  
well.	  
The	   13C	   NMR	   spectrum	   provides	   important	   structural	   information,	  
since	  it	  arises	  directly	  from	  the	  nuclei	  that	  form	  the	  framework	  of	  the	  
organic	   molecules.	   The	   normal	   13C	   spectrum	   is	   acquired	   with	   full	  
proton	  decoupling:	   in	  the	  absence	  of	  coupling	  to	  1H	  nuclei,	  all	  of	  the	  
13C	  signals	  in	  the	  spectrum	  appear	  as	  single	  lines,	  allowing	  the	  number	  
of	  carbons	  in	  the	  molecule	  to	  be	  readly	  determined.	  The	  13C	  spectrum	  
also	   confirms	   the	   presence	   of	   quaternary	   carbons	   but	   multiplicity	  
cannot	  be	  estabilished.	  	  
The	  number	  of	  hydrogens	  bonded	  to	  each	  carbon	  can	  be	  detected	  by	  
DEPT	  experiment:	  DEPT	  135	  shows	  all	  protonated	  carbon	  signals,	  with	  
CH3	  and	  CH	  resonance	  being	  positive,	  while	  CH2	  signals	  are	  negative.	  
To	  distinguish	  CH3	  from	  CH,	  DEPT	  90	  is	  used:	   in	  this	  experiment	  only	  
CH	  gives	  a	   signal,	  while	   carbons	  with	  all	  other	   substituition	  patterns	  
are	  not	  detected.	  	  
The	  Attached	  Proton	  Test	  (APT)	  experiment	  is	  another	  way	  to	  assign	  
C-­‐H	  multiplicities	   in	   13C	  NMR	  spectra.	   It	  provides	   the	   information	  on	  
all	  sorts	  of	  carbons	  within	  one	  experiment.	  Depending	  on	  the	  number	  
of	   hydrogens	   bound	   to	   a	   carbon	   atom,	   n,	   CHn	   spin	   vectors	   evolve	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differently	   after	   the	   initial	   pulse:	   CH	   and	   CH3	   vectors	   have	   opposite	  
phases	  compared	  to	  quaternary	  caarbons	  and	  CH2.	  	  
Two	  dimensional	  NMR	  spectra	  are	  obtained	  by	   recording	  a	   series	  of	  
1D	  spectra	  differing	  only	  by	  a	  time	  increment.	  They	  could	  be	  divided	  
into	  two	  groups:	  homonuclear	  and	  heteronuclear	  methods.	  
Within	   the	   homonuclear	   experiments,	  DQF-­‐COSY	   (Double	   Quantum	  
Filtered	  COrrelation	  Spectroscopy)	  shows	  vicinal	  and	  geminal	  protons	  
correlated	  via	  scalar	  coupling.	  	  
The	   Nuclear	   Overhauser	   Effect	   (NOE)	   allows	   the	   identification	   of	  
those	   nuclei	   within	   a	   molecule	   that	   are	   close	   in	   space.	   	   A	   2D	   NOE	  
experiment	  (NOESY	  or	  ROESY)	  therefore	  provides	  information	  on	  the	  
three	   dimensionl	   molecular	   structure,	   hence	   the	   relative	  
sterochemistry	  of	  the	  molecule.	  	  
Heteronuclear	   experiments	   are	   used	   in	   the	   form	   of	   HSQC	  
(Heteronuclear	  Single	  Quantum	  Coherence)	   to	  assign	   the	  protons	   to	  
their	   attached	   carbons.	   HMBC	   (Heteronuclear	   Multiple	   Bond	  
Correlations)	  provides	  a	  wealth	  of	  structural	  information	  by	  the	  ability	  
to	   identify	   1H-­‐13C	   correlations	   across	   carbon-­‐carbon	   or	   carbon-­‐




6.2	  Mass	  Spectrometry	  	  
Mass	   spectrometry	  (MS)	   is	   an	   analytical	   technique	   that	   produces	  
spectra	  of	  the	  masses	  of	  the	  atoms	  or	  molecules	  comprising	  a	  sample	  
of	   material.	   Mass	   spectrometry	   works	   by	   ionizing	   chemical	  
compounds	   to	   generate	   charged	   molecules	   or	   molecule	   fragments	  
and	  measuring	  their	  mass-­‐to-­‐charge	  ratios.	  
The	   ions	  are	  detected	  by	  a	  mechanism	  capable	  of	  detecting	  charged	  
particles.	   Signal	   processing	   results	   are	   displayed	   as	   spectra	   of	   the	  
relative	  abundance	  of	   ions	  as	  a	  function	  of	  the	  mass-­‐to-­‐charge	  ratio.	  
The	   atoms	   or	   molecules	   can	   be	   identified	   by	   correlating	   known	  
masses	   to	   the	   identified	   masses	   or	   through	   a	   characteristic	  
fragmentation	  pattern.	  
A	  standard	  method	  is	  Electrospray	  Ionization	  Mass	  Spectrometry	  (ESI	  
MS)	   that	   is	   typically	   used	   to	   determine	   the	  molecular	   weights	   of	   a	  
wide	   range	  of	  molecules.	   Soft	   ionization	   is	   a	   useful	   technique	  when	  
considering	  biological	  molecules	  of	  large	  molecular	  mass,	  such	  as	  the	  
aformetioned,	   because	   this	   process	   does	   not	   fragment	  
the	  macromolecules	   into	   smaller	   charged	   particles,	   rather	   it	   turns	  
the	  macromolecule	   being	   ionized	  into	   small	  droplets.	  These	   droplets	  
will	   then	   be	   further	   desolvated	   into	   even	   smaller	   droplets,	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which	  creates	   molecules	   with	   attached	   protons.	   These	   protonated	  
and	  desolvated	  molecular	  ions	  will	   then	  be	  passed	  through	  the	  mass	  
analyzer	  to	   the	   detector,	   and	   the	   mass	   of	   the	   sample	   can	   be	  
determined.	  
The	   High	   Resolution	   Electrospray	   Ionization	  Mass	   Spectrometry	   (HR	  




7.	  BIOLOGICAL	  EXPERIMENTS	  
 
 
7.1	  Binding	  Assay	  	  
The	   main	   parameters	   that	   characterize	   a	   drug	   interaction	   with	   its	  
specific	   interaction	   sites	   are	   generally	   determined	   through	   binding	  
studies.	   Execution	   of	   binding	   studies	   involves	   incubation	   of	   a	  
preparation	  containing	  the	  receptor,	  whether	  or	  not	  purified,	  with	  a	  
ligand	  of	  this	  receptor,	  marked	  with	  a	  radioactive	  isotope.	  During	  the	  
incubation	  period,	  a	  portion	  of	  the	  labeled	  ligand	  give,	  with	  a	  certain	  
amount	   of	   receptor,	   the	   complex	   ligand-­‐receptor.	   At	   the	   end	   of	  
incubation,	  the	  portion	  of	  free	  ligand	  is	  separated	  from	  the	  complex.	  
The	  most	  widely	   used	  method	   is	   to	   filter	   the	   sample	   at	   the	   end	   of	  
incubation	  over	  glass	  fiber	  filters;	  cells	  (or	  membranes)	  and	  therefore	  	  
the	   receptor	   therein	   contained,	   are	   retained	  by	   the	   filter,	  while	   the	  
free	   ligand	   passes	   through	   it.	   The	   radioactivity	   of	   bound	   labeled	  
ligand	  collected	  on	  the	   filters	   is	  counted;	   for	  β	  ray	  emitting	   isotopes	  
e.g.,	  3H-­‐labeled	  ligands,	  the	  filters	  are	  dried,	  liquid	  scintillation	  fluid	  is	  






7.2	  Tail	  Flick	  Test	  	  
The	  tail	  flick	  test	  is	  a	  test	  of	  the	  pain	  response	  in	  animals.	  It	  is	  used	  in	  
basic	  pain	  research	  and	  to	  measure	  the	  effectiveness	  of	  analgesics,	  by	  
observing	   the	   reaction	   to	   heat.	   A	   light	   beam	   is	   focused	   on	   the	  
animal's	   tail	   and	   a	   timer	   starts.	  When	   the	   animal	   flicks	   its	   tail,	   the	  
timer	  stops	  and	  the	  recorded	  time	  (latency)	  is	  a	  measure	  of	  the	  pain	  
threshold.	  
 
7.3	  Hot	  Plate	  Test	  	  
The	  hot	   plate	   test	  is	   another	   test	   of	   the	   pain	   response	  in	   animals,	  
similar	   to	   the	   tail	   flick	   test.	   It	   is	   a	   behavioral	   model	   of	  
nociception	  where	   behaviors	   such	   as	   jumping	   and	   hind	   paw-­‐licking	  
are	   elicited	   following	   a	   noxious	   thermal	   stimulus.	   Licking	   is	   a	   rapid	  
response	   to	   painful	   thermal	   stimuli	   that	   is	   a	   direct	   indicator	   of	  
nociceptive	   threshold.	   Jumping	   represents	   a	   more	   elaborated	  
response,	  with	  a	  latency,	  and	  encompasses	  an	  emotional	  component	  
of	  escaping.	  A	  transparent	  glass	  cylinder	  is	  used	  to	  keep	  the	  animal	  on	  
the	  heated	  surface	  of	  the	  plate.	  




The	   time	  of	   latency	   is	   defined	   as	   the	   time	  period	  between	   the	   zero	  
point,	   when	   the	   animal	   is	   placed	   on	   the	   hot	   plate	   surface,	   and	   the	  




8.	  OTHANTUS	  MARITIMUS	  
 
 
8.1	  	  	  Botanical	  decription	  	  
Otanthus	  maritimus	   (L)	  Hoffmanns.	  &	  Link	  (Figure	  9)	   is	  an	  evergreen	  
chamaephyte	  plant	  belongs	  to	  the	  family	  of	  the	  Asteraceae	  and	  is	  the	  
only	  species	  of	  the	  monotypic	  genus	  Otanthus.62	  It	  looks	  like	  a	  bushy	  
plant	   10-­‐50	   cm	   tall,	   with	   dense,	   silvery-­‐white	   fluff	   with	   numerous	  
woody	   stems	   at	   the	   base	   and	   hardened	   at	   the	   top.	   The	   plant	  
possesses	   an	   effective	   adaptation	   to	   resist	   aridity	   and	   the	   direct	  
sunlight.63	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  9.	  O.maritimus	  
The	   leaves	   are	   oblong	   or	   spatulate,	   sessile,	   obtuse,	   finely	   toothed.	  
View	  spherical	   flower	  heads,	  8-­‐10	  mm	  diameter,	  with	  short	  pedicles	  
gathered	  to	  form	  corymbs	  at	  the	  top	  of	  the	  branches.	  Scarious	  bracts	  
are	  present	  on	   the	  edge.	   The	   flowers	   (Figure	  10)	   are	   yellow	   tubular	  
shaped	   with	   two	   wings	   at	   the	   base.	   The	   fruit	   is	   an	   achene	   4	   mm	  







Figure	  10.	  Flowers	  of	  O.	  maritimus	  
	  
8.2	  Geographical	  Distribution	  and	  Habitat	  	  
O.	  maritimus	  is	  distributed	  along	  the	  European	  coasts	  of	  Atlantic	  and	  
Mediterranean	   sea	   (Figure	   11).	   It	   is	   a	   species	   related	   to	   the	   sandy	  
beaches	   characterising	   with	   its	   silvery-­‐white	   small	   bushes,	   growing	  
especially	   at	   the	   shoreline	   and	  dunes	   at	   first	   colonizing	  with	   a	   long,	  





Figure	  11.	  Areal	  of	  O.	  maritimus	  
	  
O.	  maritimus	  may	  be	  considered	  very	   important	   in	  the	  consolidation	  
of	   the	   dunes	   thanks	   to	   its	   impressive	   development	   of	   underground	  
apparatus.	   The	   gradual	   degradation	   of	   coasts	   is	   drastically	   reducing	  
the	  spread	  of	  this	  species.	  	  	  	  
8.3	  	  Use	  in	  Folk	  Medicine	  
In	   traditional	   medicine	   O.	   maritimus	   is	   used	   to	   treat	   asthmatic	  
bronchitis,	  dysentery	  and	  inflammation	  of	  the	  urinary	  bladder.64	  
	  
	  
8.4	  Chemical	  Composition	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The	   roots	   of	   O.	   maritimus	   contain	   fatty	   acid	   amides	   (Figure	   12)65,	  
acetylene	   derivatives65	   (Figure	   13),	   monoterpenes	   (Figure	   14)	   and	  
sesquiterpenes66	   (Figure	   15),	   while	   from	   the	   aerial	   parts	   amides67	  
(Figure	  16)	  sesquiterpene	  lactons68	  (Figure	  17),	  monoterpenes	  (Figure	  





















































































Figure	  19.	  Lignanes	  isolated	  from	  the	  leaves	  of	  O.	  maritimus	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8.5	  Biological	  Actvity	  of	  N-­alkylamides	  	  
Certain	  alkylamides	  such	  as	  dodeca-­‐2E,4E-­‐dienoic	  acid	   isobutylamide	  
and	   dodeca-­‐2E,4E,8Z,10Z-­‐tetraenoic	   acid	   isobutylamide	   (Figure	   20)	  
have	   been	   identified	   as	   the	   main	   active	   principles	   of	   Echinacea	  
purpurea	   and	   Echinacea	   angustifolia	   preparations5,71	   that	   are	  
remedies	  widely	  used	   for	   the	  prevention	  and	   treatment	  of	   common	  
























Raduner	   and	   co-­‐workers5	   demonstrated	   that	   the	   above	   mentioned	  
alkylamides	   were	   able	   to	   act	   as	   full	   agonist	   at	   CB2	   receptor	   in	   a	  
nanomolar	   range	   showing	   a	   higher	   selectivity	   versus	   CB2	   compared	  
with	  CB1	  receptors.	  	  
It	   has	   been	   postulated	   that	   the	   affinity	   of	   the	   alkylamides	   to	   CB	  
receptor	   is	   due	   to	   their	   structural	   similarity	   with	   the	   endogenous	  
cannabinoid	   anandamide	   (Figure	   20).	   Alkylamides	   also	   showed	   to	  
inhibit	   the	   fatty	   acid	   amidohydrolase	   (FAAH)	   and	   thereby	   able	   to	  
enhance	   the	   activity	   of	   CB1	   and	   CB2	   ligands.71	   Again	   dodeca-­‐2E,4E-­‐
dienoic	   acid	   isobutylamide	   and	   dodeca-­‐2E,4E,8Z,10Z-­‐tetraenoic	   acid	  
isobutylamide	  elevated	  total	  intracellular	  Ca2+	  in	  CB2-­‐positive	  but	  not	  
in	  CB2-­‐negative	  promyelocitic	  HL	  60	  cells5.	  
This	   effect	   of	   dodeca-­‐2E,4E-­‐dienoic	   acid	   isobutylamide	   and	   dodeca-­‐
2E,4E,8Z,10Z-­‐tetraenoic	  acid	  isobutylamide	  was	  blocked	  by	  treatment	  
of	   the	   cells	   with	   SR144528,	   indicating	   that	   the	   effect	   of	   these	  
compounds	   is	  mediated	   through	   the	   CB2	   receptor
5.	   Furthermore,	   it	  
has	   been	   demonstrated	   that	   alkylamides	   are	   the	   only	   Echinacea	  
compounds	   that	   after	   oral	   administration	   showed	   high	  
bioavailability.73-­‐75	  All	  this	  data	  highlight	  that	  the	  immunomodulatory	  
effect	   of	   Echinacea	   could	   be	   connected	   to	   the	   interactions	   of	  
alkylamides	  with	  the	  CB2	  receptors.	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Most	  of	  the	  isolated	  alkylamides	  of	  O.	  maritimus	  roots	  belongs	  to	  the	  
class	   of	   the	   very	   unusual	   thienylheptatrienamides.	   In	   particular,	   no	  
biological	   activity	   for	   these	   compounds	   have	   been	   reported	   in	   the	  







9.1	  	  Botanical	  Decription	  	  
The	  plant,	  belonging	  to	  the	  family	  of	  Lamiaceae,	   looks	   like	  a	  densely	  
branched	   frutex	   woody	   at	   the	   base,	   forming	   a	   hemispherical	   high	  
bush	  until	   50	   cm;	   the	   look	   is	   thistly	   due	   to	  previous	   years	   branches	  
that	  may	  persist	   for	  years	  buckets	   (Figure	  21).	  Characteristic	  are	   the	  
tetragon	   branches	   of	   the	   year	   and	   persistent	   unpleasant	   odor	  
emanated	  from	  the	  same	  hence	  the	  adjective	  "fetid"	  associated	  with	  




               	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  21.	  	  Stachys	  glutinosa	  L.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	   leaves	   are	   opposite	   and	   sessile	  with	   linear	   lanceolate	   or	   scrape	  
leaf,	   around	  4	   cm	   length	   and	   few	  millimetres	  width,	   ruffled	  margin.	  
The	   top	   page	   is	   glabrous	   and	   bottom	   covered	   with	   glandular	  












	  	  	  	  	  	  	  	  	  
	  
Figure	  22.	  	  Leaves	  and	  flowers	  of	  S.glutinosa	  L.	  
	  
	  
The	  flowers	  (Figure	  22)	  are	  grouped,	  supported	  by	   long	  pedicels	  and	  
calyx	   preceded	   by	   	   linear	   bracteoles.	   The	   tube-­‐shaped	   and	   regular	  
calyx	  ends	  with	  5	  teeth	  sharp;	  the	  corolla,	  typical	  of	  the	  Lamiacae,	   is	  
symmetric	   and	   gamopetalous	   with	   lower	   lip	   longer	   than	   above,	  
pubescent	  and	  very	  clear	  colour:	  white,	  pink,	  violet.	  The	  stamens	  are	  
four	  with	   filaments	   inserted	   in	  corolla;	   the	  ovary	   is	  bicarpellary	  with	  
stylus	  sandwiched	  between	  carpels.	  The	  long	  flowering	  and	  climbing,	  
lasts	  from	  spring	  until	  autumn.76	  
	  
9.2	  	  Geographical	  Distribution	  and	  Habitat	  	  
S.	  glutinosa	   is	  a	  xerophilous	  plant	  that	  adapts	  to	  dry	  and	  sunny	  soils,	  
typically	  beaten	  from	  strong	  winds	  with	  acidic	  or	  calcareous	  matrix.	  It	  
does	  not	  tolerate	  shading,	  so	  its	  presence	  is	  sporadic	  in	  high	  scrub	  or	  
forest;	   is	   found	  easily	   in	   reduced	   and	   rocky	   slopes.	   Characteristic	   of	  
the	  plant	  is	  fire	  resistance	  as	  it	  is	  able	  to	  push	  through	  radical	  to	  fast-­‐
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growing	  suckers.	  S.	  glutinosa	  is	  an	  endemic	  shrub	  of	  Sardinia,	  Corsica	  
and	  Capraia	  islands	  that	  grows	  on	  different	  substrata77.	  	  
	  
	  
9.3	  Use	  in	  Folk	  Medicine	  	  
The	  decoction	  produced	  from	  the	   leaves	  of	  S.	  glutinosa	  was	  used	  as	  
an	  antispasmodic	  and	  antiseptic78-­‐80	  while	   the	  whole	  plant	  was	  used	  
as	  an	  insect	  repellent	  to	  ward	  off	  mallophaga	  (lice	  chickens).81	  
	  
9.4	  	  	  Chemical	  Composition	  	  
To	  date	  there	  are	  few	  works	  in	  the	  literature	  regarding	  chemical	  and	  
biological	   studies	   S.	   glutinosa.	   Three	   articles	   reported	   the	   chemical	  
composition	   of	   the	   essential	   oil	   and	   its	   antibacterial	   and	   antiviral	  
activity.82-­‐84	  
In	  only	  one	  work	  is	  reported	  the	  isolation	  of	  non-­‐volatile	  components	  






                 
                R=H : Arpagide                         5-Allosil-aucubin 
               R=AcO : Acetil-arpagide         
 
                           
                           Figure 23. Iridoids from S.glutinosa 




Phytochemical	  studies	  of	  members	  of	  the	  genera	  Stachys	  have	  led	  to	  
the	  isolation	  of	  a	  number	  of	  neo-­‐clerodane	  and	  labdane	  diterpenoids	  





	  	  	  	  	  	  	  	  	  	   	  
	  




Both	   classes	   have	   been	   receiving	   increasing	   interest	   for	   their	  
biological	   activities	   and	   especially	   as	   antifeedant,	   antimicrobial	   and	  
cytotoxic	  agents.86-­‐88	  
The	   first	   report	   of	   a	   diterpenoid	   from	   genus	   Stachys	   was	   from	   a	  
Moldavia	   species,	   S.	   annua.	  Moldavian	   researchers89,90	   reported	   the	  
occurrence	  of	  stachysolone	  (Figure	  25)	  and	  its	  three	  	  acetylderivatives	  
isolated	   from	   the	   aerial	   parts.	   The	   same	   compounds	   were	   also	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  25.	  Structure	  of	  stachysolone	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Continuing	   the	   investigation	   of	   S.	   annua,	   three	   further	   diterpenoids	  
were	   isolated,	   annuanone,	   stachylone	   and	   stachone93-­‐95	   (Figure	   26)	  
and	   they	  were	   later	   detected	   in	   several	   other	   species	   of	   Stachys	   of	  
the	  flora	  of	  Ukraine96.	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  Figure	  26.	  Structures	  of	  annuanone,	  stachylone	  and	  stachone	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A	   species	   collected	   in	   Cyrenaica,	   Stachys	   rosea,	   yielded	   two	   new	  
neoclerodane	  diterpenoids,	   roseostachenone	  and	   roseostachone97	  A	  
reinvestigation	   of	   the	   plant98	   led	   to	   the	   isolation	   of	   two	   new	  
neoclerodanes,	  roseostachenol	  and	  roseotetrol	  (Figure	  27).	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Figure	  27.	  Structure	  of	  roseostachenone,	  roseostachone,	  
roseostachenol	  and	  roseotetrol	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The	  pytochemical	  study	  of	  Stachys	  mucronata,	  collected	  in	  the	  island	  
of	  Karpathos	  (Greece),	  gave	  two	  labdane	  diterpenoids,	  ribenone	  and	  
ribenol	   (Figure	   28).99	   Both	   products	   had	   been	   isolated	   from	   other	  
plants.	   In	   literature	   many	   works	   reported	   these	   compounds	   as	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  Structure	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The	  species	  S.	  plumosa,	  native	  of	  the	  Balkan	  peninsula,	  yielded	  three	  
new	   labdane	   diterpenoids:	   (+)-­‐6-­‐deoxyandalusol,	   (+)-­‐13-­‐
epijabugodiol,	  (+)-­‐plumosol	  (Figure	  29).104	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Other	  compounds	  isolated	  from	  S.	  rosea	  were	  13-­‐epi-­‐sclareol	  (Figure	  
30),	   which	   showed	   activity	   against	   Leishmania	   spp.,	   as	   well	   as	  
ribenone	  and	  ribenol.105-­‐107	  
	  
	  	  
                                  	  
	  
	  











10.	  WITHANIA	  SOMNIFERA	  
 
 
10.1	  Botanical	  Description	  	  
W.	  somnifera	  (L.)	  Dunal	  also	  known	  as,	  Ashwaganda	  or	  indian	  ginseng,	  
is	  a	  green	  shrub	  belonging	  to	  the	  family	  of	  Solanaceae.	  This	  species	  is	  
35	   to	   75	   centimeters	   tall	   and	   possesses	  tomentose	  branches	   extend	  
radially	  from	  a	  central	  stem.	  The	  flowers	  are	  small	  and	  green.	  The	  ripe	  
fruit	  is	  orange-­‐red.	  Roots	  are	  20-­‐30	  cm	  long	  and	  6-­‐12	  mm	  in	  diameter,	  
with	   a	   few	   (2	   to	   3)	   lateral	   roots	   of	   slightly	   smaller	   size	   (Figure	   31).	  
Outer	  surface	  is	  buff	  to	  gray-­‐yellow	  with	  longitudinal	  wrinkles	  and	  in	  
the	   center	   soft,	   solid	  mass	  with	   scattered	   pores.	   The	   taste	   is	   bitter	  
and	  acrid.	  The	  ripe	  fruit	  is	  orange-­‐red.108	  
10.2	  Geographical	  Distribution	  and	  Habitat	  
W.	   somnifera	  is	   found	   in	   many	   of	   the	   dry	   regions	   of	  	   India,	   such	  
as	  Mandsaur	  district	  of	  	  Madhya	  Pradesh,	  Punjab,	  Sindh,	  Gujarat	  and	  
Rajasthan.	   It	   is	   also	   found	   in	   Pakistan,	   Nepal,	   Afganistan,	   Sri	   Lanka,	  
Congo,	  South	  Africa,	  Egypt	  and	  Morocco.109	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10.3	  Use	  in	  Folk	  Medicine	  	  
Ashwaganda	  holds	   a	  place	   in	  Ayurveda	   similar	   to	   that	  of	  Ginseng	   in	  
Chinese	  medicine.	   It	   is	   reputed	   to	  be	   capable	  of	   imparting	   long	   life,	  
youthful	  vigour	  and	  intellectual	  prowess	  and	  is	  an	  ingredient	  of	  many	  
traditional	   preparations.	   The	   name	   Ashwaganda	   comes	   from	   the	  
smell	   of	   horses,	  which	   the	   root	   (Figure	  32)	   emits,	   and	   the	  botanical	  
suffix	  somnifera	   from	  the	  use	  of	   the	  plant	  as	  a	  sedative	  The	  plant	   is	  
used	   to	   to	   treat	   various	   neurological	   disorders,	   geriatric	   debilities,	  
arthritis,	  stress	  and	  behavior-­‐related	  problems.110,111	  In	  the	  traditional	  
system	   of	   medicine	   Ayurveda,	   this	   plant	   is	   claimed	   to	   have	   potent	  
aphrodisiac,	   rejuvenative	   and	   life	   prolonging	   propreties.	   It	   improves	  
learning	  ability	  and	  memory	  capacity.112,113	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  somnifera	  roots	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10.4	  Pharmacological	  Studies	  of	  W.	  somnifera	  
Extracts	   
Pharmacological	  studies	  have	  shown	  that	  W.	  Somnifera	  extracts	  have	  
anticancer,	   antianxiety,	   antiinflammatory,	   immunomodulatory,	  
adaptogenic,	   cardiovascular,	   free	   radical	   scavenging	   and	   central	  
nervous	   system	   activities.114	   Among	   the	   central	   nervous	   system	  
activities	  of	  W.	  somnifera,	  the	  action	  on	  neurodegenerative	  disorders	  
have	  been	  well	  documented.	  In	  particular,	  W.	  somnifera	  preparations	  
have	  shown	  beneficial	  effects	  against	  Huntington's115,	  Alzheimer's116, 
and Parkinson's	  diseases.117	  
W.	   somnifera	   root	   extract	   is	   widely	   used	   to	   reduce	   symptoms	   of	  
anxiety	   and	   stress	   and	   these	   effects	   have	   been	   demonstrated	   in	   a	  
study	   that	   showed	   a	   trend	   for	   the	   anxiolytic	   superiority	   of	   W.	  
somnifera	   over	   placebo	   at	   week	   2,	   and	   statistically	   significant	  










10.5	  	  CHEMICAL	  COMPOSITION	  
 
 
10.5.1	  	  Withanolides	  	  
The	  major	   constituents	   of	   the	  W.	   somnifera	   roots	   and	   leaves	   are	   a	  
group	   of	   steroidal	   lactones	   called	   withanolides	   that	   have	   been	  
considered	  exclusive	  of	  Solanaceae	  plants.	  Withanolides	  	  are	  a	  group	  
of	   at	   least	   300	   naturally	   occurring	  chemical	   compounds	   and	  
structurally,	  they	  consists	  of	  a	  C-­‐28-­‐steroidal	  skelelton	  	  in	  which	  C-­‐22	  
and	  C-­‐26	  are	  appropriately	  oxidized	  to	  form	  a	  six-­‐membered	  lactone	  
ring	  .	  
In	   the	   roots	   17-­‐hydroxy-­‐27-­‐deoxy	   withaferin	   A,	   withanolide	   A	   and	  
withanone	  have	  been	  identified	  as	  the	  major	  withanolides	  (Figure	  33)	  
while	   27-­‐hydroxy	  withanone,	  withaferin	   A,	   17-­‐hydroxy	  withaferin	   A,	  
27-­‐hydroxy	  withanolide	   B	   and	   27-­‐deoxy	  withaferin	  A	  were	   detected	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The	   withanolides	   composition	   of	   leaves	   differed	   only	   from	   a	  
quantitative	  point	  of	  view	  with	  the	  exception	  of	  withanolide	  D	  (Figure	  
35)	   	   found	  only	   in	   the	   leaves.	   The	  minor	  withanolides	   of	   the	   leaves	  
were	  27-­‐deoxy	  withaferin	  A	  and	  27-­‐hydroxy	  withanolide	  B	  (Figure	  34)	  	  
while	  all	  other	  seroidal	  lactones	  occurred	  substantially.119	  
	  
	  
                          	  







Figure	  35.	  Structure	  of	  withanolide	  D	  isolated	  from	  the	  leaves	  of	  






10.5.2	  	  	  Alkaloids	  
In	   addition	   to	  withanolides,	   both	   leaves	   and	   roots	   contain	   relatively	  
high	  amounts	  of	  alkaloids	  possessing	  a	  pyperidin,	  pyrrolidin	  or	  pyrazol	  
ring.	  Up	  to	  now	  ten	  alkaloids	  have	  been	   isolated:	  D-­‐L-­‐isopelletierine,	  
anaferine,	  hygrine,	  cuscohygrine,	  anahygrine,	  tropine,	  pseudotropine,	  
3alfa-­‐tigloyloxytropane,	  withasomnine	  and	  coline120,121	   (Figure	  36-­‐37)	  
Among	  the	  W.	  somnifera	  alkaloids,	  anaferine,	  has	  been	  found	  only	  in	  
this	  plant	  (roots)	  and	  therefore	  can	  be	  considered	  a	  chemical	  marker	  
for	  this	  species.   
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10.5.3	  	  Biological	  Activities	  of	  Withania	  somnifera	  
Withanolides	  	  
The	   first	   compound	  of	   this	   group	   to	  be	   isolated	  was	  withaferin	  A,	   a	  
highly	   oxygenated	   withanolide.	   Several	   studies	   indicated	   that	  
withaferin	   A	   (figure	   34)	   is	   one	   of	   the	   main	   biologically	   active	  
withanolides,	   exerting	   a	   wide	   variety	   of	   activities,	   including	   anti-­‐
inflammatory,	   tumor	   preventive,	   cell	   death	   inducing,	   anti-­‐tumor,	  
radiosensitizing,	   as	   well	   as	   anti-­‐	   angiogenic	   effects.122	   From	   a	  
biological	   point	   of	   view,	   the	   others	   withanolids	   isolated	   from	   W.	  
somnifera	  were	  much	   less	   studied	   respect	   to	  withaferin	  A	  and	  were	  
mainly	  investigated	  as	  cytotoxic	  agents	  against	  cancer	  cells.123	  
In	  orden	  to	   justify	   the	  multiple	  targets	  of	  withaferin	  A	   (Figure	  34),	   it	  
has	   been	   postulated	   an	   acylation	   or	   alkylation	   of	   critical	  
macromolecules	  or	  enzymatic	  active	  sites	  by	  covalent	  attachment.124	  
These	  effects	  could	  be	   justified	  by	  at	   least	   three	   reactive	  position	   in	  
the	   steroidal	   skeleton	   which	   might	   be	   involved	   in	   the	   alkylation	  
reactions	   with	   nucleophilic	   sites	   like	   sulfhydryl	   groups	   of	   cysteine	  
residues	  in	  target	  proteins.	  These	  include	  the	  double	  bond	  at	  C3	  in	  A-­‐
ring,	   the	   epoxide	  moiety	   at	   position	   5	   and	   C-­‐24	   in	   its	   E-­‐ring.	   These	  
sites	  are	  potentially	  highly	  susceptible	  for	  nucleophilic	  attack,	  and	  by	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Michael	   addition	   alkylation	   reaction,	   lead	   to	   a	   covalent	   binding	   of	  
withaferin	  A	  with	  the	  target	  protein.125	  
The	   antiinflammatory,	   proapoptotic,	   antiangiogenic	   and	   anti-­‐
proliferative	   activities	   of	   withaferin	   A	   have	   been	   attributed	   to	   the	  
inhibition	  of	  the	  transcription	  factor	  NF-­‐kB,126	  of	  the	  members	  of	  the	  
signal	   transducer	   and	   activator	   of	   transcription	   family	   (STAT1	   and	  
STAT3),127	  and	  to	  the	  activation	  the	  liver	  X	  receptor	  α	  (LXRα).128	  
Interestingly,	   withaferin	   A	   was	   also	   able	   to	   inhibit	  
acetylcholesterinases	   and	   butyrylcholinesterases129	   justifing,	   at	   least	  
in	  part,	  the	  positive	  effect	  of	  W.	  Somnifera	  exracts	  in	  the	  treatment	  of	  


















11.	  	  OTHANTUS	  MARITIMUS	  
	  
11.1	  	  Extraction	  of	  O.maritimus	  Roots	  	  
The	   powered	   dried	   roots	   of	  O.	   maritimus	   (780	   g)	   were	   succesively	  
extracted	  with	  DCM	  and	  MeOH	  yielding	  23.9	  g	  and	  51	  g	  ,	  respectively.	  
The	  extraction	  was	  carried	  out	  by	  percolation	  during	   the	  day	  and	  at	  
night	  the	  roots	  were	  left	  to	  maceration.	  	  
	  
11.2	  	  Isolation	  of	  Metabolites	  from	  O.maritimus	  	  
The	  DCM	  extract	   showed	   significant	  binding	  affinity	   to	  CB1	  and	  CB2	  
receptors	  and	  moderate	  affinity	  to	  µ	  and	  δ	  opioid	  receptors	  (Table	  1)	  
and	   was	   therefore	   subjected	   to	   fractionation	   by	   silica	   gel	   vacuum-­‐
liquid	  chromatography	   (VLC),	   column	  chromatography	   (silica	  gel	  and	  
Sephadex	   LH	   20)	   and	   semi-­‐preparative	   NP	   (normal-­‐phase)	   or	   RP	  
(reversed-­‐phase)	   HPLC	   to	   give	   two	   new	   thienylheptatrienamides	  
namely	  (2E,4E,6E)-­‐N-­‐isopentyl-­‐7-­‐(2-­‐thienyl)-­‐2,4,6-­‐heptatrienamide	  (1)	  
and	   	   (2Z)-­‐5-­‐{[(2E,4E,6E)-­‐7-­‐(2-­‐thienyl)-­‐2,4,6-­‐heptatrienoyl]amino}-­‐2-­‐
pentenyl-­‐3-­‐methylbutanoate	  (5)	  (Figure	  38),	  and	  one	  new	  neo-­‐lignan	  	  	  
9-­‐isovaleroxy	  balanophonin	   (12)	   (Figure	  39),	  along	  with	  eight	  known	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amides	   (2-­‐4,	   6-­‐10)	   (Figure	   38),	   pontica	   epoxide	   (11),	   sesamin	   (13),	  









	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




Figure	  39.	  Other	  compounds	  isolated	  from	  O.	  maritimus	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11.3	  	  STRUCTURE	  ELUCIDATION	  OF	  METABOLITES	  FROM	  	  
O.	  MARITIMUS	  
 
11.3.1	  	  Structure	  Elucidation	  of	  Compound	  	  1	  	  
 
The	   ESIMS	   and	   the	   HR-­‐TOF-­‐ESIMS	   of	   compound	   (1)	   showed	   the	  
molecular	   ion	   peak	   at	   m/z	   276	   [M	   +	   H]+	   and	   276.1408	   (calc.	  	  
276.1417),	  respectively,	  accounting	  for	  the	  elemental	  composition	  of	  
C16H21NOS,	  possessing	  seven	  degrees	  of	  unsaturation	  (Figure	  40).	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  40.	  HR-­‐TOF-­‐ESIMS	  spectrum	  of	  1	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The	   1H	  NMR	   spectrum	  of	  1	   suggested	   the	  presence	  of	   a	   conjugated	  
trienamide	  by	  the	  presence	  of	  two	  doublet	  at	  δH	  5.85	  (J	  =	  15	  Hz,	  H-­‐2)	  
and	  6.83	  (J	  =	  15	  Hz,	  H-­‐7)	  and	  four	  double	  doublet	  at	  7.29	  	  (J	  =	  15,	  10	  
Hz,	  H-­‐3),	  6.37	  (J	  =	  15,	  10	  Hz,	  H-­‐4),	  6.61	  (J	  =	  15,	  10	  Hz,	  H-­‐5)	  and	  6.65	  (J	  
=	  15,	  10	  Hz,	  H-­‐6)	  (Figure	  41,	  table	  2).	  	  
	  
	  




















The	   HSQC	   spectrum	   revealed	   the	   proton	   connectivities	   with	   the	  
corresponding	  carbon	  (Figure	  43).	  	  
	  







The	   large	   coupling	   constants	   of	   the	   above	   mentioned	   protons,	  
besides	   the	  HMBC	  correlations	  of	   the	  protons	  at	  5.85	  and	  7.29	  ppm	  
with	  the	  carbonyl	  group	  at	  δH	  166.0	  ppm	  (Figure	  44),	  clearly	  indicated	  
the	  presence	  of	  trans-­‐α,	  β,	  γ,	  δ,	  ε,	  ζ,-­‐	  double	  bonds	  conjugated	  	  with	  a	  
carbonyl	  group.	  
	  



















The	  1H	  NMR	  spectrum	  revealed	  three	  further	  protons	  at	  δH	  7.20	  (1H,	  
d,	   J	  =	   5	  Hz),	   7.02	   (1H,	   d,	   J	  =	   5	  Hz),	   and	   6.98	   (1H,	   dd,	   J	  =	   5,	   3.5	  Hz)	  
characteristic	  of	  a	  2-­‐thienyl	  moiety131.	  The	  connectivity	  of	  the	  sulphur	  
heterocycle	   with	   the	   trienamide	   chain	   was	   confirmed	   by	   HMBC	  
correlations	  between	  H-­‐7	  (δH	  =	  6.83)	  and	  C-­‐1′	  (δC	  =	  142.3)	  and	  C-­‐2′	  (δC	  
=	  127.0),	  and	  between	  H-­‐6	  and	  C-­‐1′	   (Figure	  45).	   	  A	  quartet	   in	  the	  1H	  
NMR	  spectrum	  at	  δH	  3.37	  (J	  =	  5	  Hz,	  H-­‐1′′),	  two	  multiplet	  at	  δH	  1.43	  (H-­‐
2′′)	  and	  1.64	  (H-­‐3′′),	  and	  a	  six-­‐proton	  doublet	  at	  0.93	  (J	  =	  6.5	  Hz,	  H-­‐4′′,	  
H-­‐5′′),	  suggested	  the	  presence	  of	  an	  isopentyl	  group.	  	  
The	   1H-­‐1H	   COSY	   experiment	   showed	   correlations	   of	   H-­‐1′′/H-­‐2′′,	   H-­‐
2′′/H-­‐3′′,	   and	   between	   H-­‐3′′	   and	   H-­‐4′′	   and	   H-­‐5′′	   (Figure	   46-­‐47).	   This	  
confirmed	  the	  presence	  of	  an	  isopentyl	  moiety,	  and	  the	  cross	  peak	  in	  
the	   HMBC	   spectrum	   between	   the	   protons	   at	   δH	   3.37	   and	   C-­‐1	   (δC	  
166.0),	  demonstrated	  that	  this	  group	  was	  attached	  to	  the	  NH	  group.	  










	  	  	  	  	  	  	  









	  	  	  	  	  	  	  Figure	  47.	  DQF-­‐COSY	  (500	  MHz)	  of	  compound	  1	  	  
 
 
   	  
                        	  
	  




Table	   2.	   1H	   (500	   MHz)	   and	   13C	   (100	   MHz)	   NMR	   spectral	   data	   of	  
compound	  1	  	  (CDCl3,	  δ	  in	  ppm)	  
	  
	  aMultiplicity	   was	   determined	   by	   analysis	   of	   the	   APT	   spectrum.	   bJ	  
values	  (Hz)	  in	  parentheses.	  
	  
	  
 δC, multiplicitya δH, multiplicityb 
1 166.0, s 	  
2 123.3, d 5.85, d (15.0) 
3 140.7, d 7.29, dd (15.0, 10.0) 
4 130.2, d 6.37,  dd (15.0, 10.0) 
5 139.0, d 6.61,  dd (15.0, 10.0) 
6 127.9, d 6.65,  dd (15.0, 10.0) 
7 128.4, d 6.83, d  (15.0) 
1′ 142.3, s  
2′ 127.0, d 7.02, d (3.5) 
3′ 127.8, d 6.98, dd (5.0, 3.5) 
4′ 125.4, d 7.20, d (5.0) 
1′′ 38.0, t 3.37, q, (5.0) 
2′′ 38.6, t 1.43, m  
3′′ 25.9, q 1.64, m 
4′′ 22.5, q 0.93, d (6.5) 
5′′ 22.5, q 0.93, d (6.5) 
NH 5.40, br, s	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11.3.2	  	  Structure	  Elucidation	  of	  Compound	  	  5	  	  
Compound	  5	   showed	   a	   pseudomolecular	   ion	   peak	   at	  m/z	  374	   [M	   +	  
H]+,	   in	   low	   resolution	   ESIMS	   and	   a	   pseudomolecular	   ion	   at	   m/z	  
374.1785	   [M	   +	   H]+	   (calc.	   	   374.1784)	   in	   HR-­‐TOF-­‐ESI	   mass	   spectrum	  
(Figure	  49),	  accounting	  for	  the	  elemental	  composition	  of	  	  C21H27NO3S,	  










                 




Analysis	  of	  the	  1H	  (Figure	  50)	  and	  APT	  (Figure	  51)	  NMR	  data	  (Table	  3)	  
and	  the	  HSQC	  spectrum	  (Figure	  53)	  of	  5	  revealed	  the	  presence	  of	  one	  
sp3	  methine,	  four	  sp3	  methylene,	  two	  methyl,	  eleven	  sp2	  methine,	  and	  
three	  sp2	  quaternary	  carbons.	  	  The	  downfield	  region	  (5.7<	  δH	  <7.5)	  of	  
the	  1H	  NMR	  spectrum	  of	  5	  was	  almost	  superimposable	  to	  those	  of	  2,	  
suggesting	   the	   presence	   of	   a	   (2-­‐thienyl)-­‐2,4,6-­‐heptatrienamidic	  
moiety	   (Table	   2),	   and	   the	   only	   significant	   difference	   between	   this	  
spectrum	  portion	  of	  2	  with	   that	  of	  5	  was	   the	  downfield	   shift	   of	   the	  
secondary	  amide	  proton	  signal	  to	  δH	  6.16.	  	  
	  
















	  	  	  	  	  	  	  	  	  	  Figure	  51.	  APT	  spectrum	  (100	  MHz)	  of	  5	  measured	  in	  CDCl3	  
	  
	  	  	  	  	  	  	  Figure	  52.	  HSQC	  spectrum	  (500	  MHz)	  of	  5	  measured	  in	  CDCl3	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In	  the	  same	  spectrum	  a	  doublet	  at	  δH	  2.23	  (J	  =	  7	  Hz,	  H-­‐2′′′),	  a	  multiplet	  
at	  2.13	  (H-­‐3′′′)	  and	  a	  six-­‐proton	  doublet	  at	  1.0	  (J	  =	  6.5	  Hz,	  H-­‐4′′′,	  H-­‐5′′′)	  
suggested	  the	  presence	  of	  an	  isobutyl	  group	  which	  was	  substantiated	  










	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  54.	  DQF-­‐COSY	  (500	  MHz)	  of	  compound	  5	  
	  
This	  moiety	  was	   linked	   to	  an	  ester	  carbonyl	  group,	   judged	  by	  HMBC	  
connectivities	   of	   the	   methylene	   and	   oxymethylene	   protons,	  
respectively	  at	  2.23	  (J	  =	  7.0	  Hz,	  H-­‐2′′′)	  and	  4.66	  (J	  =	  5.5	  Hz,	  H-­‐5′′)	  ppm,	  
with	  the	  quaternary	  carbon	  at	  δC	  173.5	  (Figure	  53).	  HMBC	  cross-­‐peaks	  
of	   the	   protons	   at	   4.66	   and	   2.43	   (2H,	   m,	   H-­‐2′′)	   ppm	   with	   olefinic	  
carbons	   at	   δC	   131.6	   and	   126.2	   (C-­‐3′′,	   C-­‐4′′),	   and	   of	   the	   methylene	  
protons	  at	  δH	  3.45	  (H-­‐1′′,	  q,	  J	  =	  6	  Hz)	  with	  C-­‐3′′	  (δC	  131.6)	  revealed	  a	  2-­‐
butenyl	   chain	   directly	   linked	   to	   C-­‐5′′	   (δC	   =	   60.2)	   (Figure	   53).	   The	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geometry	  of	  the	  C-­‐3′′	  and	  C-­‐4′′	  double	  ond	  was	  determined	  to	  be	  the	  
Z-­‐form	  by	  the	  same	  chemical	  shift	  of	  H-­‐3′′/H-­‐4′′	  and	  by	  the	  upfield	  13C	  
NMR	   shift	   of	   the	   allylic	   C-­‐2′′	   (δC	   =	   27.1)	   (Table	   3).	   Generally,	   the	  
chemical	   shifts	   of	   allylic	   carbons	   of	   linear	   olefins	   of	   Z-­‐isomers	  
resonate	  at	  ca	  5	  ppm	  higher	  fields	  (δ	  <	  29)	  than	  those	  of	  E-­‐isomers	  	  (δ	  
>	  31)132.	   	  Further	  HMBC	  correlation	  of	  H-­‐1′′	  with	  C-­‐1	   (δC	  166.4)	   fixed	  
the	  ester	  chain	  to	  the	  secondary	  amide	  group	  (Figure	  53).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  55.	  DQF-­‐COSY	  (500	  MHz)	  of	  5	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DQF-­‐COSY,	   HSQC	   and	   HMBC	   experiments	   (allowed	   the	   complete	  














                       
 
	  









Table	   3.	   1H	   (500	   MHz)	   and	   13C	   (100	   MHz)	   NMR	   spectral	   data	   of	  
compounds	  5	  	  (CDCl3,	  δ	  in	  ppm)	  
Position	   δC,	  multiplicity
a	   δH,	  multiplicity
b	  
1	   166.4,	  s	   	  
2	   123.6,	  d	   5.97,	  d	  (15.0)	  
3	   140.3,	  d	   7.32,	  dd	  (15.0,	  10.0)	  
4	   130.3,	  d	   6.37,	  dd	  (15.0,	  10.0)	  
5	   138.8,	  d	   6.62,	  dd	  (15.0,	  10.0)	  
6	   127.9,	  d	   6.67,	  dd	  (15.0,	  10.0)	  
7	   128.3,	  d	   6.83,	  d	  (15.0)	  
1′	   142.3,	  s	   	  
2′	   127.0,	  d	   7.04,	  d	  (3.5)	  
3′	   127.8,	  	   7.02,	  dd	  (5.0,	  3.5)	  
4′	   125.3,	  d	   7.23,	  d	  (5.0)	  
1′′	   38.9,	  t	   3.45,	  q	  (6.0)	  
2′′	   27.1,	  t	   2.43,	  m	  
3′′	   131.6,	  d	   5.60,	  m	  
4′′	   126.2,	  d	   5.60,	  m	  
5′′	   60.2,	  t	   4.66,	  d	  (5.5)	  
1′′′	   173.5,	  s	   	  
2′′′	   43.4,	  t	   2.23,	  d	  (7.0)	  
3′′′	   25.7,	  d	   2.13,	  m	  
4′′′	   22.4,	  q	   1.00,	  d	  (6.5)	  
5′′′	   22.4,	  q	   1.00,	  d	  (6.5)	  
NH	   	   6.16,	  br,	  s	  
aMultiplicity	   was	   determined	   by	   analysis	   of	   the	   APT	   spectrum.	   bJ	  





11.3.3	  	  Strucure	  Elucidation	  of	  Compound	  	  12	  
Compound	  12	  showed	  a	  pseudomolecular	  ion	  peak	  at	  m/z	  441.1908	  
[M	  +	  H]+	  (calc.	  441.1908)	   in	  HR-­‐TOF-­‐ESI	  mass	  spectrum	  (Figure	  57),	  
accounting	   for	   the	   elemental	   composition	   of	   C25H28O7,	   possessing	  














Analysis	  of	  the	  1H,	  13C	  and	  APT	  NMR	  data	  (Figures	  58-­‐59)	   (Table	  4)	  
and	   the	   HSQC	   spectrum	   of	   12	   revealed	   the	   presence	   of	   three	   sp3	  
methine,	   two	   sp3	  methylene,	   four	  methyl,	   eight	   sp2	  methine,	   and	  
eight	  sp2	  quaternary	  carbons.	  The	  1H	  NMR	  spectrum	  of	  12	  (Table	  4)	  
revealed	   the	   presence	   of	   a	   dihydrobenzofuran-­‐type	   lignan	  moiety	  
[δH	  5.55	  (1H,	  d,	  J	  =	  7.0	  Hz,	  H-­‐7),	  3.82	  (1H,	  m,	  H-­‐8),	  4.41	  (2H,	  d,	  J	  =	  6.0	  
Hz,	   H-­‐9)],	   which	   was	   supported	   by	   resonances	   in	   the	   13C	   NMR	  
spectrum	  (Table	  4)	  [δC	  89.4	  (CH,	  C-­‐7),	  50.0	  (CH,	  C-­‐8),	  64.6	  (CH2,	  C-­‐9)].	  
	  












Furthermore,	  a	  ferulyl	  aldehyde	  group	  [δH	  9.67	  (1H,	  d,	  J	  =	  7.5	  Hz,	  H-­‐
9′),	  7.42	  (1H,	  d,	  J	  =	  15.5	  Hz,	  H-­‐7′),	  7.11	  (1H,	  s,	  H-­‐6′),	  7.06	  (1H,	  s,	  H-­‐2′),	  
6.61	   (1H,	   dd,	   J	   =	   15.5,	   7.5	   Hz,	   H-­‐8′)]	   and	   a	   3-­‐metoxy-­‐4-­‐
hydroxyphenyl	  	  moiety	  [δH	  6.89	  (1H,	  d,	  J	  =	  1.5	  Hz,	  	  H-­‐2),	  6.90	  (1H,	  dd,	  
J	  =	  7.5,	  1.5	  Hz,	  H-­‐6),	  6.91	  (1H,	  d,	  J	  =	  7.5	  Hz,	  H-­‐5)]	  could	  be	  detected	  
in	  the	  1H	  NMR	  spectrum	  (Figure	  58).	  
 
	  
Figure	  60.	  HSQC	  spectrum	  (500	  MHz)	  of	  12	  measured	  in	  CDCl3	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According	   to	   HMBC	   (Figure	   61)	   and	   COSY	   (Figure	   62)	   cross-­‐peaks,	  
the	   above	   groups	   were	   connected	   to	   the	   dihydrofuran	   nucleus,	  













	  	  	  	  	  	  





Figure	  62.	  DQF-­‐COSY	  (500	  MHz)	  of	  12	  measured	  in	  CDCl3	  
	  
Moreover,	  the	  1H	  and	  13C	  NMR	  spectra	  showed	  a	  isovaleroyl	  group	  
[δH	  2.18	  (2H,	  d,	  J	  =	  7.0	  Hz,	  H-­‐2′′),	  2.04	  (1H,	  m,	  H-­‐3′′),	  0.91	  (6H,	  d,	  J	  =	  
7.0	   Hz,	   H-­‐4′′,	   	   H-­‐5′′)	   linked	   at	   C-­‐9	   (δC	   =	   64.6),	   judged	   from	   the	  
observed	   correlations	   in	   the	   HMBC	   spectrum	   (Figure	   61)	   between	  











	  Figure	  63.	  	  Main	  HMBC	  and	  DQF-­‐COSY	  correlations	  of	  	  12	  	  	  	  	  	  
	  	  	  	  	  	  	  	  
The	  relative	  configuration	  of	  C-­‐7	  and	  C-­‐8	  was	  determined	  by	  ROESY	  
experiments	   and	   analyzing	   scalar	   (3JHH)	   coupling	   of	   the	   protons.	  
Namely,	  since	  the	  coupling	  constant	  of	  H-­‐7	  was	  7.0	  Hz,	  the	  relative	  
configuration	  of	  C-­‐7	  and	  C-­‐8	  was	  assigned	  as	  trans.	  	  
This	  observation	  was	  supported	  on	  the	  basis	  of	  the	  ROESY	  spectrum,	  
which	  showed	  correlations	  between	  H-­‐7	  and	  H-­‐9,	  and	  between	  H-­‐8	  
and	  H-­‐2	  and	  H-­‐6	  (Figure	  64).	  The	  absolute	  configuration	  of	  12	  could	  
not	   be	   determined	   due	   to	   the	   fact	   that	   a	   crystalline	   derivative	  
suitable	  for	  an	  X-­‐ray	  structure	  determination	  could	  not	  be	  obtained	  
from	  the	  compound	  isolated.	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Consequently,	  the	  structure	  of	  compound	  12	  was	  established	  as,	  9-­‐












Figure	  65.	  Structure	  of	  9-­‐isovaleroxy	  balanophonin	  (12)	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Table	   4.	   1H	   (500	   MHz)	   and	   13C	   (100	   MHz)	   NMR	   spectral	   data	   of	  
compound	  12	  	  (CDCl3,	  δ	  in	  ppm)	  
Position	   δC,	  multiplicity
a	   δH,	  multiplicity
b	  
1	   131.6,	  s	   	  
2	   108.6,	  d	   6.89,	  d	  (1.5)	  
3	   146.8,	  s	   	  
4	   146.1,	  s	   	  
5	   114.5,	  d	   6.91,	  	  d	  (7.5)	  
6	   119.6,	  d	   6.90,	  	  dd	  (7.5,	  1.5)	  
7	   89.4,	  d	   5.55,	  d	  	  (7.0)	  
8	   50.0,	  d	   3.82,	  m	  
9	   64.6,	  t	   4.41,	  d	  (6.0)	  
1′	   128.6,	  s	   	  
2′	   112.2,	  d	   7.06,	  s	  
3′	   144.8,	  s	   	  
4′	   151.2,	  s	   	  
5′	   128.3,	  s	   	  
6′	   118.3,	  d	   7.11,	  s	  
7′	   152.6,	  d	   7.42,	  d	  (15.5)	  
8′	   126.6,	  d	   6.61,	  dd	  (15.5,	  7.5)	  
9′	   193.4,	  d	   9.67,	  d	  (7.5)	  
1′′	   172.7,	  s	   	  
2′′	   43.2,	  t	   2.18,	  d	  (7.0)	  
3′′	   25.6,	  d	   2.04,	  m	  
4′′	   22.3,	  q	   0.91,	  d	  (7.0)	  
5′′	   22.3,	  q	   0.91,	  d	  (7.0)	  
3-­‐OCH3	   56.0	   3.89,	  s	  
3′-­‐OCH3	   56.1	   3.95,	  s	  	  




11.3.4	  	  In	  Silico	  Modelling	  Study	  	  
Up	   to	  now,	   it	   is	  believed	   that,	   for	  a	  high	  affinity	   to	  CB2	   receptors,	  
alkylamides	   should	   be	   N-­‐substituted	   with	   an	   isobutyl	   or	  
dimethylbutyl	  group	  and	  represented	  by	  a	  secondary	  alkylamide	  as	  
the	   amide	   proton	   seems	   to	   be	   involved	   in	   the	   CB2	   receptor	  
interaction.134	   	   Our	   findings	   are	   somewhat	   surprising	   because	  
among	   all	   tested	   compounds	   the	   most	   potent	   and	   selective	  
alkylamide	   resulted	   the	   tertiary	   amide	   1-­‐[(2E,4E,8Z)-­‐
tetradecatrienoyl]piperidine	  (10)	  which	  contain	  a	  piperidinyl	  moiety	  
linked	   to	   a	   C14	   acyl	   chain	   (see	   biological	   section,	   12.1,p.196).	  
Compound	   10	   showed	   CB2	   affinity	   higher	   than	   that	   of	   dodeca-­‐
2E,4E-­‐dienoic	   acid	   isobutylamide	   6,	   that	   is	   one	   of	   the	   active	  
principles	  of	  Echinacea	  species.	  In	  our	  hands,	  compound	  6	  displayed	  
a	  KiCB2	  value	  of	  0.9	  µM	  that	  is	  higher	  than	  that	  reported	  by	  Raduner	  
et	  al.5	   (KiCB2	  =	  0.06	  µM)	  but	   lower	   in	  respect	  to	  that	  measured	  by	  
Woelkart	   et	   al.71	   (KiCB2	   =	   9.694	   µM).	   As	   reported	   in	   a	   previous	  
work,5	   the	  discrepancy	  between	   the	  Ki	   values	   could	  be	  due	   to	   the	  




Until	  now,	  the	  presence	  of	  secondary	  amide	  group	  was	  described	  to	  
be	  essential	  for	  the	  activity	  of	  alkylamides	  isolated	  from	  Echinacea.5	  
In	   order	   to	   explore	   the	   nature	   of	   the	   ligand-­‐receptor	   interactions,	  
we	   have	   carried	   out	   docking	   experiments	   into	   CB2	   receptor	   by	  
means	  of	  GlideXP.136	  	  
We	   focused	   on	   the	   compound	   6	   and	   10,	   which	   show	   interesting	  
activity	  but	  differ	  for	  the	  presence	  of	  secondary	  and	  tertiary	  amide	  
moiety	   respectively.	   3D	  models	   of	   CB2	   human	   receptor	   has	   been	  
generated	   by	   homology	   modeling	   using	   as	   template	   the	   X-­‐ray	  
structure	   of	   the	   human	   A2A	   adenosine	   receptor	   with	   UK-­‐432097	  
(PDB:3QAK)137	  as	  reported	  by	  Ruhl	  et	  al.138	  The	  obtained	  complexes	  
were	  optimized	  by	   energy	  minimization	   and	   successive	   interaction	  
energies	   calculation	   applying	  molecular	  mechanics	   and	   continuum	  
solvation	   models	   using	   the	   molecular	   mechanics	   generalized	  
Born/surface	  area	  (MM-­‐GBSA)	  method.139	  According	  to	  the	  available	  
literature	   information,	   we	   validated	   our	   simulation	   protocol	   by	  
docking	  the	  compound	  WIN55212-­‐2	  in	  both	  wild	  type	  and	  mutated	  
F5.46(197)V	   receptor.	   In	   fact	   a	   decreased	   ligand	   affinity	   for	   the	  
mutated	  CB2	  was	  disclosed.140	  
The	  applied	  protocol	  confirmed	  the	  importance	  of	  F197	  residue.	  The	  
complex	   is	   stabilized	   by	   tilted	   T-­‐shaped	   edge-­‐to-­‐face	   aromatic	  
110 
 
interaction	  between	  the	  indole	  ring	  of	  the	  ligand	  and	  F5.46(197),	  by	  
π-­‐π	   stacking	  with	  F3.36(117)	  and	  cation-­‐	  π	  with	  K3.28(109)	   (Figure	  
66	   and	   Table	   5).	   The	   same	   experiment	   with	   the	   mutated	  
F5.46(197)V,	   produced	   a	   	   loss	   of	   the	   stability	   of	   the	   complex	   as	  





Table	  5.	  ΔTotal	   Interaction	  Energy	   (IE)	   Term	  expressed	   in	   kcal/mol	  
per	  complex	  
	  
CB2	  receptor	   Ligand	   DTotal-­‐IE	  
wt	   WIN55212-­‐2	   -­‐28.24	  
F197V	   WIN55212-­‐2	   -­‐24.44	  
wt	   6	   -­‐27.93	  










Figure	  66.	  Optimized	  docked	  poses	  of	  complexes	  CB2-­‐Ligand:	  a)	  wt-­‐
WIN55212-­‐2;	   b)	   F197Vmut-­‐WIN55212-­‐2;	   c-­‐d)	   	   2D	   visualization	   of	  




Consecutively,	   the	   analysis	   of	   the	   putative	   binding	   modes	   of	  
compounds	  	  6	   	  and	  10	  	  (Figure	  67)	  highlighted	  the	  accommodation	  
of	  the	  amide	  group	  in	  a	  hydrophilic	  area,	  enclosed	  by	  polar	  residues	  
(e.g.	   Asn	   188,	   Asp-­‐189,	  Gln-­‐276	   and	   Lys	   279),	   and	   of	   the	   alkyl	   tail	  
into	  a	  hydrophobic	  cleft,	   surrounded	  by	  aromatic	  and	  hydrophobic	  
residues	   (e.g.	   Phe-­‐87-­‐91-­‐94-­‐117-­‐197,	   Trp-­‐258	   and	   Val261,	   Leu264,	  
Leu262	  respectively).	  
Both	  compounds	  6	   and	  10	  are	  able	   to	  establish	  a	   strong	  hydrogen	  
bond	   with	   Asn188:	   in	   the	   former	   compound	   the	   amide	   group	  
behaves	   as	   a	   donor,	  while	   in	   the	   latter	   as	   an	   acceptor.	   Therefore,	  
the	  presence	  of	  the	  secondary	  amide	  as	  donor	  group	   is	  not	  critical	  
for	  activity.	  Furthermore	  the	  docking	  of	  compound	  10	  confirms	  the	  
importance	  of	  double	  bond	  with	  Z	  configuration	  at	  C8	  position.	  This	  
diasteroisomer	  can	  adopt	  an	  U	  shape	  conformation	  which	  perfectly	  
fit	   into	   the	   binding	   pocket	   and	   increases	   the	   number	   of	   good	  
contacts	  between	  ligand-­‐receptor	  (Figure	  67).	  This	  particular	  feature	  




























Figure	   67.	   Optimized	   docked	   poses	   of	   complexes	   CB2-­‐Ligand:	   a)	  
CB2wt-­‐6;	   b)	   CB2wt-­‐10;	   c-­‐d)	   2D	   visualization	   of	   interactions	   of	  




11.3.5	  	  Structure	  Elucidation	  of	  Known	  
Compounds	  
The	   structure	   of	   the	   known	  metabolites	  were	   deduced	   from	  NMR	  
spectroscopy	  and	  mass	  spectrometry	  and	  confirmed	  by	  comparison	  





heptatrienamide  (2) 
	  
(2E,4E,6E)-­‐N-­‐isobutyl-­‐7-­‐(2-­‐thienyl)-­‐2,4,6-­‐heptatrienamide	   	   (2)	   was	  
identified	   by	   comparison	   of	   the	   1H	   (Figure	   69)	   and	   13C	   (Figure	   70)	  























































1-­‐[(2E,4E,6E)-­‐7-­‐(2-­‐thienyl)-­‐2,4,6-­‐heptatrienoyl]piperidine	   (3)	   was	  
identified	  by	  comparison	  of	  the	  1H	  (Figure	  72)	  and	  APT	  (Figure	  
73)	   NMR	   chemical	   shifts	   and	   ESI-­‐MS(Figure	   71)	   data	   with	  
literature	  values.142	  
 
            





































dehydropiperidine	  (4)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  
75)	  and	  13C	  (Figure	  76)	  NMR	  chemical	  shifts	  and	  ESI-­‐MS	  (Figure	  74)	  
data	  with	  literature	  values.65	  
 
              
 
































Dodeca-2E,4E-dienoic acid isobutylamide (6) 
 
dodeca-­‐2E,4E-­‐dienoic	   acid	   isobutylamide	   (6)	   was	   identified	   by	  
comparison	  of	  the	  1H	  (Figure	  78)	  and	  13C	  (Figure	  79)	  NMR	  chemical	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Tetradeca-2E,4E-dienoic acid isobutylamide (7) 
 
Tetradeca-­‐2E,4E-­‐dienoic	   acid	   isobutylamide	   (7)	   was	   identified	   by	  
comparison	  of	  the	  1H	  (Figure	  80)	  and	  13C	  (Figure	  81)	  NMR	  chemical	  




























Tetradeca-2E,4E,8Z-trienoic acid isobutylamide (8) 
	  
Tetradeca-­‐2E,4E,8Z-­‐trienoic	  acid	  isobutylamide	  (8)	  was	  identified	  by	  












1-­‐[(2E,4E)-­‐tetradecadienoyl]piperidine	   (9)	   was	   identified	   by	  
comparison	  of	  the	  1H	  (Figure	  83)	  and	  13C	  (Figure	  84)	  NMR	  chemical	  



























1-­‐[(2E,4E,8Z)-­‐tetradecatrienoyl]piperidine	   (10)	   was	   identified	   by	  
comparison	  of	   the	   1H	   (Figure	  85)	  NMR	  chemical	   shifts	   	  and	  ESI-­‐MS	  




















Pontica epoxide (11) 
	  
Pontica	   epoxide	   (11)	  was	   identified	   by	   comparison	  of	   the	   1H	  NMR	  
(Figure	  87)	  chemical	  shifts	  data	  with	  literature	  values.65	  
13C	   NMR	   assignments	   for	   compound	   11	   (Figure	   88),	   which	   are	  


































Table	  6.	  13C	  (100	  MHz)	  NMR	  spectral	  data	  of	  compound	  11	  (CDCl3,	  δ	  
in	  ppm)	  
Position	   δC,	  multiplicity
a	  
1	   	  
2	   143.9	  
3	   59.0	  
4	   61.2	  
5	   134.2	  
6	   111.7	  
7	   76.6	  
8	   68.0	  
9	   58.7	  
10	   72.8	  
11	   64.8	  
12	   78.7	  


















Sesamin	  (13)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  89)	  and	  



























Puberulin	  (14)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  91)	  




























Espeletone	  (15)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  93)	  
























(2Z,6E,10E)-­‐geranylgeraniol	  (16)	  was	  identified	  by	  comparison	  of	  the	  



























11.4	  	  Extraction	  of	  S.	  glutinosa	  Aerial	  Parts	  	  
The	   powered	   dried	   aerial	   parts	   of	   S.	   glutinosa	   (548	   g)	   were	  
succesively	  extracted	  with	  DCM	  and	  MeOH	  yielding	  52.4	  g	  and	  110	  
g,	  respectively.	  The	  extraction	  was	  carried	  out	  by	  percolation	  during	  
the	  day	  and	  at	  night	  the	  roots	  were	  left	  to	  maceration.	  	  
	  
11.5	  	  Isolation	  of	  Metabolites	  from	  S.	  glutinosa	  	  	  
The	  DCM	  extract	  exhibited	  good	  binding	  affinity	   to	  µ	  and	  δ	  opioid	  
receptors	  (Table	  1)	  and	  was	  therefore	  subjected	  to	  fractionation	  by	  
silica	   gel	   vacuum-­‐liquid	   chromatography	   (VLC)	   and	   column	  
chromatography	  (silica	  gel	  and	  Sephadex	  LH	  20)	  to	  give	  four	  known	  
flavones	   (17,	   18,	   19,	   20),	   one	   known	   neo-­‐clerodane	   (21)	   and	   one	  










	  Figure	  97.	  Structures	  of	  the	  compounds	  isolated	  from	  S.	  glutinosa	  
11.6	  	  Semi-­Synthesis	  of	  5-­demethyltangeretin	  and	  
Tangeretin	  	  
In	  order	  to	  find	  a	  structure-­‐activity	  relationship,	  two	  key	  derivatives,	  
5-­‐demethyltangeretin	   (23)150	   and	   tangeretin	   (24)151,152	   were	   also	  
prepared	   by	   methylation	   with	   dimethyl	   sulfate	   of	   compound	   17	  
(Figure	  98).	  
	  
	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  98.	  Synthesis	  of	  compounds	  	  23	  	  and	  	  24	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11.7	  	  STRUCTURE	  ELUCIDATION	  OF	  SECONDARY	  	  	  	  	  	  	  	  	  	  	  
METABOLITES	  FROM	  S.	  GLUTINOSA	  
 
11.7.1	  	  Structure	  Elucidation	  of	  Compound	  22	  
Compound	  22	  was	  obtained	  as	  white	  amorphous	  solid.	  The	  13C	  NMR	  
spectrum	  of	  compound	  22	  (Figure	  100)	  exhibited	  20	  carbon	  signals,	  
which	  were	  sorted	  by	  APT	  NMR	  (Figure	  101)	   into	   five	  CH3,	  six	  CH2,	  
five	  CH,	  and	  four	  quaternary	  carbons	  (Table	  7).	  This	  corresponded	  to	  
the	   molecular	   formula	   C20H34O3,	   in	   agreement	   with	   a	  
pseudomolecular	  ion	  at	  m/z	  345.2418	  [M	  +	  Na]+	  (calc.	  345.2406)	  in	  
HR-­‐TOF-­‐ESI	  mass	  spectrum	  (Figure	  99).	  	  	  
	  
	  











Figure	   100.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   22	  











Figure	   101.	   APT	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   22	  




The	   1H	   NMR	   spectrum	   of	   22	   (Figure	   102)	   (Table	   7)	   exhibited	   four	  
methyl	  groups	  at	  δH	  0.66	  (3H,	  s,	  H3-­‐20),	  1.04	  (3H,	  s,	  H3-­‐19),	  1.20	  (3H,	  
s,	  H3-­‐18),	  and	  1.28	  (3H,	  s,	  H3-­‐16),	  one	  secondary	  methyl	  group	  at	  δH	  
0.76	  (3H,	  d,	  J	  =	  6.5	  Hz,	  H3-­‐17),	  a	  vinyl	  system	  (δH	  5.08,	  1H,	  dd,	  J	  =	  1,	  
10.8	  Hz,	  H-­‐15A;	  5.21,	  1H,	  dd,	  J	  =	  1,	  17.2	  Hz,	  H-­‐15B;	  5.88,	  1H,	  dd,	  J	  =	  
10.8,	   17.2	   Hz,	  H-­‐14),	   two	   oxygenated	  methine	   protons	   at	   δH	   3.06	  
(1H,	  br	  s,	  H-­‐3),	  and	  3.90	  (1H,	  ddd,	  J	  =	  2.0,	  6.0	  Hz,	  H-­‐2),	  two	  methines	  
at	  δH	  0.88	  (1H,	  bd	  ,	  J	  =	  11.5	  Hz),	  and	  1.42	  (1H,	  m,	  H-­‐8),	  and	  partially	  




Figure	  102.	  1H	  NMR	  spectrum	  (500	  MHz)	  of	  compound	  22	  measured	  
in	  CDCl3	  
	  The	   1H	  and	   13C	  NMR	  spectra	   (Table	  7	   )	   of	  22	  were	  very	   similar	   to	  
those	  of	  the	  neo-­‐clerodane	  diterpene	  21,	  roseostachenone,	  and	  the	  
main	  differences	  between	  the	  two	  compounds	  were	  the	  presence	  of	  
two	  oxy-­‐methines	  at	  δH	  3.90	  (δC	  70.7)	  and	  δH	  3.06	  (δC	  65.2)	  instead	  
of	  a	  ketone	  group	  (δC	  200.5)	   	  and	  of	  an	  olefinic	  proton	  signal	  at	  δH	  
5.67	  (δ	  125.5)	  in	  roseostachenone.	  
The	  observed	  HMBC	  correlations	  of	  the	  oxy-­‐methine	  at	  δH	  3.06	  with	  
C-­‐1	  (δC	  25.3),	  C-­‐2	  (δC	  70.7),	  C-­‐4	  (δC	  70.4),	  C-­‐18	  (δC	  19.4),	  and	  of	  the	  
further	   oxy-­‐methine	   at	   δH	   3.90	  with	   C-­‐1	   and	   C-­‐3	   (δC	   65.2),	   and	   of	  
methylene	  protons	  at	  δH	  1.63	  and	  1.16	  with	  C-­‐2,	  C-­‐3,	  C-­‐5	  (δC	  36.2),	  
and	   C-­‐10	   (δC	   46.3)	   (Figure	   104-­‐105),	   suggested	   that	   the	   two	   oxy-­‐
methine	  protons	  at	  δH	  3.90	  and	  δH	  3.06	  were	  attached	  to	  C-­‐2	  and	  C-­‐





















Figure	  104.	  HMBC	  spectrum	  (500	  Mhz)	  of	  compound	  22	  measured	  









Figure	  105.	  HMBC	  spectrum	  (500	  Mhz)	  of	  compound	  22	  measured	  


























The	   location	   of	   the	   above	  mentioned	   protons	   were	   confirmed	   by	  
DQF-­‐COSY	  experiments.	  In	  fact,	  in	  the	  COSY	  spectrum	  the	  proton	  at	  
δH	   3.90	   correlated	   with	   the	   methine	   at	   δH	   3.06	   and	   with	   the	  
methylene	   protons	   at	  δH	   1.63	   and	   1.16	  while	   the	  methine	   at	   3.06	  
ppm	  showed	  cross-­‐peaks	  with	  the	  proton	  at	  3.90	  but	  not	  with	  those	  
at	  1.63	  and	  1.16	  ppm	  (Figure	  108-­‐109).	  	  
	  
	  	  	  	  	  	  	  Figure	  108.	  DQF-­‐COSY	  (500	  MHz)	  of	  compound	  22	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Since	  compound	  22	  has	  4°	  of	  unsaturation,	  22	  may	  also	  contain	  one	  
epoxide	  ring.	  This	  proposal	  was	  confirmed	  by	  a	  broad	  singlet	  at	  δH	  
3.06	  (H-­‐3)	  in	  the	  1H	  NMR	  spectrum,	  indicating	  a	  3,4-­‐epoxy	  group.	  
	  
	  






























The	   relative	   configuration	   of	   22	   was	   elucidated	   analyzing	   the	   13C	  
NMR	  values	  and	  by	  ROESY	  experiment.	  The	  chemical	  shifts	  of	  C-­‐19	  
and	  C-­‐20	  clearly	   indicated	  a	  trans-­‐AB	  ring	   junction.153	  ROESY	  cross-­‐
peaks	  of	  H-­‐2/H-­‐10,	  H-­‐1β/H-­‐2,	  and	  H-­‐2/H-­‐3	  were	  congruent	  with	  a	  α-­‐
orientation	   both	   for	   the	   C-­‐2	   hydroxyl	   group	   and	   3,4-­‐epoxy	   group	  
(Figure	  111-­‐112).	  Thus,	  compound	  22	  is	  3,4α-­‐epoxy	  roseostachenol.	  
	  


















                 	  







Table	   7.	   1H	   (500	   MHz)	   and	   13C	   (100	   MHz)	   NMR	   spectral	   data	   of	  
compounds	  4	  	  (CDCl3,	  δ	  in	  ppm)	  
	  
	  aMultiplicity	   was	   determined	   by	   analysis	   of	   the	   APT	   spectrum.	   bJ	  
values	  (Hz)	  in	  parentheses.	  
Position δC, multiplicitya δH, multiplicityb 
1 25.3, t α 1.16,m ; β 1.63, m 
2 70.7, d 3.90, m 
3 65.2, d 3.06,d,br 
4 70.4, s  
5 36.2, s  
6 36.8, t α 1.25,m ; β 1.65, m 
7 27.9, t 1.45, m 
8 35.8, d 1.42, m 
9 38.6, s  
10 46.3, d 0.88, d,br 
11 31.8, t α 1.24,m ; β 1.36, m 
12 35.3, t α 1.23,m ; β 1.37, m 
13 73.3, s  
14 144.9, d 5.88, dd 
15 112.0, t cis 5.08, dd 
trans 5.21, dd 
16 27.8, q 1.28, s 
17 15.8, q 0.76, d 
18 19.4, q 1.20, s 
19 16.5, q 1.04, s 
20 18.7, q 0.66, s 
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11.7.2	  	  Structure	  Elucidation	  of	  Known	  
Compounds	  
The	  following	  known	  compounds	  were	  also	  identified:	  xanthomicrol	  
(17),	   sideritoflavone	   (18),	   8-­‐methoxycirsilineol	   (19),	   eupatilin	   (20),	  
roseostachenone	   (21),	   5-­‐demethyltangeretin	   (23)	   and	   tangeretin	  
(24).	   They	   were	   confirmed	   by	   comparison	   of	   physical	   and	  






Xanthomicrol	  (17)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  




















Figure	   114.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   17	  






Sideritoflavone	  (18)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  



















Figure	   116.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   18	  









8-­‐methoxycirsilineol	  (19)	  was	  identified	  by	  comparison	  of	  the	  1H	  



















Figure	   118.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   19	  





Eupatilin	  (20)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  120)	  
and	  13C	  (Figure	  121)	  NMR	  chemical	  shifts	  and	  EI-­‐MS	  (Figure	  119)	  
































Figure	   121.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   20	  





Roseostachenone	  (21)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Fig-­‐




















Figure	   123.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   21	  







5-­‐demethyltangeretin	  (23)	  was	  identified	  by	  comparison	  of	  the	  1H	  
(Figure	  124)	  and	  13C	  (Figure	  125)	  NMR	  chemical	  shifts	  data	  with	  lit-­‐
erature	  values.150 
	  













Figure	   125.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   23	  







Tangeretin	  (24)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  126)	  
NMR	  chemical	  shifts	  data	  with	  literature	  values.151,152 
 
	  





11.8	  	  Isolation	  of	  Metabolites	  from	  W.	  somnifera	  
The	   commercial	   MeOH	   extract	   of	   W.	   somnifera	   (WSE)	   (Natural	  
Remedies	  Pvt.	  Ltd.,	  Bangalore,	   India)	  showed	  an	  interesting	  affinity	  
to	  GABAA	  and	  a	  very	  low	  affinty	  to	  CB	  and	  opioid	  receptors	  whereas	  
the	  alcaloid	  fraction	  of	  WSE	  (WSAE),	  obtained	  by	  liquid-­‐liquid	  parti-­‐
tion	  of	  WSE,	  besides	  the	  good	  affinity	  towards	  GABAA,	  displayed	  an	  
appreciable	  affinity	   to	  CB,	  µ	   and	  δ	  opioid	   receptors	   (Table	  1).	  As	  a	  
consequence,	  WSE	   and	  WSAE	  were	   subjected	   to	   chromatographic	  
techinques	   to	   give	   withanolide	   A	   (30),	   withanone	   (31,)	   and	  
withaferin	  A	  (32,)	  (Figure	  127)	  from	  the	  first	  and	  (+)-­‐sedridine	  (25),	  
anaferine	  (26),	  tropine	  (27),	  choline	  (28)	  and	  ferulic	  acid	  methyl	  es-­‐
ter	  (29),	  from	  the	  latter	  (Figure	  128).	  	  
As	   far	  as	  we	  know,	  (+)-­‐sedridine	  has	  been	   isolated	  from	  W.	  somni-­‐







	  	  Withanolide	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  (31)	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                           (+)-Sedridine	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  acid	  methyl	  ester	  (29)	  	  	  	  
	  




11.8.1	  	  Structure	  Elucidation	  of	  Known	  
Compounds	  
The	   structure	   of	   the	   known	  metabolites	  were	   deduced	   from	  NMR	  
spectroscopy,	   mass	   spectrometry	   and	   optical	   rotation	   and	  
confirmed	   by	   comparison	   either	   with	   reference	   compounds	  






The	  structure	  of	  (+)-­‐sedridine	  was	  confirmed	  by	  comparing	  the	  MS,	  	  
1H,	  13C	  NMR	  (Figure	  129-­‐131)	  data	  and	  optical	  rotation	  with	  those	  of	  
authentic	  sample.	  
	  
























Figure	  131.	  13C	  NMR	  spectrum	  (100	  MHz)	  of	  compound	  25	  




Anaferine  (26) 
 
Anaferine	  (26)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  133)	  
and	  13C	  (Figure	  134)	  NMR	  chemical	  shifts	  and	  ESI-­‐MS	  (Figure132)	  




























Figure	   134.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   26	  






Tropine	  (27)	  was	  identified	  by	  comparison	  of	  the	  13	  C	  NMR	  (Figure	  





Figure	   135.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   27	  




Choline  (28) 
 
Choline	  (28)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  136)	  and	  















Figure	   137.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   28	  





Ferulic acid methyl ester (29) 
	  
Ferulic	  acid	  methyl	  ester	  (29)	  was	  identified	  by	  comparison	  of	  the	  1H	  
(Figure	  139)	  and	  13C	  (Figure	  140)	  NMR	  chemical	  shifts	  and	  ESI-­‐
MS(Figure	  138)	  data	  with	  literature	  values.161	  
 
             





















Figure	   140.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   29	  




Withanolide A (30) 
 
Withanolide	  A	  (30)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  

















Figure	   142.	   13C	   NMR	   spectrum	   (500	   MHz)	   of	   compound	   30	  






Withanone	  (31)	  was	  identified	  by	  comparison	  of	  the	  1H	  (Figure	  143)	  
NMR	  chemical	  shifts	  with	  literature	  values.162 
 
	  





Withaferin A (32) 
	  
Withaferin	   A	   (32)	   was	   identified	   by	   comparison	   of	   the	   1H	   (Figure	  















Figure	   145.	   13C	   NMR	   spectrum	   (100	   MHz)	   of	   compound	   32	  





12.	  	  BIOLOGICAL	  RESULTS	  
 
12.1	  	  Opioid	  and	  Cannabinoid	  Binding	  Affinity	  of	  
Compounds	  Isolated	  from	  O.maritimus	  
As	  shown	   in	   table	  8,	  DCM	  extract	   from	  O.	  maritimus	  exhibited	   the	  
highest	   affinity	   for	   the	  CB1	  and	  CB2	   receptor	  with	  Ki	   values	  of	   2.2	  
µg/ml	  and	  1.3	  µg/ml	  respectively.	  The	  same	  extract	  was	  able	  to	  bind	  
to	   µ	   and	   δ	   with	   Ki	   values	   higher	   than	   those	   showed	   in	   the	   CB	  
radioligand	   screening	   assay.	   All	   the	   isolated	   amides	   (1-­‐10),	   the	  
known	   pontica	   epoxide	   (11)	   and	   the	   new	   neo-­‐lignan	   (12)	   were	  
evaluated	  for	  the	  first	  time,	  except	  6,	  for	  their	  binding	  affinity	  to	  the	  
µ	   and	   δ	   opioid	   as	   well	   as	   to	   the	   CB1	   and	   CB2	   receptors	   and	   the	  
corresponding	  Ki	  values	  were	  expressed	  in	  µM	  (Table	  8).	  
	  1-­‐[(2E,4E,8Z)-­‐tetradecatrienoyl]piperidine	  (10)	  was	  the	  most	  potent	  
binder	  to	  both	  CB1	  and	  CB2	  receptors	  with	  a	  Ki	  value	  of	  0.8	  µM	  and	  
0.16	  µM,	  respectively.	  It	  showed	  also	  the	  most	  CB2	  selectivity	  with	  a	  
KiCB1/KiCB2	  =	  5	  (Table	  1).	  Compound	  9	  compared	  with	  10	  displayed	  
a	   strong	   reduced	   CB2	   affinity	   (KiCB2	   about	   150	   times	   higher).	  
Compound	  10	  with	  respect	  to	  9	  contain	  a	  further	  double	  bond	  with	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Z	   configuration	   at	   C8	   position	   of	   the	   acyl	   chain	   that	   seems	   to	   be	  
essential	  for	  a	  high	  affinity	  of	  the	  piperidide	  to	  the	  CB2	  receptor.	  
	  The	  influence	  of	  Z	  double	  bond	  at	  C8	  of	  the	  tetradeca-­‐2E,4E-­‐dienoic	  
acid	   isobutylamides	   to	   CB2	   receptor	   affinity	   was	   decisively	   minor	  
but	   still	   valuable	   as	   observed	   for	   amides	  7	   and	  8	   (Table	   1).	   In	   the	  
case	   of	   ∆8-­‐containing	   compound	   (8)	   2	   fold	   increased	   affinity,	   as	  
compared	   to	   7,	   was	   observed.	   The	   influence	   of	   double	   bonds	  
geometry	   in	  dodeca-­‐tetraenoic	  acid	   isobutylamides	  with	  regards	  to	  
CB2	   receptor	   affinity	   has	   been	   reported	   previously	   by	  Matovic	   et	  
al.141	  They	  found	  that	  tetraenes	  alkylamides	  with	  8Z,	  10Z	  geometry	  
displayed	  high	  binding	  affinity	  for	  CB2	  receptor.	  
Among	  the	  thienylheptatrienamides	   (1-­‐5),	  piperidide	  3	   showed	  the	  
highest	   affinity	   and	   selectivity	   to	   CB2	   receptors	   (KiCB2	   =	   1.24	  µM;	  
KiCB1/KiCB2	  =	  3.3).	  The	  substitution	  of	  piperidinyl	  group	  in	  3	  with	  a	  
2,3-­‐dehydropiperidinyl	  ring,	  as	  in	  compound	  4,	  significantly	  reduced	  
binding	  affinity	  to	  CB2	  receptor	  (Ki	  =	  13.5	  µM)	  and	  annulled	  the	  CB1	  
binding	  affinity	  (Ki	  >	  50	  µM).	  The	  replacement	  of	  piperidinyl	  moiety	  
of	   3	   with	   an	   amino-­‐isopentyl,	   amino-­‐isobuthyl	   or	   5-­‐amino-­‐2-­‐
pentenyl	   3-­‐methylbutanoyl	   group	   reduced	   CB2	   and	   increased	   CB1	  
affinity.	   The	  new	  neo-­‐lignan	   12	   exhibited	  moderate	  affinity	   to	  CB1	  
(Ki	  =	  2.7	  µM)	  and	  CB2	  (Ki	  =	  4.2	  µM)	  receptors.	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Furthermore,	   compounds	   1-­‐12	   were	   screened	   for	   inhibition	   of	  
binding	  to	  µ	  and	  δ	  receptors	  (MOR	  and	  DOR)	  (Table	  8).	  	  
The	   most	   active	   compounds	   resulted	   amides	   8-­‐10	   and	   the	   new	  
compound	   9-­‐isovaleroxy	   balanophonin	   (12)	   displaying	   moderate	  
binding	  affinity	   to	  both	  MOR	  and	  DOR	  with	  Kì	   values	   ranging	   from	  
3.8	   to	   9	   µM.	   The	   Z	   double	   bond	   at	   C8	   of	   tetradeca	   acid	  
isobutylamides	   increased	  once	  a	   time	  the	  receptor	  binding	  but	  did	  
not	   influence	   the	   affinity	   for	   piperidides.	   In	   fact,	   despite	  what	  we	  
observed	   in	   the	   CB	   receptors	   screenings,	   piperidinyl	   amide	   10	  
showed	   MOR	   and	   DOR	   affinity	   comparable	   to	   that	   of	   9.	  
Interestingly,	  alkylamide	  6	  had	  the	  highest	  MOR	  to	  DOR	  selectivity	  
(KiDOR/KiMOR	   =	   5.2)	   among	   all	   tested	   compounds.	   In	   the	  
thienylheptatrienamides	   series	   a	   N-­‐isopentyl	   chain	   improved	   the	  
affinity	   for	   MOR	   while	   a	   N-­‐2-­‐pentenyl	   3-­‐methylbutanoyl	   moiety	  
increased	   the	   affinity	   for	   DOR	   as	   compared	   to	   compound	   2	  
containing	  a	  N-­‐isobutyl	  chain.	  In	  our	  previous	  work164	  we	  found	  that	  
falcarinol,	   a	   polyacetilene	   relatively	   widespread	   in	   Apiaceae	   and	  
Araliaceae,	  bound	  CB1	  receptor	  as	  covalent	  inverse	  agonist.	  On	  the	  
basis	   of	   the	   structural	   similarity	   between	   falcarinol	   and	   pontica	  
epoxide	  (11),	  we	  evaluated	  the	  binding	  affinity	  also	  for	  polyyne	  11,	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but	   we	   did	   not	   find	   any	   affinity	   neither	   for	   CB	   nor	   for	   opioid	  
receptors	  up	  to	  50	  µM	  (Table	  8).	  	  
Up	   to	  now,	   it	   is	  believed	   that,	   for	  a	  high	  affinity	   to	  CB2	   receptors,	  
alkylamides	   should	   be	   N-­‐substituted	   with	   an	   isobutyl	   or	  
dimethylbutyl	  group	  and	  represented	  by	  a	  secondary	  alkylamide	  as	  
the	   amide	   proton	   seems	   to	   be	   involved	   in	   the	   CB2	   receptor	  
interaction.165	  
Our	   findings	   are	   somewhat	   surprising	   because	   among	   all	   tested	  
compounds	   the	  most	  potent	   and	   selective	   alkylamide	   resulted	   the	  
tertiary	  amide	  1-­‐[(2E,4E,8Z)-­‐tetradecatrienoyl]piperidine	  (10)	  which	  
contain	  a	  piperidinyl	  moiety	   linked	   to	  a	  C14	  acyl	   chain.	  Compound	  
10	   showed	   CB2	   affinity	   higher	   than	   that	   of	   dodeca-­‐2E,4E-­‐dienoic	  
acid	   isobutylamide	   6,	   that	   is	   one	   of	   the	   active	   principles	   of	  
Echinacea	   species.	   In	   our	   hands,	   compound	   6	   displayed	   a	   KiCB2	  
value	  of	  0.9	  µM	  that	  is	  higher	  than	  that	  reported	  by	  Raduner	  et	  al.5	  
(KiCB2	   =	   0.06	   µM)	   but	   lower	   in	   respect	   to	   that	   measured	   by	  
Woelkart	   et	   al.71	   (KiCB2	   =	   9.694	   µM).	   As	   reported	   in	   a	   previous	  
work,5	   the	   discreancy	   between	   the	   Ki	   values	   could	   be	   due	   to	   the	  
different	   source	   of	   CB2	   receptors,	   as	   well	   as	   experimental	  
condition.135	  Docking	  experiments	  into	  CB2	  receptor	  of	  compounds	  
6	   and	   10	   by	   means	   of	   GlideXP136	   (see	   in	   silico	   	   modeling	   	   study,	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11.3.4,	  p.106)	  revealed	  that	  the	  presence	  of	  the	  secondary	  amide	  as	  
donor	  group	   is	  not	   critical	   for	   activity,	   confirming	   the	  high	  binding	  
affinity	  of	  alkilamide	  10.	  
	  
Table	  8.	  Ki	   values	  of	  DCM	  extract	  and	   isolated	  compounds	  for	  can-­‐
nabinoid	  and	  opioid	  receptors	  
 
aValues expressed in µg/mL. 
Ki values were obtained from four independent experiments carry out in triplicate and are expressed as 
mean ± standard error. 
	  
Receptor Affinity  
(µM) 
    CB2 Selectivity Receptor Affinity 
           (µM) 
MOR Selectivity Extract/ 
Compd 
KiCB2 KiCB1 KiCB1/KiCB2 KiMOR KiDOR KiDOR/KiMOR 
DCM 1.3 ± 0.3a 2.2 ± 0.9a 1.69 : 1 10 ± 0.7 a 8.5 ± 1.3a 0.85 : 1 
1 5 ± 0.1 2.2 ± 1 0.44 : 1 8.1 ± 0.1 26.5 ± 1.5 3.27 : 1 
2 8.25 ± 1.4 8.8 ± 2.2 1.07 : 1 52 ± 0.5 25.5 ± 1.5 0.49 : 1 
3 1.24 ± 0.3 4.1 ± 0.8 3.3 : 1 12.8 ± 3.3 8 ± 1 0.63 : 1 
4 13.5 ± 0.5 > 50 - 29 ± 4 11.5 ± 2.1 0.40 : 1 
5 10.2 ± 2.3 5.6 ± 0.3 0.55 : 1 41.5 ± 13 11 ± 2 0.27 : 1 
6 0.9 ± 0.2 2.6 ± 0.4 2.89 : 1 8.2 ± 0.8 43 ± 9 5.24 : 1 
7 1.17 ± 0.28 1.4 ± 0.1 1.20 : 1 51 ± 0.4 22.5 ± 2.5 0.44 : 1 
8 0.55 ± 0.07 1.2 ± 0.3 2.18 : 1 7.5 ± 0.73 7.7 ± 1.4 1.03 : 1 
9 24 ± 2.5 6.7 ± 1.4 0.28 : 1 5.75 ± 0.25 6.5 ± 1.6 1.13 : 1 
10 0.16 ± 0.04 0.8 ± 0.1 5 : 1 7.4 ± 0.1 3.8 ± 0.7 0.51 : 1 
11 > 50 > 50 - > 50 > 50 - 




12.2	  Opioid	  Binding	  Affinity	  of	  Compounds	  
Isolated	  from	  S.glutinosa	  
Affinities	  for	  δ	  and	  µ	  opioid	  receptors	  from	  mouse	  brain	  membranes	  
were	   computed	   by	   displacement	   of	   [3H-­‐DPDPE]	   and	   [3HDAMGO],	  
respectively,	   in	   binding	   assays	   (Table	   9).	   The	   DCM	   extract	   from	   S.	  
glutinosa	   exhibited	   an	   interesting	   affinity	   for	   the	   µ	   and	   δ	   opioid	  
receptors	  with	  Ki	  values	  of	  10.3	  µg/ml	  and	  9.0	  µg/ml,	   respectively.	  
Among	   the	   isolated	   compounds,	   xanthomicrol	   (17)	   displayed	   the	  
strongest	   opioid	   binding	   affinity	   to	   both	   µ	   and	   δ	   opioid	   receptors	  	  	  
(Ki	   for	  MOR	  =	  0.825	  µM,	  Ki	   for	  DOR	  =	  3.6	  µM).	   It	   showed	  also	   the	  
most	  MOR	  selectivity	  with	  a	  KiDOR/KiMOR	  =	  4.4.	  The	  presence	  of	  a	  
further	   hydroxy	   group	   at	   3'	   position,	   as	   in	   sideritoflavone	   (18),	  
significantly	   reduced	   binding	   affinity	   to	  MOR	   (Ki	   =	   18.5	   µM)	  while	  
the	   replacement	   of	   this	   group	   with	   a	   methoxy	   moiety,	   as	   in	   8-­‐
methoxycirsilineol	   (19),	   annulled	   the	   affinity	   to	   the	  MOR	   (Ki	   >	   50	  
µM).	   In	   the	   semi-­‐synthetic	   derivative	   of	   1,	   5-­‐demethyltangeretin	  
(23),	   the	   4'-­‐hydroxy	   group	   has	   been	   substituted	   with	   a	   methoxy	  
moiety	  and	  the	  Ki	  value	  indicated	  that	  5-­‐demethyltangeretin	  had	  no	  
significant	  affinity	   for	  µ	   (Ki	   >	  50	  µM)	   receptor,	   as	   compared	   to	  17.	  
When	   both	   the	   free	   hydroxy	   groups	   of	   compound	   17	   were	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methoxylated,	  as	  in	  tangeretin	  (24),	  the	  affinity	  for	  the	  MOR	  was	  20-­‐
fold	  lower	  than	  that	  of	  17.	  Taken	  together,	  these	  results	  suggested	  
that,	   for	   a	   high	   affinity	   to	   µ	   receptors,	   5-­‐hydroxy-­‐6,7,8-­‐
trimethoxyflavones	   should	   be	   substituted	   with	   only	   one	   free	  
hydroxyl	   group	   at	   4'	   position	   of	   B	   ring.	   Roseostachenone	   (21)	  
exhibited	  very	  low	  affinity	  to	  µ	  (Ki	  =	  40.5	  µM)	  and	  δ	  (Ki	  =	  23.5	  µM)	  
receptors.	  
	  
Table	  9.	  Ki	  values	  of	  DCM	  extract	  and	  isolated	  compounds	  for	  opioid	  
receptor	  
aValues	  expressed	  in	  μg/ml.	  
Ki	  values	  were	  obtained	  from	  four	  independent	  experiments	  carry	  out	  in	  triplicate	  and	  are	  expressed	  
as	  mean	  ±	  standard	  error.	  
	  
Receptor	  Affinity	  (µM)	   MOR	  Selectivity	  Extract/Compound	  
KiMOR	   KiDOR	   KiDOR/KiMOR	  
DCM	   10.3	  ±	  0.2a	   9.0	  ±	  1a	   0.87	  :	  1	  
17	   0.825	  ±	  0.025	   3.6	  ±	  0.8	   4.36	  :	  1	  
18	   18.5	  ±	  0.8	   12.5	  ±	  1	   0.68	  :	  1	  
19	   >50	   37.5	  ±	  4	   -­‐	  
20	   28	  ±	  0.4	   12.0	  ±	  2	   0.43	  :	  1	  
21	   40.5	  ±	  7.5	   23.5	  ±	  0.5	   0.58	  :	  1	   	  
23	   >50	   >50	   	  




12.2.1	  	  Effects	  of	  Xanthomicrol	  on	  Morphine-­
induced	  Analgesia	  
Since	   the	  µ	   receptor	   is	   thought	   to	  be	  primarily	   responsible	   for	   the	  
mediation	   of	   opioid	   anti-­‐nociception,	   we	   evaluated	   the	   anti-­‐
nociceptive	  activity	  of	  xanthomicrol	  in	  the	  tail	  flick	  test.	  To	  evaluate	  
the	  pharmacological	  effect	  of	   the	  most	  potent	  methoxyflavone	  17,	  
antinociceptive	  effect	  of	  xanthomicrol	  was	  assayed	  in	  animal	  model	  
of	  acute	  pain	  (tail-­‐flick	  test).	  
Figure	   146	   showed	   the	   effects	   of	   xanthomicrol	   (40	   and	   80	  mg/Kg,	  
body	  wt.	   i.p.)	  pre-­‐treatment	  on	  morphine-­‐induced	  analgesia	   in	   the	  
tail-­‐flick,	   carried	   out	   in	   mice.	   Xanthomicrol	   alone	   was	   devoid	   of	  
analgesic	  activity	  in	  the	  tail-­‐flick	  test.	  Morphine	  alone,	  at	  the	  dose	  of	  
5	   mg/kg,	   increased	   the	   tail-­‐flick	   latency	   along	   60	   min	   after	   its	  
administration	   [Ftreatment(1,37)=	   33.63,	   P<0.0001;	   Ftreatment	   x	  
time(2,74)=6.83,	   P<0.005;	   Tukey’s	   test,	   P<0.05	  vs.	   vehicle	   +	   saline-­‐
treated	   mice].	   Xanthomicrol	   pre-­‐treatment,	   at	   the	   dose	   of	   80	  
mg/kg,	   completely	   suppressed	   the	   	   analgesic	   effect	   of	   morphine	  
[Fpre-­‐treatment(2,37)=	   7.51,	   P<0.005;	   Fpre-­‐treatment	   x	   treatment(2,37)=3.61,	  
P<0.05;	   Fpre-­‐treatment	   x	   time(4,74)=1.09,	   P=0.37;	   Fpre-­‐treatment	   x	   treatment	   x	  
time(4,74)=0.52,	  P=0.72].	  On	  the	  contrary,	  40	  mg/kg	  of	  xanthomicrol	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failed	   to	   reduce	   the	   analgesic	   activity	   of	   morphine	   (Tukey’s	   test,	  
P<0.05	  vs.	  vehicle	  +	  saline-­‐treated	  mice).	  
Our	  data	  demonstrated	  that	  pretreatment	  of	  xanthomicrol	  inhibited	  
morphine-­‐induced	   anti-­‐nociception	   in	   the	   tail	   flick	   test,	   suggesting	  



















Figure	   146.	   Effect	   of	   xanthomicrol	   pre-­‐treatment	   on	   morphine-­‐
induced	   analgesia	   in	   the	   tail-­‐flick	   test.	   Saline	   or	   xanthomicrol	   (40	  
and	  80	  mg/kg,	   i.p.)	  were	  administered	  30	  min	  before	  5	  mg/Kg,	  s.c.	  
morphine	  injection.	  Basal	  algesia	  was	  assessed	  right	  before	  saline	  or	  
xanthomicrol	   pre-­‐treatment	   (baseline).	   The	   effects	   of	   the	   drugs	  
were	   evaluated	   30,	   60	   and	   120	   min	   after	   morphine	   treatment.	  
Results	  are	  expressed	  as	  %	  MPE.	  Each	  point	   represent	   the	  mean	  ±	  
S.E.M.	  of	  3-­‐11	  mice	  per	  group.	  *P<0.05	  vs.	  vehicle	  +	  saline-­‐treated	  




12.2.2	  	  Receptor	  Binding	  Affinity	  of	  Methanol	  and	  
Alkaloid	  Extract	  from	  W.	  somnifera	  (WSE	  and	  
WSAE)	  
We	   examined	   the	   affinity	   of	   Withania	   somnifera	   MeOH	   extract	  
(WSE)	   towards	   opioid	   (µ,	   δ,	   k),	   cannabinoid	   (CB1,	   CB2),	   GABAergic	  
(GABAA),	   receptors	   using	   radioligand	   receptor	   binding	   assays.	   As	  
shown	   in	   table	  10,	  WSE	  exhibits	   the	  highest	  affinity	   for	   the	  GABAA	  
receptors	  (Kì	  =	  13	  µg/ml).	  It	  is	  worth	  noting	  that	  WSE	  binds	  to	  GABAA	  
with	   an	   affinity	   15	   times	   greater	   than	   that	   δ	   opioid	   receptors.	   In	  
contrast,	  WSE	   showed	   a	   very	   weak	   binding	   affinity	   to	   µ,	   δ,	   and	   k	  
opioid	  receptors	  and	  to	  CB1	  receptor	  and	  no	  binding	  affinity	  for	  the	  
CB2	  receptors.	  	  
The	  alcaloid	  fraction	  of	  WSE	  (WSAE),	  respect	  to	  the	   in	  toto	  extract,	  
showed	  an	  increased	  affinity	  towards	  all	  the	  tested	  receptors	  except	  
for	  k	  (Kì	  =	  700	  µg/ml)	  and	  GABAA	  	  (Kì	  =	  14	  µg/ml).	  	  
	  
	  
Table	  10.	  Binding	  affinity	  of	  W.	  somnifera	  MeOH	  extract	  (WSE)	  and	  
alcaloid	  extract	  (WSAE)	  	  
Receptor	  affinity	  (µg/ml)	  
Extract	   µ	   δ	   k	   CB1	   CB2	   GABAA	  
WSE	   385	  ±	  14	   166	  ±	  11	   775	  ±	  56	   837	  ±	  74	   >1000	   13	  ±	  2	  
WSAE	   60	  ±	  7	   25.5	  ±	  6	   700	  ±	  120	   23.5	  ±	  1	   20.3	  ±	  2	   14	  ±	  0.5	  




12.2.3	  	  Analgesia	  Experiments	  
The	  interesting	  results	  of	  the	  binding	  assays	  for	  the	  µ,	  CB	  and	  GABA	  
A	   receptors	   (Table	   10)	   besides	   the	   observation	   that	   the	  
administration	  of	  WSE	  blocked	  the	  development	  of	  tolerance	  to	  the	  
analgesic	  effect	  of	  morphine,166	  prompted	  us	  to	  hypothesize	  that	  W.	  
somnifera	  extracts	  could	  modulate	  additional	  aspects	  of	  morphine-­‐
induced	  analgesia.	  Therefore,	  we	  aimed	  to	  determine	  whether	   the	  
combined	   administration	  of	  WSE	  with	  morphine	   could	   enhance	  or	  
prolong	   the	  antinociceptive	  effect	  of	  morphine	   in	   the	   tail-­‐flick	  and	  
hot	  plate	  tests.	  
	  
12.2.4	  	  Effects	  of	  WSE	  on	  Morphine-­induced	  
Analgesia	  	  
The	   effects	   of	   WSE	   (100	   mg/Kg)	   pre-­‐treatment	   on	   morphine-­‐
induced	  analgesia	  were	  evaluated	   	  using	   	   the	   tail-­‐flick	   (Figure	  147)	  
and	   	   the	  hot	  plate	  tests	   (Figure	  148).	  WSE	  alone	  failed	  to	  alter	   the	  	  
nociceptive	  reaction	  time.	  Morphine	  (2.5,	  5	  and	  10	  mg/Kg)	  elicited	  a	  
dose-­‐dependent	   antinociceptive	   effect	   in	   both	   tests,	   although	   its	  
efficacy	  was	  higher	  when	  the	  tail-­‐flick	  test	  was	  used.	  The	  peak	  in	  the	  
analgesic	  effect	  was	  reached	  60	  min	  after	  morphine	  administration.	  
Co-­‐administration	   of	   	  WSE	  with	  morphine	  modulated	   its	   analgesic	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activity	  depending	  on	  the	  dose	  of	  morphine	  and	  on	  the	  behavioural	  
test	  used.	  	  
In	  the	  tail-­‐flick	  test	   (Figure	  147)	  morphine	  alone	  at	   the	  dose	  of	  2.5	  
mg/Kg	   increased	   the	   tail-­‐flick	   latency	   along	   60	   min	   after	   its	  
administration	   [Ftreatment(1,30)=	   46.16,	   P<0.0001;	   Ftreatment	   x	  
time(4,120)=8.35,	  P<0.0001;	   Tukey’s	   test,	  P<0.05	   vs.	   saline	   +	   saline-­‐
treated	   mice],	   and	   along	   120	   min	   following	   5	   mg/Kg	  
[Ftreatment(1,26)=135.99,	   P<0.0001;	   Ftreatment	   x	   time(4,104)=10.97,	  
P<0.0001;	  Tukey’s	  test,	  P<0.05	  vs.	  saline	  +	  saline-­‐treated	  mice]	  or	  10	  
mg/Kg	   morphine	   administration	   [Ftreatment(1,31)=260.48,	   P<0.0001;	  
Ftreatment	   x	   time(4,124)=5.61,	  P<0.005;	  Tukey’s	  test,	  P<0.05	  vs.	  saline	  +	  
saline-­‐treated	  mice].	   Interestingly,	  although	  WSE	  co-­‐administration	  
failed	   to	  modulate	   the	  antinociceptive	  effect	  elicited	  by	  2.5	  mg/Kg	  
morphine	  [Fpre-­‐treatment(1,30)=0.78,	  not	  significant	  (N.S.);	  Fpre-­‐treatment	  x	  
treatment(1,30)=2.28,	   N.S.;	   Fpre-­‐treatment	   x	   time(4,120)=0.66,	   N.S.;	   Fpre-­‐
treatment	   x	   treatment	   x	   time(4,120)=1.19,	  N.S.],	   it	   protracted	   the	   analgesic	  
effect	   induced	   by	   5	   mg/Kg	   morphine	   [Fpre-­‐treatment(1,26)=5.76,	  
P<0.05;	   Fpre-­‐treatment	   x	   treatment(1,26)=7.66,	   P<0.05;	   Fpre-­‐treatment	   x	  
time(4,104)=2.82,	   P<0.05;	   Fpre-­‐treatment	   x	   treatment	   x	   time(4,104)=2.66,	  
P<0.05],	  and	  10	  mg/Kg	  morphine	   [Fpre-­‐treatment(1,31)=2.10,	  N.S.;	   Fpre-­‐
treatment	   x	   treatment(1,31)=3.57,	   N.S.;	   Fpre-­‐treatment	   x	   time(4,124)=19.54,	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P<0.0001;	  Fpre-­‐treatment	  x	  treatment	  x	  time(4,124)=2.85,	  P<0.05).	  In	  fact,	  the	  
analgesic	   effect	  was	   still	   evident	   240	  min	   after	   5	  mg/Kg	  morphine	  
treatment	  in	  mice	  pre-­‐treated	  with	  WSE	  (78	  ±	  11%	  MPE)	  compared	  
to	  mice	  pre-­‐treated	  with	  saline	  (16	  ±	  7%	  MPE)	  (Tukey’s	  test,	  P<0.05	  
vs.	   saline	   +	   saline-­‐treated	  mice	   and	   vs.	   saline	   +	  morphine-­‐treated	  
mice).	  Likewise,	  analgesia	  was	  still	  evident	  at	  240	  min	  (55	  ±	  7%	  MPE)	  
and	  360	  min	  (45	  ±	  11%	  MPE)	  after	  10	  mg/Kg	  morphine	  treatment,	  in	  
mice	   pre-­‐treated	   with	   WSE	   when	   compared	   to	   mice	   pre-­‐treated	  
with	  saline,	  in	  which	  the	  %	  MPE	  was	  respectively	  20	  ±	  4%	  and	  10	  ±	  
3%	   (Tukey’s	   test,	   P<0.05	   vs.	   saline	   +	   saline-­‐treated	   mice	   and	   vs.	  





















	  	  	  	  
	  	  	  	  	  	  	  
	  
Figure	   147.	   Effect	   of	   WSE	   pre-­‐treatment	   on	   morphine-­‐induced	  
analgesia	   in	  the	  tail-­‐flick	  test.	  Saline	  or	  WSE	  (100	  mg/Kg,	   i.p.)	  were	  
administered	   30	   min	   before	   2.5	   (a),	   5	   (b)	   and	   10	   (c)	   mg/Kg,	   s.c.	  
morphine	  injection.	  Basal	  algesia	  was	  assessed	  right	  before	  saline	  or	  
WSE	   pre-­‐treatment	   (baseline).	   The	   effects	   of	   the	   drugs	   were	  
evaluated	  30,	  60,	  120,	  240	  and	  360	  min	  after	  morphine	  treatment.	  
(See	  Material	  and	  Method	  for	  further	  details).	  Results	  are	  expressed	  
as	  %MPE.	   Each	  point	   represent	   the	  mean±S.E.M.	  of	   6-­‐10	  mice	  per	  
group.	  *P<0.05	  vs.	  saline	  +	  saline-­‐treated	  mice;	  #	  P<0.05	  vs.	  saline	  +	  




A	  different	  picture	  was	  observed	  in	  the	  hot	  plate	  test	  (Figure	  148)	  in	  
which	  morphine,	  at	   the	  dose	  of	  2.5	  mg/Kg	  had	  no	  analgesic	  effect	  
[Ftreatment(1,30)=0.35,	   N.S.;	   Ftreatment	   x	   time(4,120)=5.4,	   P<0.0001];	   on	  
the	   contrary,	   5	   and	   10	   mg/Kg	   increased	   the	   reaction	   time	  
respectively	  along	  the	  first	  60	  min	  [Ftreatment(1,26)=46.53,	  P<0.0001;	  
Ftreatment	  x	  time(4,104)=5.61,	  P<0.0001;	  Tukey’s	  test,	  P<0.05	  vs.	  saline	  +	  
saline-­‐treated	   mice],	   and	   along	   the	   first	   120	   min	  
[Ftreatment(1,31)=58.72,	   P<0.0001;	   Ftreatment	   x	   time(4,124)=10.27,	  
P<0.0001;	  Tukey’s	  test,	  P<0.05	  vs.	  saline	  +	  saline-­‐treated	  mice].	  WSE	  
pre-­‐treatment	  failed	  to	  modulate	  the	  analgesic	  effect	  induced	  by	  2.5	  
mg/Kg	   [Fpre-­‐treatment(1,30)=0.41,	  N.S.;	  Fpre-­‐treatment	   x	   treatment(1,30)=0.17,	  
N.S.;	   Fpre-­‐treatment	   x	   time(4,120)=0.17,	   N.S.;	   Fpre-­‐treatment	   x	   treatment	   x	  
time(4,120)=0.28,	  N.S.],	  5	  mg/Kg	  [Fpre-­‐treatment(1,26)=0.0003,	  N.S.;	  Fpre-­‐
treatment	   x	   treatment(1,26)=0.27,	  N.S.;	   Fpre-­‐treatment	   x	   time(4,104)=0.82,	  N.S.;	  
Fpre-­‐treatment	   x	   treatment	   x	   time(4,104)=0.48,	  N.S.]	  and	  10	  mg/Kg	  morphine	  
[Fpre-­‐treatment(1,31)=0.07,	   N.S.;	   Fpre-­‐treatment	   x	   treatment(1,31)=0.30,	   N.S.;	  







Figure	   148.	   Effect	   of	   WSE	   pre-­‐treatment	   on	   morphine-­‐induced	  
analgesia	  in	  the	  hot	  plate	  test.	  Saline	  or	  WSE	  (100	  mg/Kg,	  i.p.)	  were	  
administered	   30-­‐min	   before	   2.5	   (a),	   5	   (b)	   and	   10	   (c)	   mg/Kg,	   s.c.	  
morphine.	   Basal	   algesia	   was	   assessed	   right	   before	   saline	   or	   WSE	  
pre-­‐treatment	   (baseline).	   The	   effects	   of	   the	   drugs	  were	   evaluated	  
30,	  60,	  120,	  240	  and	  360	  min	  after	  morphine	  treatment.	  Results	  are	  
expressed	  as	  %MPE.	  Each	  point	  represent	  the	  mean±S.E.M.	  of	  6-­‐10	  
mice	  per	  group.	  *P<0.05	  vs.	  saline	  +	  saline-­‐treated	  mice	  (three-­‐way	  




12.2.5	  	  Effect	  of	  WSE	  on	  Morphine-­induced	  
Hyperalgesia	  	  
The	   effects	   induced	   by	   WSE	   (100	   mg/Kg)	   pre-­‐treatment	   on	  
morphine-­‐induced	   hyperalgesia	   were	   evaluated	   using	   the	   low-­‐
intensity	   tail-­‐flick	   test	   (Figure	   149).	   WSE	   alone	   failed	   to	   alter	   the	  	  
nociceptive	   reaction	   time.	   In	   agreement	   with	   Gupta	   et	   al.	  
(2001),167we	  found	  that	  a	  single	  injection	  of	  a	  low	  dose	  of	  morphine	  
(2.5	  mg/Kg)	  elicited	  a	  biphasic	  effect	  in	  the	  nociceptive	  response	  of	  
CD1	   mice.	   In	   fact,	   analgesia	   was	   reached	   at	   30	   and	   60	   after	  
morphine	  administration	   	   [Ftreatment(1,32)=13.91,	  P<0.001.	  Ftreatment	   x	  
time(6,192)=2.98,	   P<0.01;	   Tukey’s	   test,	   P<0.05	   vs.	   saline	   +	   saline-­‐
treated	  mice].	  This	  effect	  was	  followed	  by	  a	  gradual	  appearance	  of	  
hyperalgesia;	   Tukey’s	   test	   revealed	   that	   morphine	   administration	  
reduced	  the	  nociceptive	  response	  (-­‐65	  ±	  13%	  MPE)	  when	  compared	  
to	  the	  nociceptive	  response	  of	  control	  mice	  (-­‐4	  ±	  6%	  MPE)	  360	  min	  
after	   morphine	   administration	   (P<0.05).	   Consistently	   with	   the	  
results	   shown	   in	   Fig.	   149,	   pre-­‐treatment	   with	   WSE	   did	   not	  
potentiate	  the	  analgesic	  effect	  of	  morphine	  during	  the	  first	  120	  min,	  
however,	   it	   	  significantly	  prevented	  morphine-­‐induced	  hyperalgesia	  
[Fpre-­‐treatment(1,32)=7.25,	   P<0.05;	   Fpre-­‐treatment	   x	   treatment(1,32)=9.40,	  
P<0.005;	  Fpre-­‐treatment	  x	  time(6,192)=2.98,	  P<0.001;	  Fpre-­‐treatment	  x	  treatment	  x	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time(6,192)=1.67,	   N.S.].	   Tukey’s	   test	   revealed	   that	   at	   240,	   300,	   360	  
and	   420	   min	   after	   morphine	   administration	   the	   nociceptive	  
threshold	  of	  mice	  pre-­‐treated	  with	  WSE	  was	  higher	  when	  compared	  
with	  the	  one	  observed	  in	  mice	  pre-­‐treated	  with	  saline	  (P<0.05).	  	  
 
 
Figure	   149.	   Effect	   of	   WSE	   pre-­‐treatment	   on	   morphine-­‐induced	  
hyperalgesia	   in	   the	   low-­‐intensity	   tail-­‐flick	   test.	   Saline	   or	  WSE	   (100	  
mg/Kg,	  i.p.)	  were	  administered	  30	  min	  before	  morphine	  (2.5	  mg/Kg,	  
s.c.).	   Basal	   algesia	   was	   assessed	   right	   before	   saline	   or	   WSE	   pre-­‐
treatment	   (baseline).	  WSE	  pre-­‐treatment	   (baseline).	   The	   effects	   of	  
the	  drugs	  were	  evaluated	  30,	   60,	   120,	   240,	   300,	   360	   and	  420	  min	  
after	   morphine	   treatment.	   (See	  Material	   and	   Method	   for	   further	  
details).	   Results	   are	   expressed	   as	  %MPE.	   Each	  point	   represent	   the	  
mean±S.E.M.	   of	   7-­‐11	   mice	   per	   group.	   *P<0.05	   vs.	   saline	   +	   saline-­‐
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treated	  mice;	   #	   P<0.05	   vs.	   saline	   +	  morphine-­‐treated	  mice	   (three-­‐
way	  ANOVA	  followed	  by	  Tukey’s	  post-­‐hoc	  test).	  
 
12.2.6	  	  Effect	  of	  WSE	  on	  Morphine-­induced	  
	  Hyper-­locomotion	  
Figure	  150	  shows	  the	  effects	  of	  WSE	  on	  spontaneous	  motor	  activity	  
and	   on	   morphine-­‐induced	   (5	   and	   10	   mg/Kg)	   hyper-­‐locomotion.	  
Repeated	   measures	   three-­‐way	   ANOVA	   of	   the	   average	   distances	  
travelled	  revealed	  that	  morphine	  increased	  motor	  activity	  in	  a	  dose	  
dependent	   manner	   [Ftreatment(2,38)=18.43,	   P<0.0001;	   Ftreatment	   x	  
time(8,152)=19.61,	  P<0.0001;	  Tukey’s	  test,	  P<0.05	  vs.	  saline	  +	  saline-­‐
treated	  mice].	  WSE	  pre-­‐treatment	  failed	  to	  alter	  both	  spontaneous	  
motor	   activity	   and	   morphine-­‐induced	   hyper-­‐locomotion	   [Fpre-­‐
treatment(1,38)=0.09,	   N.S.;	   Fpre-­‐treatment	   x	   treatment(2,38)=0.18,	   N.S.;	   Fpre-­‐
treatment	   x	   time(4,152)=0.11,	  N.S.;	  Fpre-­‐treatment	   x	   treatment	   x	   time(8,152)=0.60,	  
N.S.].	  Specifically,	  Tukey’s	  post-­‐hoc	  analysis	  revealed	  that	  10	  mg/Kg	  
morphine,	   alone	   and	   in	   combination	   with	   WSE	   increased	   motor	  
activity	   120,	   240	   and	   360	   min	   after	   administration	   (Tukey’s	   test,	  
P<0.05	  vs.	  saline	  +	  saline-­‐treated	  mice),	  but	  WSE	  pre-­‐treatment	  did	  
















Figure	   150.	   Effect	   of	   WSE	   pre-­‐treatment	   on	   morphine-­‐induced	  
hyper-­‐locomotion.	  After	  30	  min	  of	  habituation	  in	  the	  motor	  activity	  
chambers,	  mice	  were	  pre-­‐treated	  with	   saline	  or	   	  WSE	   (100	  mg/Kg,	  
i.p.)	   30	   min	   before	   saline	   or	   morphine	   (10	   mg/Kg,	   s.c.)	  
administration.	   Immediately	   after	   morphine	   administration,	   mice	  
were	   returned	   to	   the	  motor	   activity	   chambers,	   and	  motor	   activity	  
was	   recorded	   for	   360	   min.	   Results	   are	   expressed	   as	   average	   of	  
distance	  travelled	  (m).	  Each	  bar	  represent	  the	  mean±S.E.M.	  of	  5-­‐11	  
mice	  per	  group.	  *P<0.05	  vs.	  saline	  +	  saline-­‐treated	  mice	  (three-­‐way	  







Based	   on	   the	   receptor	   binding	   assays,	   it	   was	   possible	   to	   choose	  
from	  a	  number	  of	  different	  plant	  extracts,	  four	  extracts	  from	  three	  
different	  plants.	   	   Two	  of	   these	  have	  been	  obtained	  by	  percolation	  
with	   dichloromethane	   of	   the	   roots	   of	   Otanthus	   maritimus	   (OME)	  
and	   of	   the	   aerial	   parts	   and	   Stachys	   glutinosa	   (SGE),	   plants	   which	  
grows	   wild	   in	   Sardinia.	   The	   third	   was	   a	   methanol	   extract	   (WSE)	  
obtained	  by	  maceration	  of	  the	  roots	  of	  Withania	  somnifera	  and	  was	  
provided	  by	  Natural	  Remedies	  Pvt.	  Ltd.,	  Bangalore,	  India.	  The	  fourth	  
was	  an	  alkaloids	  fraction	  (WSAE)	  obtained	  by	  liquid/liquid	  partition	  
of	  the	  WSE.	  	  
A	  total	  of	  30	  secondary	  metabolites	  were	  isolated	  from	  the	  extracts.	  
Two	  semisynthetic	  derivatives	  were	  also	  prepared.	  	  
The	   OME	   yielded	   two	   new	   alkylamides	   (1,	   5)	   and	   one	   new	   neo-­‐
lignan	   (12),	   along	   with	   thirteen	   known	   compounds.	   Among	   the	  
constituents	   identified,	   1-­‐[(2E,4E,8Z)-­‐tetradecatrienoyl]piperidine	  
(10)	   was	   the	   most	   potent	   binder	   to	   both	   CB1	   and	   CB2	   receptors	  
with	  a	  Ki	  value	  of	  0.8	  µM	  and	  0.16	  µM,	  respectively.	  Alkylamides	  6	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and	  8	  compared	  with	  10	  showed	  minor	  affinity	  to	  CB2	  receptors	  but	  
still	  significant,	  with	  Ki	  values	  at	  low	  micromolar	  concentrations.	  	  
As	   far	   as	  we	   know,	   this	   is	   the	   first	   report	   of	   fatty	   acid	   piperidides	  
and	   thienylheptatrienamides	   CB	   receptors	   screening.	   Since	   the	  
presence	   of	   secondary	   amide	   group	  was	   described	   to	   be	   essential	  
for	  the	  CB2	  binding	  affinity	  of	  Echinacea	  alkylamides,5	  we	  decided	  to	  
explore	   the	   nature	   of	   the	   ligand-­‐receptor	   interactions	   carring	   out	  
docking	   experiments	   into	   CB2	   receptor	   by	   means	   of	   GlideXP.	   We	  
focused	   on	   the	   compound	   6	   and	   10,	   which	   showed	   interesting	  
activity	   but	   differed	   for	   the	   presence	   of	   secondary	   and	   tertiary	  
amide	   moiety,	   respectively.	   The	   molecular	   modeling	   approaches	  
applied	   in	   this	   study	   put	   in	   evidence,	   important	   requirements	   for	  
the	   activity	   of	   this	   series	   of	   compounds.	   In	   particular,	   both	  
compounds	  6	  and	  10	  are	  able	  to	  establish	  a	  strong	  hydrogen	  bond	  
with	  Asn188:	  in	  the	  former	  compound	  the	  amide	  group	  behaves	  as	  
a	  donor,	  while	  in	  the	  latter	  as	  an	  acceptor.	  Therefore,	  the	  presence	  
of	   the	   secondary	   amide	   as	   donor	   group	   is	   not	   critical	   for	   activity.	  
The	   derived	   information	   gives	   several	   hints	   for	   the	   design	   of	  
optimized	  CB2	  ligands.	  
From	   the	   SGE	   one	   new	   neo-­‐clerodane,	   3,4α-­‐epoxyroseostachenol	  
along	  four	  known	  flavones	  (eupatilin,	  sideritoflavone,	  xanthomicrol,	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and	   8-­‐methoxycirsilineol)	   and	   one	   neo-­‐clerodane	   diterpene	  
(roseostachenone),	   were	   isolated.	   In	   order	   to	   find	   a	   structure-­‐
activity	   relationships,	   two	   metoxyflavones	   (5-­‐demethyltangeretin,	  
and	  tangeretin)	  were	  synthesized	  by	  methoxylation	  of	  xanthomicrol.	  
Our	   results	   showed	   that	   xanthomicrol,	   the	  main	   constituent	   of	   S.	  
glutinosa	   aerial	   parts	   (2%	   of	   the	   dried	   extract)	   is	   the	   principal	  
responsible	  of	  the	  observed	  opioid	  binding	  affinities	  of	  the	  extract.	  
We	   found	   that,	   among	  all	   the	   tested	  polymethoxyflavones	   (PMFS),	  
xanthomicrol	  presented	  the	  highest	  inhibition	  of	  the	  binding	  of	  the	  
selective	  tritiated	  ligand	  [3H]DAMGO	  to	  µ	  opioid	  receptor,	  with	  a	  Ki	  
value	  of	  0.825	  µM.	  Moreover,	  structure-­‐activity	  relationship	  studies	  
indicated	   that	   the	   presence	   of	   only	   one	   free	   hydroxyl	   group	   at	   4'	  
position	   of	   B	   ring	   seems	   to	   be	   important	   for	   a	   high	   affinity	   of	   5-­‐
hydroxy-­‐6,7,8-­‐trimethoxyflavones	  to	  the	  MOR	  receptor.	  Since	  the	  µ	  
receptor	  is	  thought	  to	  be	  primarily	  responsible	  for	  the	  mediation	  of	  
opioid	   anti-­‐nociception,	   we	   evaluated	   the	   anti-­‐nociceptive	   activity	  
of	   xanthomicrol	   in	   the	   tail	   flick	   test.	   Our	   data	   demonstrated	   that	  
pretreatment	   of	   xanthomicrol	   inhibited	   morphine-­‐induced	   anti-­‐
nociception	  in	  the	  tail	  flick	  test,	  suggesting	  an	  antagonistic	  effect	  at	  
µ	  opioid	  receptor.	  As	  far	  as	  we	  know,	  we	  reported	  for	  the	  first	  time	  
that	   a	   flavone	   administered	   intraperitoneally	   in	   mice	   significantly	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reduced	   morphine-­‐induced	   antinociception	   in	   a	   dose-­‐dependent	  
manner	  in	  the	  tail	  flick	  test,	  and	  it	  seems	  that	  its	  action	  is	  mediated,	  
at	   least	   in	   part,	   by	   opioid	   systems.	   Our	   findings	   show	   that	  
xanthomicrol	   represents	   a	   structure	   for	   further	   development	   into	  
potential	  MOR	  antagonist.	  
As	  regards	  WSE	  and	  WSAE,	  the	  results	  of	  the	  binding	  assays	  (Table	  
10)	   for	   the	   µ,	   CB	   and	   GABAA	   receptors	   suggested	   a	   possible	   anti-­‐
nociceptive	   effect	   of	  W.	   somnifera.	   Starting	   from	   these	   preliminar	  
data	   and	   from	   previous	   studies	   demonstrating	   that	   Withania	  
somnifera	  prevented	  the	  development	  of	  tolerance	  to	  the	  analgesic	  
effect	  of	  morphine,166	  using	  behavioral	  appoaches	  we	  demonstrate	  
for	   the	   first	   time	   the	   ability	   of	   WSE	   pre-­‐treatment	   to	   prolong	  
analgesia	  and	  to	  prevent	  the	  development	  of	  rebound	  hyperalgesia	  
in	  mice	  treated	  with	  morphine.	  	  
Biochemical	  analyses	  suggest	  a	  potential	  involvement	  of	  GABAA,	  CB,	  
and	  opioid	  receptors	   in	  the	  observed	  behavioral	  effects.	  This	  study	  
suggests	   the	   therapeutic	   potential	   of	   WSE	   as	   a	   valuable	   adjuvant	  
agent	  in	  opioid-­‐sparing	  therapies.	  	  
From	  WSE	  and	  WSAE	  three	  withanolides	  (withanolide	  A,	  withanone	  
and	  withaferin	   A),	   four	   alkaloids	   (anaferine,	   (+)-­‐sedridine,	   tropine,	  
choline)	  along	  ferulic	  acid	  methyl	  ester	  have	  been	  isolated.	  Binding	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experiments	  are	  currently	  undergoing	  in	  our	  laboratories	  in	  order	  to	  
evaluate	   the	   affinity	   to	   CB,	   opiod	   and	   GABAA	   receptors	   of	   the	  




14.	  EXPERIMENTAL	  SECTION	  
	  
14.1	  	  General	  Experimental	  Procedures	  
Optical	   rotations	  were	  measured	   in	   CHCl3	   at	   25	   °C	   using	   a	   Perkin-­‐
Elmer	  241	  polarimeter.	  UV	  spectra	  were	  recorded	  on	  a	  GBC	  Cintra	  5	  
spectrophotometer.	  IR	  spectra	  were	  performed	  with	  a	  Perkin-­‐Elmer	  
system	  2000	  FT-­‐IR	  spectrophotometer	  using	  KBr	  mulls.	  NMR	  spectra	  
were	   recorded	   at	   25	   °C	   on	   Unity	   Inova	   500NB	   high-­‐resolution	  
spectrometer	  (Agilent	  Technologies,	  CA,	  USA)	  operating	  at	  500	  MHz	  
for	  1H	  and	  100	  MHz	  for	  13C,	  respectively.	  All	  spectra	  were	  measured	  
at	  25	  °C	  in	  CDCl3	  and	  referenced	  against	  residual	  CHCl3	  in	  CDCl3	  (
1H	  
7.27	  ppm)	  and	  CDCl3	  (
13C	  77.0	  ppm).	  HR-­‐ESIMS	  were	  measured	  on	  a	  
Agilent	   6520	   Time	   of	   Flight	   (TOF)	   MS	   instrument	   while	   ESIMS	  	  
experiments	  were	  performed	  on	  a	  Varian	  1200	  L	  triple	  quadrupole.	  
Column	   chromatography	   was	   carried	   out	   under	   TLC	   monitoring	  
using	  silica	  gel	  (40-­‐63	  µm,	  Merck),	  and	  Sephadex	  LH-­‐20	  (25-­‐100	  µm,	  
Pharmacia).	  For	  vacuum-­‐liquid	  chromatography	  (VLC),	  silica	  gel	  (40-­‐
63	  µm)	  (Merck)	  was	  used.	  TLC	  was	  performed	  on	  silica	  gel	  60	  F254	  or	  
RP-­‐18	  F254	  (Merck).	  Semi-­‐preparative	  HPLC	  was	  conducted	  by	  means	  
of	   a	   Varian	   920	   LH	   instrument	   fitted	  with	   an	   autosampler	  module	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with	  a	  1000	  µL	   loop.	  The	  columns	  were	  a	  250	  x	  10	  mm	  Spherisorb	  
silica,	  particle	  size	  5	  µm	  (Waters)	  and	  a	  250	  x	  10	  mm	  Polaris	  C-­‐18-­‐A,	  
particle	   size	  5	  µm	   (Varian).	   The	  UV	  detection	  wavelength	  was	  254	  
nm.	   For	   molecular	   modeling	   a	   PC	   Spartan	   Pro	   software	   program	  
(Wavefunction	  Inc.)	  was	  used.	  
	  
14.2	  	  O.	  maritimus	  	  Plant	  Material	  
Otanthus	   maritimus	   roots	   were	   collected	   in	   November	   2008	   at	  
Costa	  Rei	  beach,	  (Villasimius),	  Sardinia,	  Italy.	  The	  plant	  material	  was	  
identified	  by	  Dr.	  Marco	  Leonti	  (University	  of	  Cagliari,	  Department	  of	  
Life	   and	   Environmental	   Sciences)	   and	   a	   voucher	   specimen	   (No.	  
0455)	   was	   deposited	   in	   the	   Herbarium	   of	   the	   Department	   of	   Life	  
and	   Environmental	   Sciences,	   Drug	   Sciences	   Section,	   University	   of	  
Cagliari.	  
	  
14.3	  	  O.	  maritimus	  	  Extraction	  and	  Isolation	  
Air-­‐dried	  and	  powdered	  roots	  of	  O.	  maritimus	  (780	  g)	  were	  ground	  
and	  extracted	  with	  CH2Cl2	  (5	  L)	  by	  percolation	  at	  room	  temperature	  
to	  give	  29.3	  g	  dried	  extract.	  An	  aliquot	   (20	  g)	  of	   the	  CH2Cl2	  extract	  
was	  subjected	  to	  vacuum-­‐liquid	  chromatography	  (VLC)	  (silica	  gel,	  90	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g)	  using	  a	  step	  gradient	  of	  n-­‐hexan/CH2Cl2/EtOAc	  (9	  :	  1	  :	  0	  to	  0	  :	  1	  :	  
9,	  500	  mL	  each)	  to	  yield	  11	  main	  fractions	  (F1-­‐F11).	  Fraction	  F3	  (0.62	  
g)	   eluted	   with	   n-­‐hexan/CH2Cl2	   (5:5)	   was	   separated	   by	   column	  
chromatography	  (CC)	  over	  silica	  gel	  using	  n-­‐hexan/EtOAc	  (9.75:0.25)	  
as	   eluent	   to	   obtain	   compound	   11	   (7.2	   mg).	   Fraction	   F6	   (n-­‐
hexan/CH2Cl2,	   2.5:7.5)	   yielded	   compound	   16	   (1.29	   g).	   Fraction	   F8	  
(1.26	   g)	   was	   purified	   by	   CC	   over	   silica	   gel	   using	   n-­‐hexan/EtOAc	  
(7.5:2.5)	   as	   eluent	   giving	   seven	   subfractions	   (F8.1-­‐F8.7).	   F8.6	   (300	  
mg)	   was	   further	   chromatographed	   over	   silica	   gel	   (CH2Cl2/EtOAc,	  
9.5:0.5)	  to	  obtain	  four	  subfractions	  (F8.6.1-­‐F8.6.4).	  F8.6.4	  (44.5	  mg)	  
was	   purified	   by	   RP-­‐HPLC	   using	   acetonitrile/H2O	   (8.5:1.5,	   flow	   2.5	  
mL/min)	   as	   eluent	   to	   give	   compound	   6	   (3.2	   mg,	   tR	   10.0	   min),	  
compound	  7	  (20.8	  mg,	  tR	  13.9	  min)	  and	  compound	  8	  (8.8	  mg,	  tR	  10.6	  
min).	   F8.7	   (150	   mg)	   was	   subjected	   to	   CC	   over	   silica	   gel	   using	  
CH2Cl/EtOAc	  (9.5:0.5)	  as	  eluent	  to	  obtain	  three	  subfractions	  (F8.7.1-­‐
F8.7.3).	  F8.71	  (29.4	  mg)	  was	  purified	  by	  solid-­‐phase	  extraction	  (SPE)	  
(RP-­‐18)	  using	  acetonitrile/H2O	  (8:2)	  as	  eluent	  and	  then	  with	  RP-­‐HPLC	  
using	   acetonitrile/H2O	   (7:3,	   flow	   3	   mL/min)	   as	   eluent	   to	   give	  
compound	   15	   (7.1	   mg,	   tR	   7.0	   min).	   Fraction	   F9	   (4.99	   g)	   was	  
subjected	  to	  a	  further	  VLC	  (silica	  gel,	  11	  g)	  using	  a	  step	  gradient	  of	  n-­‐
hexan/EtOAc	  (3	  :	  1	  	  to	  0	  :	  9,	  500	  mL	  each)	  to	  yield	  10	  main	  fractions	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(F9.1-­‐F9.10).	   F9.2	   (824	   mg)	   was	   purified	   CC	   over	   silica	   gel	   using	  
CH2Cl/EtOAc	  (9.5:0.5)	  as	  eluent	  to	  give	  eleven	  subfractions	  (F9.2.1-­‐
F9.2.11).	  F9.2.4	  yielded	  compound	  14	  (5.7	  mg).	  F9.2.6	  (140	  mg)	  was	  
subjected	   to	   CC	   over	   silica	   gel	   using	   n-­‐hexan/EtOAc	   (7:3)	   to	   give	  
compound	   12	   (4.7	   mg).	   	   F9.2.6	   yielded	   compound	   3	   (79.6	   mg).	  
F.9.2.8	  (40.5	  mg)	  was	  purified	  by	  NP-­‐HPLC	  using	  n-­‐hexan/tert-­‐butyl	  
methyl	  ether	  (2:8,	  flow	  4	  mL/min)	  to	  give	  compound	  5	  (12.3	  mg,	  tR	  
12.8	   min).	   F9.5	   was	   chromatographed	   by	   RP-­‐HPLC	   using	  
acetonitrile/H2O	   (8.5:1.5,	   flow	   2.5	   mL/min)	   to	   yield	   compound	   13	  
(8.7	  mg,	   tR	  6.0	  min).	  F9.7	   (742	  mg)	  was	  subjected	   to	  CC	  over	   silica	  
gel	  using	  CH2Cl/EtOAc	  (9.5:0.5)	  as	  eluent	  to	  obtain	  five	  subfractions	  
(F9.7.1-­‐F9.7.5).	  F9.7.3	  (96	  mg)	  was	  separated	  by	  CC	  on	  Sephadex	  LH-­‐
20	  with	  MeOH	   as	   eluent	   to	   give	   compound	  4	   (7.0	  mg).	  F9.7.4	   (40	  
mg)	  was	  chromatographed	  by	  RP-­‐HPLC	  using	  acetonitrile/H2O	   (8:2,	  
flow	  2.5	  mL/min)	   to	  yield	  compound	  1	   (9.6	  mg,	   tR	  7.4	  min).	   F9.7.5	  
(75	   mg)	   was	   purified	   by	   RP-­‐HPLC	   using	  
acetonitrile/MeOH/trifluoroacetic	  acid	  (TFAA)	  (8.95:1:0.05,	  flow	  2.5	  
mL/min)	  to	  yield	  compounds	  10	  (7.7	  mg,	  tR	  9	  min)	  and	  9	  (6.5	  mg,	  tR	  





14.4	  	  Analitical	  and	  Spectroscopic	  Data	  of	  the	  New	  
Compounds	  
(2E,4E,6E)-­‐N-­‐isopentyl-­‐7-­‐(2-­‐thienyl)-­‐2,4,6-­‐heptatrienamide	   (1).	  
Yellow	   amorphous	   powder.	   UV	   (CH2Cl2)	  λmax	   (log	   ε)	   259	   (0.6),	   353	  
(1.8),	   369	   (1.6).	   ).	   1H	   (CDCl3,	   500	  MHz)	   and	  
13C	   (CDCl3,	   100	  MHz)	  
NMR,	  see	  Table	  1.	  HR-­‐TOF-­‐ESIMS	  (m/z)	  276.1408	  [M	  +	  H]+	  (calcd.	  for	  
C16H21NOS	   276.1417).	   EIMS	   (m/z)	   276	   [M	   +	   H]
+.	   FT-­‐IR	   (KBr)	   νmax	  
3295,	  1690,	  1615,	  1585,	  1000	  cm-­‐1.	  
(2Z)-­‐5-­‐{[(2E,4E,6E)-­‐7-­‐(2-­‐thienyl)-­‐2,4,6-­‐heptatrienoyl]amino}-­‐2-­‐
pentenyl	   3-­‐methylbutanoate	   (5).	   Yellow	   amorphous	   powder.	   UV	  
(CH2Cl2)	  λmax	  (log	  ε)	  259	  (0.3),	  353	  (0.7).	  
1H	  (CDCl3,	  500	  MHz)	  and	  
13C	  
(CDCl3,	  100	  MHz)	  NMR,	  see	  Table	  1.	  HR-­‐TOF-­‐ESIMS	  (m/z)	  374.1785	  
[M	  +	  H]+	  (calcd.	  for	  C21H27NO3S	  374.1784).	  EIMS	  (m/z)	  374	  [M	  +	  H]
+,	  
396	  [M	  +	  Na],	  769	  [2M	  +	  Na].	  
9-­‐isovaleroxy	  balanophonin	  (12).	  Yellowish	  oil.	   [α]25	  D	  +	  9.3°	  (c	  0.08,	  
CH2Cl2).	   UV	   (CH2Cl2)	  λmax	   (log	   ε)	   207	   (1.0),	   229	   (0.2),	   341	   (0.4).	  
1H	  
(CDCl3,	  500	  MHz)	  and	  
13C	   (CDCl3,	  100	  MHz)	  NMR,	   see	  Table	  1.	  HR-­‐
TOF-­‐ESIMS	  (m/z)	  441.1908	  [M	  +	  H]+	   (calcd.	   for	  C25H28O7	  441.1908).	  




14.5	  	  Stachys	  glutinosa	  Plant	  Material	  
Stachys	   glutinosa	   aerial	   parts	   were	   collected	   in	   April	   2006	   at	  
Capoterra,	   Sardinia,	   Italy.	   The	   plant	  material	  was	   identified	   by	   Dr.	  
Marco	   Leonti	   (University	   of	   Cagliari,	   Department	   of	   Life	   and	  
Environmental	   Sciences).	   A	   voucher	   specimen	   (No.	   0425)	   was	  
deposited	   in	   the	   Herbarium	   of	   the	   Department	   of	   Life	   and	  
Environmental	  Science,	  Drug	  Sciences	  Section,	  University	  of	  Cagliari.	  
	  
14.6	  	  Stachys	  glutinosa	  Extraction	  and	  Isolation	  
Air-­‐dried	  and	  powdered	  leaves	  of	  Stachys	  glutinosa	  (547.83	  g)	  were	  
ground	   and	   extracted	   with	   CH2Cl2	   (5	   L)	   by	   percolation	   at	   room	  
temperature	   to	  give	  52.42	  g	  dried	  extract.	  An	  aliquot	   (20	  g)	  of	   the	  
CH2Cl2	   extract	   was	   subjected	   to	   vacuum-­‐liquid	   chromatography	  
(VLC)	   (silica	   gel,	   90	   g)	   using	   a	   step	   gradient	   of	   n-­‐
hexan/CH2Cl2/EtOAc/MeOH	  (7.5	  :	  2.5	  :	  0	  :	  0	  	  to	  0	  :	  0	  :	  7.5	  :	  2.5	  ,	  500	  
mL	   each)	   to	   yield	   8	   main	   fractions	   (F1-­‐F8).	   Fraction	   F3	   (1.13	   g)	  
eluted	  with	  CH2Cl2	  was	   separated	  by	   column	   chromatography	   (CC)	  
over	   silica	   gel	   using	   CH2Cl2/MeOH	   (9.9:0.1)	   as	   eluent	   to	   obtain	  
compound	  	  	  19	  	  (12.0	  mg).	  ).	  An	  aliquot	  (0.5	  g)	  of	  fraction	  F4	  (3.06	  g)	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eluted	  with	  CH2Cl2/AcOEt	  (7.5:2.5)	  was	  purified	  by	  CC	  over	  sephadex	  
LH-­‐20	  using	  MeOH	  as	  eluent	  giving	  five	  subfractions	  (F4.1-­‐F4.5).	  F4.3	  
(230	   mg)	   was	   further	   chromatographed	   over	   sephadex	   LG-­‐20	  
(MeOH)	  to	  obtain	  four	  subfractions	  (F4.3.1-­‐F4.3.4).	  F4.3.3	  (44.5	  mg)	  
was	   subjected	   to	  C18	  SPE	  using	  acetonitrile/H2O	   (7:3)	   as	  eluent	   to	  
give	   compound	  20	   	   (15.2	  mg).	   F5	   (0.91	  g)	  was	  washed	  with	  EtOAc	  
under	  vacuum	  and	  the	  insoluble	  give	  compound	  17	  	  (404.4	  mg).	  F8	  
(1.48	   g)	   was	   cromatographated	   on	   silica	   gel	   using	   as	   eluent	  
CH2Cl2/MeOH	   (9.9:0.1)	   to	   give	   five	   subfractions	   (F8.1-­‐F8.5).	   F8.3	  
(145.3	  mg)	  was	  purified	  by	  sephadex	  LH-­‐20	  (MeOH)	  to	  give	  18	  (15.0	  
mg)	  and	  22	  (40	  mg).	  F6	  (0.70	  g)	  was	  subjected	  to	  CC	  (silica	  gel)	  using	  
n-­‐hexan/EtOAc	  (6.5	  :	  3.5)	  as	  eluent	  to	  obtain	  21	  (47.7	  mg).	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14.7	  	  Semi-­synthesis	  of	  5-­demethyltangeretin	  (23)	  
A	  mixture	  of	  xanthomicrol	   (17)	   (50.0	  mg,	  0.1453	  mmol)	  and	  K2CO3	  
(1.2	   equiv.	   24.1	   mg)	   in	   mixture	   of	   acetone/DCM	   (1:1,	   8	   ml)	   was	  
added	  Me2SO4	   (16.5	   µl,	   0.1744	  mmol),	   and	   then	   refluxed	   for	   4	   h.	  
The	  resulting	  solution	  was	  cooled	  and	  added	  Na2CO3	   (25	  ml,	  10%).	  
The	  solution	  was	  extracted	  with	  CH2Cl2	  (3	  x	  10	  ml).	  The	  organic	  layer	  
was	  concentrated	  under	  vacuum	  and	  the	  methylated	  derivative	  was	  
subsequently	  purified	  over	  silica	  gel	  using	  MeOH/DCM	  (9.9	  :	  0.1)	  to	  
give	  23	  (23.2	  mg,	  44.6%)	  as	  a	  white	  solid:	  mp	  172-­‐173	  °C	  (hexane);	  
spectroscopic	  data	  (UV,	  MS,	  NMR)	  identical	  to	  those	  reported	  in	  the	  
literature.150	  
	  
14.8	  	  Semi-­synthesis	  of	  tangeretin	  (24)	  
A	  mixture	  of	  xanthomicrol	   (17)	   (65.9	  mg,	  0.1916	  mmol)	  and	  K2CO3	  
(2.5	   equiv.	   66.2	   mg,	   in	   mixture	   of	   acetone/DCM	   (1:1,	   10	  ml)	   was	  
added	  Me2SO4	  (45.3	  µL,	  0.479	  mmol),	  and	  then	  refluxed	  for	  4	  h.	  The	  
resulting	  solution	  was	  cooled	  and	  added	  Na2CO3	   (35	  ml,	  10%).	  The	  
solution	  was	  extracted	  with	  CH2Cl2	  (3	  x	  10	  ml).	  The	  organic	  layer	  was	  
concentrated	   under	   vacuum	   and	   the	   residue	   was	   subsequently	  
purified	  over	  Sephadex	  LH-­‐20	   (MeOH)	   to	  give	  23	   (21.8	  mg,	  31.8%)	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and	  24	   (5.4	  mg,	   8%).	   Tangeretin	   (24)	  was	   obtained	   in	   8%	   yield	   as	  
white	   solid:	  mp	   151-­‐152	   °C	   (hexane);	   spectroscopic	   data	   (UV,	  MS,	  
NMR)	  identical	  to	  those	  reported	  in	  the	  literature.151,152	  
 
14.9	  	  	  W.	  somnifera	  	  Plant	  Material	  
	  Standardized	   root	  methanolic	   extract	   of	   	  WS	   (Withania	   somnifera	  
Dunal,	  Natural	  Remedies	  Pvt.	  Ltd.,	  Bangalore,	  India)	  was	  given	  by	  Dr.	  
Amit	  Agarwal	  (Natural	  Remedies	  Pvt	  Ltd.	  Bangalore,	  India).	  	  
14.10	  W.	  SOMNIFERA	  EXTRACTION	  AND	  ISOLATION	  
 
 
14.10.1	  	  Extraction	  and	  Separation	  Procedure	  of	  
Alkaloids	  	  
Approximately	  100	  g	  of	  methanol	  extract	  have	  been	  dissolved	   in	  a	  
mixture	  of	  MeOH/H2O	  (3	  :	  1)	  (500	  ml)	  and	  the	  obtained	  solution	  was	  
subsequently	   treated	  with	  diluted	  HCl	   (2	  N)	  up	   to	  pH	  2.	  The	  acidic	  
solution	  was	  exhaustively	  extracted	  with	  dichloromethane	  (DCM)	  to	  
remove	   non-­‐alkaloid	   compounds.	   The	   remaining	   aqueous	   solution	  
was	  made	   alkaline	   with	   diluted	   NH4OH	   up	   to	   pH	   9	   and	   extracted	  
with	  DCM	  by	  liquid-­‐liquid	  partition	  in	  a	  separation	  funnel.	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The	  organic	  phase	  was	  evaporated	  under	  reduced	  pressure	  resulting	  
in	   a	   light	   brown	   crude	   residue	   (WSa,	   1.77	   g)	   that	   gave	   a	   positive	  
response	  to	  the	  alkaloids	  reagent	  (Dragendorff).	  The	  basic	  aqueous	  
extract	  was	  evaporated	  at	  reduced	  pressure	  to	  obtain	  a	  dark	  brown	  
solid	  that	  was	  treated	  with	  MeOH	  and	  the	  resulting	  mixture	  filtered	  
under	   vacuum	   to	   remove	   the	   insoluble	   residue.	   The	   obtained	  
solution	   was	   concentrated	   under	   vacuum	   to	   give	   a	   rubbery	   dark	  
brown	  solid	  (36.31	  g)	  mainly	  represented	  by	  inorganic	  salts	  (WSb).	  
The	   crude	   residue	   (DCM2)	   was	   purified	   by	   gel-­‐chromatography	  
(Sephadex	   LH-­‐20)	  with	  MeOH	   as	   eluent	   to	   give	   30	   fractions.	   After	  
comparison	   of	   the	   30	   fractions	   by	   Silica	   gel	   thin	   layer	  
chromatography	   (TLC)	   they	   were	   combined,	   according	   to	   visual	  
similarities,	   and	   to	   positive	   response	   to	   Dragendorff	   reagent,	   in	  
three	   main	   fractions	   (F1-­‐F3).	   The	   alkaloid-­‐containing	   fraction	   (F2,	  
0.5123	  g),	  was	  purified	  by	  column	  chromatography	  (CC)	  using	  basic	  
alumina	   (activity	   grade	   II)	   as	   stationary	   phase	   eluting	   with	  
toluol/MeOH	  (7:	  3)	  to	  obtain	  four	  subfractions	  (F2.1-­‐F1-­‐4)	  and	  then	  
with	  MetOH/H2O	  (8:	  2)	  to	  give	  the	  subfraction	  F2.5.	  
F2.5	  (69.7	  mg)	  was	  separated	  by	  CC	  on	  silica	  gel	  eluting	  with	  MeOH,	  
then	   with	   MeOH/H2O	   (7:	   3)	   (8A4,	   100	   ml)	   and	   finally	   with	  
H2O/MeOH/trifluoroacetic	  acid	   (7	   :	  3	   :	  0.025).	  The	   fractions	  eluted	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with	  MeOH/H2O	  (7:	  3)	  gave	  (+)-­‐sedredine	  (25)
	  	  (16.0	  mg)	  and	  those	  
eluted	  with	  H2O/MeOH/trifluoroacetic	  acid	  (7	  :	  3	  :	  0.025),	  anaferine	  
(26)	  (68.5	  mg).	  Anaferine	  was	  isolated	  as	  meso	  isomer,	  according	  to	  
Schwarting	  et	  al.120	  
Fraction	   F1	   (63.2	  mg),	  which	   resulted	   negative	   to	   the	  Dragendorff	  
reagent,	   was	   purified	   by	   CC	   on	   silica	   gel	   using	   n-­‐hexane-­‐ethyl	  
acetate	   (3:	   7)	   as	   eluent	   yielding	   ferulic	   acid	  methyl	   ester	   (29)	   (8.5	  
mg).	  
An	   aliquot	   (10	   g)	   of	   WSb	   was	   purified	   by	   Vacuum-­‐Liquid	  
Chromatography	   (VLC)	   (neutral	   alumina)	   using	   a	   step	   gradient	   of	  
DCM/MeOH	  (9	  :	  1	  to	  0	  :	  10)	  to	  yield	  5	  main	  fractions	  (A1-­‐A5).	  	  
Fraction	  A5	  (347	  mg)	  was	  cromatographated	  using	  neutral	  alumina	  
as	  stationary	  phase	  and	  DCM/MeOH	  (8	  :	  2)	  as	  eluent,	  to	  give	  tropine	  
(27)	  (12.3	  mg)	  and	  choline	  (28)	  (8.5	  mg).	  
14.10.2	  	  Separation	  Procedure	  of	  Withanolides	  	  
20	  g	  of	  dry	  MeOH	  extract	  were	  purified	  by	  VLC	  using	  a	  step	  gradient	  
of	  n-­‐hexane/DCM	  (9	  :	  1	  to	  0	  :	  10)	  to	  yield	  4	  main	  fractions	  (B1-­‐B5).	  
Fraction	   B2	   (579	   mg)	   was	   chromatographed	   by	   Sephadex	   LH-­‐20	  
using	  MeOH	  as	  eluent	   to	  yield	   three	  subfractions	   (B2.1-­‐B2.3).	  B2.2	  
(96.5	   mg)	   was	   further	   purified	   by	   CC	   on	   silica	   gel	   using	   n-­‐
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hexane/ethyl	   acetate	   (7	   :	   3)	   to	   give	   withanone	   (31)	   	   (9	   mg).	  
Subfraction	  B2.3	  (400	  mg)	  was	  separated	  by	  CC	  over	  silica	  gel	  using	  
hexane/EtOAc	   (7	   :	   3)	   as	   eluent	   to	   obtain	  withanolide	   A	   (30)	   (68.1	  
mg).	  	  
Fraction	   B3	   (480	   mg)	   was	   purified	   by	   CC	   over	   silica	   gel	   using	  
hexane/EtOAc	   (6	   :	   4)	   as	   eluent	   to	   obtain	   400	   fractions.	   The	  
collection	   346-­‐377	   was	   dissolved	   in	   thert-­‐but-­‐met-­‐ether	   and	   then	  




15.	  MOLECULAR	  MODELING	  
 	  
15.1	  	  	  Ligands	  Preparation	  
	  Ligands	  were	  docked	   in	   the	  global	  minimum	  energy	   conformation	  
as	   determined	   by	   molecular	   mechanics	   conformational	   analysis	  
performed	  with	  Macromodel	  software.168	  Theoretical	  3D	  models	  of	  
the	  most	   active	   compounds	  were	   built	   by	  means	   of	  Maestro	  GUI.	  
The	   inhibitors	   structures	  were	   then	  submitted	   to	  a	  conformational	  
search	  of	  1000	  steps	  with	  an	  energy	  window	  for	  saving	  structure	  of	  
10	   kJ/mol.	   The	   algorithm	   used	  was	   the	  Monte	   Carlo	  method	  with	  
MMFFs	   (Merck	   molecular	   force	   fields)170	   followed	   by	   an	   energy	  
minimization	   carried	   out	   using	   the	   MMFFs,	   the	   GB/SA171	   water	  
implicit	   solvation	   model	   and	   the	   Polak-­‐Ribier	   Coniugate	   Gradient	  
(PRCG)	   method,	   converging	   on	   gradient	   with	   a	   threshold	   of	   0.01	  
kJ(mol•Å)-­‐1.	  
15.2	  	  Protein	  




15.3	  	  Docking	  and	  Post-­Docking	  Experiments	  
	  Glide	  XP	  was	  applied	  for	  docking	  experiments136.	  Then,	  to	  take	  into	  
account	  induced	  fit	  mechanism,	  the	  resulting	  top	  ranked	  theoretical	  
complexes	   were	   subject	   to	   10000	   steps	   of	   the	   Polak-­‐Ribier	  
conjugate	   gradient	   (PRCG)	   energy	   minimization	   method	   using	  
OPLS_2005	   force	   field.	   The	   residues,	   located	   in	   a	   radius	   of	   5	   Å	  
around	  the	  ligand,	  were	  left	  free	  to	  move.	  The	  optimization	  process	  
was	  performed	  up	  to	  the	  derivative	  convergence	  criterion	  equal	  to	  
0.01	  kJ/(mol•Å)-­‐1.	  The	  binding	   interaction	  energies	  were	  computed	  
applying	  molecular	  mechanics	  and	  continuum	  solvation	  models	  with	  
the	  molecular	  mechanics	  generalized	  Born/Surface	  area	  (MM-­‐GBSA)	  
method.171	   Depictions	   were	   taken	   by	   means	   of	   Pymol	   (PyMOL	  








16.	  	  BIOLOGY	  ASSAY	  
 	  
16.1	  	  Animals	  
Male	   CD1	   mice	   (Charles	   River,	   Calco,	   Italy)	   20-­‐25	   g	   were	   used.	  
Animals	  were	  housed	  in	  an	  animal	  facility	  on	  a	  12h	  light/dark	  cycle	  
(lights	  on	  from	  08:00	  AM),	  at	  a	  constant	  room	  temperature	  of	  21	  ±	  
1°C	   (relative	   humidity	   approximately	   60%).	   Standard	   rodent	   chow	  
and	  water	  were	  available	  ad	  libitum.	  Animals	  were	  allowed	  to	  adapt	  
to	  the	  animal	  facility	  conditions	  for	  at	  least	  two	  weeks	  after	  arrival.	  
Procedures	   involving	   animals	   and	   their	   care	   were	   conducted	   in	  
accordance	  with	   the	   institutional	  guidelines	   that	  are	   in	  compliance	  
with	  national	   (D.L.	  number	  116,	  Gazzetta	  Ufficiale,	   supplement	  40,	  
February	   18,	   1992;	   Circolare	  number	  8,	  Gazzetta	  Ufficiale,	   July	   14,	  
1994)	   and	   international	   laws	   and	   policies	   (EEC	   Council	   Directive	  
86/609,	  OJL	   358,	   1,	   Dec.	   12,	   1987;	  Guide	   for	   the	   Care	   and	  Use	   of	  
Laboratory	   Animals,	   U.S.	   National	   Research	   Council,	   1996).	   Every	  
effort	   was	   made	   to	   minimize	   animal	   pain	   and	   discomfort	   and	   to	  





16.2	  	  Drugs	  and	  Chemicals	  
Morphine	  hydrochloride	  (Salars,	  Como,	  Italy)	  was	  dissolved	  in	  saline	  
(NaCl	  0.9%)	  and	  administered	  subcutaneously	  (s.c.)	  in	  a	  volume	  of	  5	  
ml/Kg.	   The	   standardized	   root	  methanolic	   extract	   of	  WS	   (Withania	  
somnifera	  Dunal,	  Natural	  Remedies	  Pvt.	  Ltd.,	  Bangalore,	   India)	  was	  
dissolved	   in	   saline	   for	   analgesia	   experiments	   [administered	  
intraperitoneally	   (i.p.)	   in	   a	   volume	   of	   5	   ml/Kg]	   and	   in	   dimethyl	  
sulfoxide	  (DMSO,	  Sigma-­‐Aldrich,	  Milan,	  Italy)	  for	  binding	  assay.	  The	  
dose	  of	  WSE	  for	  analgesia	  experiments	  was	  selected	  on	  the	  basis	  of	  
previous	   studies173,174	   [3H]-­‐DAMGO	   ([d-­‐Ala2,	   N-­‐Me-­‐Phe4,Gly-­‐ol5]-­‐
enkephalin),	   [3H]-­‐DPDPE	   ([D-­‐Pen2,	   D-­‐Pen5]-­‐enkephalin),	   [3H]-­‐U-­‐
69,593,	   [3H]-­‐CP55,950,	   [3H]-­‐MK801,	   [3H]-­‐Muscimol,	   [3H]-­‐Baclofen,	  
[3H]-­‐Clonidine	   and	   [3H]-­‐Ketanserine	   were	   purchased	   from	   Perkin	  
Elmer,	   Monza	   (MB),	   Italy.	   CP-­‐55,940,	   Naloxone,	   U-­‐69,593,	  
muscimol,	   MK801,	   yohimbine	   and	   methysergide	   were	   obtained	  







16.3	  	  [3H]-­‐DAMGO-­‐[3H]-­‐DPDPE	  (opioid	  receptors)	  
Binding	  Assay	  
Ligand	  binding	  assays	  were	  carried	  out	  according	  to	  the	  procedure	  
described	  by	  Ruiu	  et	  al.173	  Briefly,	  the	  whole	  brain	  minus	  cerebellum	  
was	  homogenized	  with	  Polytron	  in	  50	  volumes	  (w/v)	  of	  50	  mM	  Tris-­‐
HCl	   (pH	   7.4),	   centrifuged	   at	   48,000xg	   for	   20	   minutes	   at	   4°C,	   re-­‐
suspended	  in	  50	  volumes	  of	  the	  same	  buffer	  solution,	  and	  incubated	  
at	   37	   °C	   for	   45	   minutes.	   After	   a	   further	   centrifugation	   step	   at	  
48,000xg	  for	  20	  minutes	  at	  4	  °C,	  the	  final	  pellet	  was	  re-­‐suspended	  in	  
the	  same	  buffer	  solution.	  Brain	  membranes	  (150-­‐200	  µg	  of	  protein)	  
were	  incubated	  with	  the	  appropriate	  concentration	  of	  [3H]-­‐DAMGO	  
[(D-­‐Ala2,	  N-­‐Me-­‐Phe4,	  Gly5-­‐ol-­‐)	  enkephalin]	  (1	  nM)	  or	  [3H]-­‐DPDPE	  [(D-­‐
Pen	   2,5)-­‐enkephalin]	   (1	   nM)	   in	   Tris-­‐HCl	   buffer	   at	   25	   °C	   for	   60	  
minutes	  in	  the	  absence	  or	  presence	  of	  naloxone	  (1	  µM).	  The	  binding	  
reaction	   was	   stopped	   by	   rapid	   filtration	   under	   vacuum	   through	  
glass-­‐fibre	   filters	   (Whatman	   GF/B)	   using	   a	   Brandell	   36-­‐sample	  
harvester	   (Gaithesburg,	   MD,	   USA)	   and	   thereafter	   the	   filters	   were	  
washed	  with	   4×5	  ml	   ice-­‐cold	   50	  mM	  Tris–HCl	   buffer	   (pH	   7.4).	   The	  
affinity	  of	  compounds	  1-­‐21	  was	  compared	  with	  that	  of	  the	  reference	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compound	  Morphine	  hydrochloride	  (MOR	  Kì	  =	  1.2	  ±	  0.03	  nM;	  DOR	  Kì	  
=	  100	  ±	  12	  nM).	  
16.4	   [3H]-­CP-­55,940	   (cannabinoid	   receptors)	  
Binding	  Assay	  
The	  whole	  brain	  minus	  cerebellum	  and	  spleen	  were	  homogenized	  in	  
20	   volumes	   (w/v)	   of	   ice-­‐cold	   TME	   buffer	   (50	   mM	   Tris-­‐HCl,	   1	   mM	  
EDTA	   and	   3.0	   mM	  MgCl2,	   pH	   7.4),	   centrifuged	   at	   1,086xg	   for	   10	  
minutes	  at	  4	  °C,	  and	  the	  resulting	  supernatants	  were	  centrifuged	  at	  
45,000	  x	  g	  for	  30	  min,	  at	  4	  °C.	  [3H]-­‐CP-­‐55,940	  binding	  was	  performed	  
by	   the	   method	   previously	   described	   by	   Ruiu	   et	   al.174.	   Briefly,	   the	  
membranes	   (30-­‐80	   µg	   of	   protein)	   were	   incubated	  with	   0.5	   nM	   of	  
[3H]-­‐CP-­‐55,940	   for	  1	  h	  at	  30	   °C	   in	  a	   final	   volume	  of	  0.5	  ml	  of	  TME	  
buffer	  containing	  5	  mg/ml	  of	   fatty	  acid-­‐free	  bovine	  serum	  albumin	  
(BSA).	  Non-­‐specific	  binding	  was	  estimated	  in	  the	  presence	  of	  10	  µM	  
of	  CP-­‐55,940.	  All	  binding	  studies	  were	  performed	  in	  disposable	  glass	  
tubes	  pre-­‐treated	  with	  Sigma-­‐Cote	  (Sigma	  Chemical	  Co.	  Ltd.,	  Poole,	  
UK),	   in	   order	   to	   reduce	   non-­‐specific	   binding.	   The	   reaction	   was	  
terminated	   by	   rapid	   filtration	   through	   Whatman	   GF/C	   filters	  
presoaked	   in	   0.5%	   polyethyleneimine	   (PEI)	   using	   a	   Brandell	   96-­‐
sample	  harvester	  (Gaithersburg,	  MD,	  USA).	  Filters	  were	  washed	  five	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times	   with	   4	   ml	   aliquots	   of	   ice	   cold	   Tris	   HCl	   buffer	   (pH	   7.4)	  
containing	   1	   mg/ml	   BSA.	   The	   affinity	   of	   compounds	   1-­‐12	   was	  
compared	  with	  that	  of	  the	  reference	  compound	  SR144528	  (CB1	  Kì	  =	  
70	  ±	  10	  nM;	  CB2	  Kì	  =	  0.28	  ±	  0.04	  nM).	  	  
	  
16.5	  	  [3H]-­Muscimol	  (GABAA	  receptor)	  Binding	  
Assay	  
Ligand	  binding	  assays	  were	  carried	  out	  according	  to	  the	  procedure	  
described	   by	   Beaumont	   et	   al.	   (1978)175	   with	   slight	   modifications.	  
Briefly,	   the	   cerebral	   cortex	   were	   homogenized	   in	   0.32M	   sucrose,	  
centrifuged	   at	   1,000xg	   and	   the	   resulting	   supernatants	   were	  
centrifuged	  at	  20,000xg.	  The	  resulting	  pellet	  was	  suspended	   in	   ice-­‐
cold	   water,	   homogenised	   and	   centrifuged	   at	   8,000xg.	   The	  
supernatant	   together	   with	   the	   buffy	   layer	   on	   the	   pellet	   was	   then	  
centrifuged	   at	   48,000xg.	   The	   resulting	   pellet	   was	   re-­‐suspended	   in	  
water,	  and	  once	  more	  centrifuged	  at	  48,000xg.	  The	  final	  pellet	  was	  
frozen	  and	  stored	  at	  -­‐80°C.	  On	  the	  day	  of	  analysis,	  membrane	  pellet	  
was	   allowed	   to	   thaw	   at	   4°C	   before	   re-­‐suspension	   in	   50	  mM	   Tris–
citrate	  buffer,	  pH	  7.1,	  containing	  0.05%	  Triton	  X-­‐100	  and	  incubated	  
for	   30	   min	   at	   37°C.	   Following	   incubation,	   the	   suspension	   was	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centrifuged	  at	  48,000xg.	  The	  washing	  step	  was	  repeated	  three	  more	  
times	   and	   the	   final	   pellet	   was	   then	   re-­‐suspended	   in	   the	   binding	  
buffer.	  Non-­‐specific	   binding	  was	   estimated	   in	   the	   presence	  of	   200	  
µM	  of	  GABA.	  	  
	  
16.6	  	  Analysis	  of	  samples	  
Displacement	  curves	  were	  carried	  out	  using	  serial	  dilutions	  ranging	  
from	  1	  mg/ml	  to	  0.001	  mg/ml	  of	  DCM	  extract	  and	  from	  100	  µM	  to	  
0.01	  µM	  of	  all	  other	  compounds.	  To	  avoid	  possible	  undesired	  effects	  
on	  radioligand	  binding,	  DMSO	  concentration	  in	  the	  different	  assays	  
never	  exceeded	  1%	  (v/v).	  
Filter-­‐bound	   radioactivity	   were	   counted	   in	   a	   liquid	   scintillation	  
counter	  (Tricarb	  2900;	  PerkinElmer	  Life	  Sciences,	  Boston,	  MA,	  USA)	  
using	   Ultima	   Gold	   as	   scintillation	   fluid	   (Packard,	   USA).	   Protein	  
content	   was	   determined	   using	   the	   Bio-­‐Rad	   Dc	   Kit	   (Bio-­‐Rad	  
Laboratories	  GmbH,	  Munich,	  Germany)	  and	   following	  manufacture	  
instructions.	   Data	   from	   radioligand	   inhibition	   experiments	   were	  
analyzed	  by	  nonlinear	   regression	  analysis	  of	  a	  Sigmoid	  Curve	  using	  
GraphPad	  Prism	  program	  (Graph	  Pad	  Software,	  Inc.,	  San	  Diego,	  CA,	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USA).	   Ki	   values	   were	   calculated	   from	   the	   obtained	   IC50	   values	   by	  
means	  of	  the	  equation	  of	  Cheng	  and	  Prusoff176.	  
	  All	   receptor	  binding	  experiments	  were	  performed	   in	   triplicate	  and	  
results	   were	   confirmed	   in	   at	   least	   four	   independent	   experiment.
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17.	  	  ANALGESIA	  EXPERIMENTS	  
 
 
17.1	  	  WSE	  	  Tail-­flick	  and	  Hot-­plate	  Test	  	  
The	   antinociceptive	   effects	  were	   quantified	   using	   the	   tail-­‐flick	   test	  
and	   the	   hot	   plate	   test.174	   An	   automated	   device	   (model	   7360,	   Ugo	  
Basile,	  Italy)	  was	  used	  to	  determine	  the	  tail-­‐flick	  latency,	  defined	  by	  
the	   time	   (s)	  at	  which	   the	  animals	  withdraw	   the	   tail	   from	  a	   radiant	  
heat	   source.	   Mice	   were	   held	   and	   gently	   restrained	   above	   the	  
apparatus;	   the	   light	  beam	  was	   focused	  1.5	   cm	   from	   the	   tip	  of	   the	  
ventral	   surface	   of	   the	   tail.	   The	   stimulus	   intensity	   was	   adjusted	   to	  
result	  in	  a	  mean	  pre-­‐drug	  control	  latency	  of	  2-­‐3	  s,	  and	  a	  cut-­‐off	  time	  
of	  12	  s	  was	  applied	  to	  avoid	  tissue	  damage.	  	  
A	  semi-­‐automated	  device	   (model	  7280,	  Ugo	  Basile,	   Italy)	  was	  used	  
to	  determine	  the	  reaction	  of	  mice	  placed	  on	  the	  hot	  plate,	  defined	  
by	   the	   time	   (s)	   at	  which	  mice	   exhibited	   a	   nociceptive	   response	   or	  
discomfort	   (licking	   or	   fanning	   the	   paws,	   jumping).	   A	   50	   cm	   high	  
Plexiglas	   cylinder	   was	   suspended	   over	   the	   hot	   plate	   and	   the	  
temperature	  was	  maintained	  at	  55	  ±	  0.2	  °C;	   to	  avoid	  skin	  damage,	  
after	  15	   s	  mice	  were	   removed	   from	  the	  hot	  plate.	  Mice	  were	  pre-­‐
treated	   with	   saline	   or	   WSE	   100	   mg/Kg	   30	   min	   before	   saline	   or	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morphine	  treatment;	  increasing	  doses	  of	  morphine	  were	  used	  (2.5,	  
5	  and	  10	  mg/Kg).	  Basal	   algesia	  was	  assessed	   right	  before	   saline	  or	  
WSE	   pre-­‐treatment	   (baseline).	   The	   effects	   of	   the	   drugs	   were	  
evaluated	  30,	  60,	  120,	  240	  and	  360	  min	  after	  morphine	  treatment.	  	  
	  
17.2	  	  Tail-­flick	  Test	  of	  xanthomicrol	  
The	   anti-­‐nociceptive	   effects	   were	   quantified	   using	   the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
tail-­‐flick	   test.177	   	   An	   automated	   device	   (model	   7360,	   Ugo	   Basile,	  
Italy)	   was	   used	   to	   determine	   the	   tail-­‐flick	   latency,	   defined	   by	   the	  
time	  (s)	  at	  which	  the	  animals	  withdraw	  the	  tail	  from	  a	  radiant	  heat	  
source.	  Mice	  were	  held	  and	  gently	  restrained	  above	  the	  apparatus;	  
the	   light	   beam	   was	   focused	   1.5	   cm	   from	   the	   tip	   of	   the	   ventral	  
surface	  of	  the	  tail.	  The	  stimulus	  intensity	  was	  adjusted	  to	  result	  in	  a	  
mean	  pre-­‐drug	   control	   latency	  of	   2-­‐3	   s,	   and	  a	   cut-­‐off	   time	  of	   12	   s	  
was	  applied	  to	  avoid	  tissue	  damage.	  	  
Mice	   were	   pre-­‐treated	   with	   saline	   or	   xanthomicrol	   (40	   and	   80	  
mg/kg)	  30	  min	  before	  saline	  or	  morphine	  (5	  mg/kg)	  treatment.	  Basal	  
algesia	   was	   assessed	   right	   before	   saline	   or	   xanthomicrol	   pre-­‐
treatment	  (baseline).	  The	  effects	  of	  the	  drugs	  were	  evaluated	  30,	  60	  
and	  120	  min	  after	  morphine	  treatment.	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17.3	  	  Morphine-­induced	  Hyperalgesia	  Experiment	  	  	  	  
The	  ability	  of	  WSE	  to	  inhibit	  the	  development	  of	  morphine-­‐induced	  
hyperalgesia	   was	   evaluated	   using	   the	   low-­‐intensity	   tail-­‐flick	   test	  
according	  to	  Gupta	  and	  colleagues	  (2011)167	  with	  few	  modifications.	  
Briefly,	  the	  stimulus	  intensity	  was	  adjusted	  to	  result	  in	  a	  mean	  pre-­‐
drug	  control	  latency	  of	  5-­‐7	  s,	  and	  a	  cut-­‐off	  time	  of	  10	  s	  was	  applied.	  
Mice	  were	  pre-­‐treated	  with	  saline	  or	  WSE	  100	  mg/Kg	  30	  min	  before	  
saline	   or	   morphine	   treatment	   (2.5	   mg/Kg).	   Basal	   algesia	   was	  
assessed	   right	   before	   saline	   or	  WSE	   pre-­‐treatment	   (baseline).	   The	  
effects	  of	  the	  drugs	  were	  evaluated	  30,	  60,	  120,	  240,	  300,	  360	  and	  
420	  min	  after	  morphine	  treatment.	  	  
	  
17.4	  	  Spontaneous	  and	  Morphine-­induced	  Motor	  
Activity	  Experiments	  	  
In	   order	   to	   evaluate	   the	   ability	   of	   WSE	   to	   modulate	   further	  
pharmacological	   effects	   induced	   by	   morphine,	   spontaneous	   and	  
morphine-­‐induced	   motor	   activity	   experiments	   have	   been	   carried	  
out	  173.	  Mice	  were	  tested	  in	  chambers	  made	  of	  transparent	  Plexiglas	  
(40Lx30Wx40H	   cm)	   interfaced	   to	   a	   computer	   equipped	  with	   a	   TSE	  
software	   (TSE	   Systems,	   Bad	   Homburg,	   Germany).	   The	   distance	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travelled	   (m)	   by	   mice	   inside	   the	   chambers	   was	   detected	   by	   8	  
horizontal	  photocells.	  Mice	  were	  habituated	  to	  the	  chambers	  for	  30	  
min.	   Immediately	   after	   habituation,	  mice	  were	   treated	  with	   saline	  
or	  WSE	   100	  mg/Kg	   and	   30	  min	   later	   were	   injected	   with	   saline	   or	  
morphine	  (5	  or	  10	  mg/Kg).	  Motor	  activity	  was	  evaluated	  for	  360	  min	  
after	  morphine	  administration.	  
	  
17.5	  	  Data	  Analysis	  
Treatment-­‐induced	   variations	   in	   tail-­‐flick	   and	   hot	   plate	   response	  
were	  calculated	  as	  the	  percentage	  of	  maximal	  possible	  effect	  (MPE)	  
according	   to	   the	   following	   formula:	   MPE	   [%]:	   [(T1-­‐T0)/(T2-­‐T0)]	   x	  
100,	   where	   T0	   and	   T1	   are	   the	   latency	   before	   (baseline)	   and	   after	  
treatment,	  and	  T2	  is	  the	  cut-­‐off	  time	  (12	  s	  in	  the	  tail-­‐flick,	  15	  s	  in	  the	  
hot	   plate	   and	   10	   s	   in	   the	   low-­‐intensity	   tail-­‐flick	   tests).	   Data	   from	  
behavioural	   experiments	   are	   expressed	   as	   mean	   ±	   standard	   error	  
(S.E.M.)	  of	  %MPE.	  The	  %MPE	  in	  tail-­‐flick	  and	  hot	  plate	  experiments	  
were	   analyzed	   separately	  by	   repeated	  measure	   three-­‐way	  analysis	  
of	   variance	   (ANOVA)	   with	   pre-­‐treatment	   (saline	   and	   WSE)	   and	  
treatment	   (saline	   and	  morphine)	   as	   between-­‐subjects	   factors,	   and	  
time	  as	  within-­‐subjects	  factor	  (repeated	  measures).	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In	   the	   spontaneous	   and	   morphine-­‐stimulated	   motor	   activity	  
experiments,	   the	   average	   distance	   travelled	   (m)	   after	   WSE	   pre-­‐
treatment	   and	   morphine	   treatment	   was	   analyzed	   by	   repeated	  
measures	   three-­‐way	  ANOVA,	  with	   pre-­‐treatment	   (saline	   and	  WSE)	  
and	   treatment	   (saline	   and	   morphine)	   as	   between-­‐subjects	   factors	  
and	  time	  (min)	  as	  within-­‐subjects	  factor	  (repeated	  measures).	  
For	   each	   of	   the	   statistical	   analysis	   described	   above,	   when	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